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ABSTRACTS 
 
     Apoptosis is a key event occurring in living organisms. In order to maintain tissue 
homeostasis, a comparable number of cells have to die to compensate for the cells produced 
by mitosis. However in many diseases this mechanism is altered. Once a malignancy is 
established, the conventional approach is to treat cells with drugs able to induce apoptosis. 
Although the execution of apoptosis is a common pathway leading to caspase activation, the 
triggering events are usually distinct for the different anti-cancer drugs. 
In this report, we studied apoptosis in general and in specific situations like in HIV infection, 
we then applied our knowledge to comprehend how several drugs, mainly synthesized in our 
laboratory, may be effective in cancer therapy.  We expose how nucleoside analogs, 
compounds commonly used for the treatment of Chronic Lymphocytic Leukemia (B-CLL), are 
able to damage DNA and, in some cases, can even directly affect mitochondria. We explain 
how the newly synthesized microtubule-disrupting agent indanocine is effective in the killing 
of multidrug-resistant cells and how etodolac, a nonsteroidal anti-inflammatory drug, may 
become a useful drug for the treatment of B-CLL. 
Hopefully, the data reported in this thesis (13 works that have been or are being officially 
published) can be successfully translated into clinical applications for improved treatment of 
cancers.  
 
     L’apoptose (ou mort cellulaire programmée) est un processus cellulaire essentiel présent dans la 
majorité des organismes. Afin de préserver l’homéostase des tissus, un nombre comparable de 
cellules doit mourir pour maintenir l'équilibre avec les cellules produites par mitose. Cependant, dans 
de nombreuses maladies (en particulier le cancer), ce méchanisme de mort cellulaire est alteré. Une 
fois la maladie établie, on traite généralement les cellules avec des médicaments capables d’induire 
l’apoptose. 
Bien que le programme d’exécution de l’apoptose soit un méchanisme qui conduit en général à 
l’activation des caspases, les événements qui mènent á la libération du cytochrome C (un autre 
acteur important dans l’apoptose) sont différents pour chaque médicament. 
Dans ce travail de thèse, nous avons essayé de comprendre le méchanisme de l’apoptose en général 
et dans certain cas spécifiques comme lors de l’infection par le virus du SIDA. Notre but est donc 
d’appliquer nos connaissances afin de comprendre comment certain médicaments, dont quelques 
uns ont été synthétisés dans notre laboratoire, peuvent etre efficaces dans le traitement de certain 
cancer. 
Nous démontrons comment des analogues de nucléosides, médicaments utilisés pour le traitment de 
la leucémie lymphocitaire chronique (B-CLL), sont capables d’endommager l’ADN et quelques fois 
aussi les mitochondries. Nous démontrons aussi comment un agent destructeur de microtubules 
(indanocine) est efficace pour tuer les cellules résistantes a plusieurs substances utilisées contre les 
cancers, et comment etodolac, un médicament antiinflammatoire non-steroïdale, réduit le nombre de 
cellules chez les patients B-CLL. 
On espère que les résultas reportés dans cette thèse (treize travaux publiés ou en voie de 
publication) vont pouvoir être appliqués dans le domaine clinique pour l’amélioration des traitements 
contre le cancer. 
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PROLOGUE 
     When I first started my studies about ten years ago, the leading idea directing me to biology was 
that one day I might be able to discover the reason why so many diseases were afflicting human 
beings and maybe I would be able to go inside a cell and say “You! You villain! I blame you for all this 
damage”. 
Now, at the end of my Ph.D., I realize that this is a wonderful, magnificent utopia. In most of the 
cases, diseases are not the result of a single erroneous event, but rather several circumstances 
occurring at the same time usually causing sufferance to many people. Because different 
combinations of events can cause the same illness, it results in the complex task of finding the villain. 
Still more frustrating is that even if the cause is pinpointed, the identification of the bad guy does not 
give us the possibility to switch its status from bad into good, simply by snapping our fingers.  
Restoration of the damage is practically impossible. Maybe one day technology will be so powerful 
and our knowledge so great that the images seen in Star Trek will not be purely fiction, but we will 
have enough knowledge to repair DNA and fight any disease with the use of a single instrument. By 
that time, we will probably be traveling with Tele-transport or Quantum-transport. Presently, the most 
efficient approach to deal with diseases is not to repair the damage, but to prevent the malady or to 
kill the affected cells. Prevention can be obtained by vaccines or just by information campaigns with 
the purpose of warning the people of the danger. If the disease is already present in the body, the 
only solution is the treatment. Fortunately, in the past we were able to use natural and chemical 
products capable of fighting many diseases. Unfortunately, only some of the battles have been won, 
but not the war. Everyday new opponents appear on the enemy battlefield, threatening our health. 
Malignancy in most of the cases cannot be specifically treated and often side effects of the actual 
treatments are observed. The tendency is therefore to find new approaches that affect primarily the 
sick cells, without damaging healthy organs. New compounds are constantly synthesized, tested, and 
proofed against every kind of disorder. Usually, chance allows a new therapy to be discovered, 
without even knowing the mechanism of action used by the drug. The fascinating peculiarity of biology 
is to dig into the field, among the microscopic proteins contained in the cells and find out what is the 
target that mediates a positive response to the treatment. 
This is exactly the idea that drove us to our research. Years ago Professor Dennis Carson and our 
chemist Dr. Howard Cottam synthesized one of the compound that is still currently used for the 
treatment of Chronic Lymphocytic Leukemia and Hairy Cell Leukemia, cladribine. The mechanism by 
which this drug induces lymphocyte depletion in patients was unknown. The cool thing was that this 
therapy was working in patients. Years later X. Wang and coworkers shed a new light on the intrinsic 
machinery of apoptosis in cells. Adding one plus one, Dr. Carson realized that the possible machinery 
we were looking for was somehow related to this discovery. This basically was the starting point of the 
path, which led us to climb the mountain. On my way I had the unique opportunity to see the whole 
development of drugs starting from synthesis, screening, application in vitro, and discovery of the 
biochemical pathway, to the clinical application with patients in phase II of clinical trial. With the 
increasing knowledge in the field we were then able to apply our understanding of cell death to other 
fields. And other fields are not so difficult to find: many cancers, infective diseases, neurodegenerative 
disorders (…) are present in the world and many more are about to be discovered. What we have to 
do is simply find the way to KILL these disordered pathogens. Kill them by inducing cell death. The 
plot will be destroying malignancies, featuring apoptosis in the leading role. 
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ABSTRACT 
     Thirty years ago, the term apoptosis was conceived to define a mechanism of cell death programmed by the 
cell itself. Since then, apoptosis has become one of the most studied events in the cell, because it has been 
correlated to several diseases. Cancers arise in some cases from the inability of a set of cells to undergo 
apoptosis. Other malignancies like immunodeficient diseases and neurodegenerative disorders often present a 
defect in regulation of apoptosis. 
     In this thesis I mostly present data on drug-induced and virus-mediated apoptosis. Novel drugs were 
synthesized and developed in our laboratory, tested for their cytotoxicity in tumor models and their mechanism 
of action was elucidated.  
     The antitumoral agents most commonly used in the clinical treatment of Chronic Lymphocytic Leukemia (B-
CLL), are nucleoside analogs. Developed more than 20 years ago in the laboratory of Dr. Dennis Carson, 
Cladribine (2CdA) together with other analogs such as Fludarabine (F-ara-A) and CaFdA, were shown to reduce 
the count of B-CLL cells in the patients, but their complete mechanism of action was unresolved until a few 
years ago. In our research, we were able to demonstrate the ability of these compounds to induce DNA 
damage, activate the p53 pathway and induce cytochrome c release from mitochondria. We also demonstrated 
that the same compounds can also activate the complex downstream cytochrome c release of Apaf-1 and 
caspase-9 in a cell-free system. Interestingly, big differences were observed in the mitochondrial toxicity of the 
various purine nucleoside analogs. 2CdA and CaFdA were able to induce direct cytochrome c release by 
directly damaging mitochondria. F-ara-A on the other hand absolutely required a p53 intact pathway to kill B-
CLL cells. We showed that CLL cells isolated from patients with non-functional p53 pathway were resistant to F-
ara-A. 
     Indanocine, a novel microtubule-binding drug, was also developed in our laboratory. Indanocine was shown 
to induce apoptosis in multidrug-resistant cell lines by binding to tubulin and inducing its depolymerization. To 
better understand its mechanism of action, we selected and analyzed a resistant clone (CEM-178) from a T 
lymphoblastoid CCRF-CEM cell line.  
B-CLL cells have been known to be hypersensitive to microtubule-binding antimitotic agents, such as colchicine, 
for more than 30 years, but the mechanism of this cytotoxicity was never fully elucidated. For this reason, we 
tested indanocine on primary B-CLL cells, and demonstrated its potent and selective cytotoxicity. We carefully 
studied the anti-CLL activity of indanocine, and showed the activation of the intrinsic pathway of apoptosis. The 
anti-apoptotic molecule Bcl-2 was phosphorylated and this resulted in its dimerization, subcellular relocalization, 
and inactivation. In addition, indanocine treatment reduced the amount of cytosolic pro-apoptotic Bax, released 
cytochrome c from the mitochondria to the cytosol, and activated the caspases. Concomitantly with Bcl-2 
phosphorylation activation of the JNK pathway was observed. 
     Etodolac, a non-steroidal anti-inflammatory drug already used in the clinic for the treatment of rheumatoid 
arthritis, was able to give relief to patients affected by B-CLL. Here I report the data about the mechanisms by 
which etodolac induces apoptosis in B-CLL cells, which include the down-regulation of the anti-apoptotic 
molecule Mcl-1, the reduction of the mitochondrial membrane potential and the activation the PPAR-γ receptor, 
which is over-expressed in B-CLL. Etodolac also activated cell movement (chemotaxis) in B-CLL cells. 
     Depletion of CD4+ T lymphocytes is observed during infection by HIV-virus. In this thesis, we elucidated the 
mechanism of action by which CD4+ are depleted by HIV. We propose that, once cells are infected, the virus 
integrates in the genomic DNA, activating the intrinsic pathway of apoptosis, by phosphorylation of p53 at 
residue Ser15. The p53 phosphorylation results in the up-regulation of pro-apoptotic protein Bax, which causes 
the release of cytochrome c from the mitochondria and the activation of the caspase cascade. 
     The results reported in this thesis help us understand the mechanism of action of widely used and newly 
synthesized drugs. Application of these findings in the clinic will help lead to more affective treatment of cancer 
and AIDS. Moreover a deeper interpretation of the data and an aimed design of new compounds will result in 
the development of more potent and less toxic treatments. 
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 INTRODUCTION 
Genesis of death 
     At the beginning there was only life! The biology of the cell was mainly development, metabolism and 
division. Then researchers realized one important thing: every second in the human body hundreds of 
thousands of cells were produced by mitosis. The dilemma was where those cells were ending up. Since the 
size of the human body is maintained and the number of cells is growing, an important event not previously 
considered had to be part of normal life. Hence death as a daily occurrence was recognized. Cell death is so 
important that more than 99.9% of the total number of cells generated during the course of a human lifetime go 
on to die (1). 
     Good and bad ways for cells to die exist. The “good” cell death is observed when cells silently die, vanishing 
without a trace, without any accompanying inflammatory response. This usually happens in normal development 
or tissue homeostasis. Cells shrink and condense, whereas the plasma membrane retains its integrity. Then the 
cells are rapidly phagocytosed by macrophages or degraded. Almost 30 years ago, this process was termed as 
“apoptosis” (2). The “bad” cell death usually occurs at the center of acute lesions such as traumas and ischemia, 
and lead to an inflammatory response. Those cells and their organelles tend to swell and disrupt, leaking their 
contents into the environment. This is also called “necrosis”. 
     The most shocking discovery for these scientists was that finally they could talk about death without fear. 
Death was no longer a taboo, the end of the human being, the constant impending threat, growing bigger with 
time, but rather it was something helping life. Cell death is used by multicellular organisms for development and 
morphogenesis to control cell number, as defensive strategy to remove infected, mutated or damaged cells. 
Apoptosis is important in the formation of the fetus (3, 4). It is involved in the formation of tubes, the separation 
of the digits, the remodeling of bones, and involution of the mammary gland (5). 
Dysfunction of Programmed Cell Death Induces Debilitating Disorders 
     Closer analysis however revealed that death was still playing a role in the termination of life. Dysfunction of 
cell death was leading to debilitating disorders. Predominance of cell survival over death or death over survival 
contributes to the pathogenesis of a number of human diseases, including cancer, viral infection, autoimmune 
disease, neurodegenerative disorders, and AIDS (6).  
 
MALIGNANCIES CAUSED BY INEFFICIENT DEATH 
     Cell death is a strictly regulated process. Mediators of apoptosis are constitutively expressed in many cell 
types and these are controlled by the environment. Most normal cells are programmed to commit suicide if 
survival signals are not received from the environment (7). For example, in metastatic tumors cells have 
circumvented this homeostatic mechanism and can survive at sites distinct from the tissue in which they arose. 
     Clearly all tumors demonstrate this progress of life leading over death. A tumor is considered as an 
uncontrolled overgrowth of cells. Death mechanisms are not capable to compensate for cell overgrowth and 
usually the reason lays in the inability of genes and proteins that control apoptosis to give the right orders to 
induce apoptosis. It is now clear that some oncogenic mutations disrupt apoptosis, leading to tumor initiation, 
progression and metastasis (8).  
     Excessive survival is also observed in autoimmune diseases. During development of the immune system an 
abundant number of immune cells are produced.  In healthy individuals auto-reactive cells and excessive cells 
are generally removed from the body. Failure of the apoptotic machinery promotes survival of cells that are 
shown to be autoimmune responsive during development of the disease.  
     Sometimes cell survival overcome cell death thanks to the help received from the exterior. During viral 
infections, cells usually undergo suicide as a cellular defense mechanism to prevent viral spread. Sometimes 
viral proteins help survival armies to circumvent the host defense, favoring virus replication and infection.  
 
DAMAGE INDUCED BY EXCESSIVE DEATH 
     Excessive cell death is also a problem and can result from conditions that enhance the accumulation of 
signals that induce apoptosis. 
 3
     In HIV-induced lymphocyte depletion, AIDS has been directly correlated with the CD4+ T cell depletion. CD4+ 
cells are involved in the immune response against viral infection. HIV virus can lead directly to apoptosis in 
defensive host cells, reducing the host defensive barrier to promote self-survival (9). 
     A wide variety of neurological diseases are characterized by the gradual loss of specific sets of neurons (10). 
Such disorders include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, retinitis 
pigmentosa, spinal muscular atrophy, and various forms of cerebrellar degeneration. The cell loss in these 
diseases does not induce an inflammatory response, and apoptosis appears to be the mechanism of cell death 
(11). 
     Disorders of blood cell production, such as myelodysplastic syndrome and some forms of aplastic anemia 
are also associated with increased apoptotic cell death within the bone marrow (12). These disorders could 
result from the activation of genes that promote apoptosis, acquired deficiencies in stromal cells or 
hematopoietic survival factors. 
Exploration of Death 
     Aware that death was still to be feared, researchers started to explore cell death. This was the only way to 
face cell death disorders and fight them. Cell death was thus taken apart. Apoptosis and necrosis were analyzed 
in their small details. Scientists realized that there was no good and bad cell death. Apoptosis was not 
necessarily a good way to die and necrosis a bad way to die. Moreover, a distinct demarcation could not be 
designated between the two deaths (13). If damage is too violent, cells have no choice but to undergo the 
genetically uncontrolled necrotic form of death. On the other hand, when damage is subtler biochemical signals 
will decide whether the cell may continue to live or should die. In this case, death normally occurs through 
apoptosis. The reality is usually somewhere in the middle.  
 
THE PROGRAMMED CELL DEATH OR APOPTOSIS 
     Navigation into meanders of cell death brought scientists to face a death process encoded by the organism 
for the sole purpose of killing its own cells. The great majority of our cells are destined to die by just such a 
physiological process. The programmed cell death that occurs as part of normal mammalian development was 
first observed nearly a century ago (14), but the idea that animal cells had a built-in death program was 
generally accepted only 20 years ago (15). Biologists started to appreciate that the regulation of apoptosis is just 
as complex as the regulation of cell proliferation only at the beginning of the nineties (16). 
     The evolution of multicellularity and cell specialization brought with it a need for the regulation of cell death 
by intracellular signaling (17). Genetic studies in the nematode Caenorhabditis elegans identified genes that 
seem dedicated to the death program and its control. Although diverse signals can induce apoptosis in a wide 
variety of cell types, a number of evolutionarily conserved genes regulate a final common cellular suicide 
pathway that is conserved from worm to human (18, 19). 
     Apoptosis results in cytoskeletal disruption, cell shrinkage, and membrane blebbing. Apoptosis also involves 
characteristic changes within the nucleus. The nucleus undergoes condensation as endonucleases are 
activated and begin to degrade nuclear DNA. In many cell types, DNA is degraded into DNA fragments the size 
of oligonucleosomes, whereas in others larger DNA fragments are produced. Apoptosis is also characterized by 
a loss of mitochondrial function. The dying cells maintain their plasma membrane integrity. However, alteration 
in the plasma membrane of apoptotic cells signals neighboring phagocytic cells with specific receptors (20) to 
engulf them and thus complete the degradation process. Cells not immediately phagocytosed break down into 
smaller membrane-bound fragments called apoptotic bodies (16, 21). 
 
INFLAMMATORY NECROSIS 
     Another research route led to the study of inflammation-accompanied necrosis. Necrosis involves 
cytoplasmic blebbing, dilatation of the endoplasmic reticulum (ER), swelling of the cytosol, alteration of 
mitochondria, and dissolution of other organelles (22). Disruption of the cell membrane and release of cytosolic 
and nuclear proteins leads to an inflammatory response (23). 
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DEATH OF ELDERLY CELLS, SENESCENCE 
     In addition to apoptosis and necrosis, other types of cell death were also observed. Senescence is an 
irreversible program of cell-cycle arrest that is disrupted in many tumors or tumor-derived lines. Replicative 
senescence was originally defined by the observation that primary cells have a genetically determined limit to 
their proliferation potential in cell culture. Telomeres shorten during each cell division unless telomerase is 
expressed, and it is thought that some aspect of excessive telomere shortening activates cell-cycle arrest and 
other characteristics of senescence (24). 
Apoptosis Is A Complicated and Well-Regulated Process 
     Researchers started to dig into the apoptosis field by studying an animal, which usually digs into the ground. 
The worm Caenorhabditis elegans is a small (about 1 mm long) soil nematode found in temperate regions. In 
the 1960's, Sydney Brenner began using it to study the genetics of development and neurobiology (25). Since 
then, hundreds of scientists around the world have been working full time investigating the biology of C. 
elegans. C. elegans is a primitive organism, which shares many of the essential biological characteristics found 
also in human biology. The worm is conceived as a single cell, which undergoes a complex process of 
development, starting with embryonic cleavage, proceeding through morphogenesis and growth to the adult. It 
has a nervous system with a 'brain' (the circumpharyngeal nerve ring). It exhibits behavior and is even capable 
of rudimentary learning. It produces sperm and eggs, mates and reproduces. After reproduction it gradually 
ages, loses vigor and finally dies. Embryogenesis, morphogenesis, development, nerve function, behavior and 
aging, and how genes determine them: the list includes most of the fundamental mysteries of modern biology. 
     C. elegans has been used as a model system to study the genetics of apoptosis (26). Ced-3 was identified 
as the most important protein among the 14 gene products that have been characterized as important for the 
process of programmed cell death (27, 28). The discovery that the structure of Ced-3 was closely similar to 
Interleukin-1β Converting Enzyme (ICE), a cytoplasmic protease responsible for the cleavage of the inactive 
precursor cytokine IL-1β to the mature pro-inflammatory active cytokine in mononuclear cells, suggested that 
ICE might represent a mammalian counterpart of Ced-3 and therefore might play a role in apoptosis (29). IL-1β 
was cleaved at the Asp 116 residues by ICE, also called caspase-1, which was identified as the prototype of a 
new family of cytoplasmatic endoproteinases (30). Transfection of ICE into mammalian cells was shown to 
induce apoptosis through the Fas pathway (31). Cells without measurable ICE proteins were still able to 
undergo apoptosis induced by gamma-irradiation, viral infection, or addition of various drugs or biosynthetic 
inhibitors. This precluded the presence in the cells of enzymes similar to ICE, able to induce cell death (32). 
A caspase family was then characterized. Caspases were recognized as the executioners of apoptosis. Once 
activated, cells are committed to death. Fourteen mammalian members of this protease family have been 
identified so far (Table 1) (33-35). Sequence analysis and X-ray cristallography data suggested that all 
caspases (Cysteinyl ASPartate-specific proteASE) share common structures within three domains: An N-
terminal prodomain, a large subunit containing the active site cystein within a conserved QACXG motif, and a C-
terminal small subunit. An aspartate cleavage site separates the prodomain from the large subunit, and an 
interdomain linker containing one or two aspartate cleavage site separate the large and the small subunit 
(Figure 1). Activation involves proteolytic processing between small and large domains, followed by association 
of the large and small subunit to form heterodimer, usually accompanied by the removal of the prodomain. 
Homodimerization of two caspases will follow catalytic cleavage, where both homodimers contain an 
independent active site (Figure 2).  
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 Table 1  Caspase family members
14 mammalian members of this family have been identified. All these proteins have
similar structure. The table describes the characteristics of the single caspases.
Zymogen Size of prodomain
and activated form
(kDa)
Contained
motif
Adaptor
molecule
Tetrapeptide
preference
Apoptotic Initiators P1 P2 P3 P4
Caspase-2 51 ý  20 / 12 CARD RAIDD D Q Q D
Caspase-8 55 ý  18 / 11 DED FADD V E T D
Caspase-9 45 ý  17 / 10 CARD Apaf-1 P E P D
Caspase-10 55 ý  17 / 12 DED FADD I E A D
Granzyme B I E T D
Apoptotic Executioners
Caspase-3 32 ý  17 / 12 I E T D
Caspase-6 34 ý  18 / 11 T E V D
Caspase-7 35 ý  20 / 12 I Q A D
Cytokine Processors
Caspase-1 45 ý  20 / 10 CARD W F K D
Caspase-4 43 ý  20 / 10 CARD W V R D
Caspase-5 48 ý  20 / 10 W V R D
Caspase-11 42 ý  20 / 10 D
Caspase-12 50 ý  20 / 10 D
Caspase-13 43 ý  20 / 10 D
Caspase-14 30 ý  20 / 10 D
Invertebrate Caspase
CED-3 56 ý  17 / 14 CARD CED-4 D S V D
DCP-1g 36 ý  22 / 13 D
 
N-peptide Large subunit Small subunitQACXG
P1  P2  P3  P4
DED
CARD
DED
CARD
Figure 1  Caspase Structure
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(36) 
Figure 2  Caspase activation by proteolysis and zymogenicity
Pro-caspases are stored in the cells in an inactive zymogen form. Activation usually
proceeds in all caspases by cleavage at the conserved Asp-297. The small and the
large subunit associate and the functional active site is localized in the white circle.
Frequently an N-terminal peptide is removed. For their activation caspases have to
homodimerize. Both homodimers contain a substrate binding site (Black peptide in the
3D representation (36))
LARGE
SUBUNITS
SMALL
SUBUNITS
N-PEPTIDE
LARGE
SUBUNIT
SMALL
SUBUNIT
Proteolytic
 Activation
 
     Caspases are the most specific proteases, with an absolute requirement for cleavage after aspartic acid. The 
recognition of a tetrapeptide pocket is also a necessary requirement for efficient catalysis. Substrate specificity 
of caspases has been extensively studied by using synthetic tetrapeptides (37) (Figure 1). The tertiary structure 
may also influence the substrate recognition. Cleavage of proteins by caspases is not only specific, but also 
highly efficient (Kcat /K m > 106 M-1S-1). Caspase prodomains also vary in length and sequence. Long prodomains 
function as signal integrators and promote interactions with activator molecules. Caspases involved in apoptosis 
are divided into two groups: initiator caspases (2, 8, 9 and 10), which generally act upstream of the small 
prodomain apoptotic executioner caspases (3, 6 and 7) (38). By contrast caspase-1 and 11 function 
predominantly as cytokine processors (39, 40). Less is known about caspase 4, 5, 12, 13 and 14. 
 
THE DECISION IS TAKEN: CASPASE ACTIVATION   
     Caspases are the executioners in the apoptotic process. What is the triggering event inducing these slayers 
to kill? Caspases are constitutively expressed in living cells as inactive zymogens. Zymogenicity represents the 
ratio of activity of the cleaved form compared to the zymogen form (Table 2). Initiator caspases zymogenicity in 
fact is low, indicating that cleavage is not essential for their initiation, implying another mechanism for the 
cascade activation. In contrast executioner caspases requires processing for their activation. Evidence suggests 
caspase activation may proceed by autoactivation, transactivation or proteolysis by other proteinases (41). (42) 
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Protease Zymoge nicity
Caspase-3 >10 ,000
Caspase-8 100
Caspase-9 10
Trypsin >10 ,000
Table 2  Zymogenicity is defined as the ratio of the activity of a processed
protease to the activity of the zymogen on any given substrate (42). Data for trypsin
is taken from ref. (42).  
 
According to these observations, caspase oligomerization is thought to be important for caspase activation. 
Vicinity allows autoactivation of the initiator caspases, which consequently activate the executioner caspases in 
the apoptotic cascade. Forced oligomerization of Caspase-9, -8 or Ced-3 has been shown to promote apoptosis 
(43-45). 
      In vivo adapter molecules mediate oligomerization of long prodomain caspases. The pro-caspases have 
been demonstrated to possess low but detectable proteolytic activity. Once activated, caspases transactivate 
other procaspases, providing the opportunity for cascade amplification and positive feedback. Caspase-8 
efficiently activates caspase-3 (Kcat /K m > 8.7 × 105 M-1S-1) and caspase-3 in turn may activate procaspase-8 
(46). Caspases can be activated also by non-caspase proteinases such as granzyme B, which is excreted by T 
cells in immunologic response (47). Granzyme B is also an aspartate-specific serine protease, which can 
activate several caspases and induce apoptosis (48). 
 
ACTIVATION OF THE CASPASES CASCADE BY GATHERING 
     In order to be efficient, caspases require adaptor molecules, which are essential to bring initiator caspases 
together to induce their activation by vicinity. Induction of the interaction is triggered by proapoptotic signals. 
Specific domains mediate the binding. Activation of caspase-8 requires association with its cofactor FADD (Fas-
Associated protein with Death Domain) through death effector domains (DED), also found in caspase-10 (49, 
50). Procaspase-9 activation involves the formation of a complex with cofactor Apaf-1 (APoptotic Activating 
Factor-1) through the CAspase Recruitment Domain (CARD), present also in procaspase-1, -2, -4, and –5 (51). 
Hydrophobic interactions are important for DED-DED binding, whereas electrostatic interactions are critical for 
CARD-CARD binding. The result in each case of caspase recruitment is the formation of a complex called 
“apoptosome”, whose functions to mediate the activation of caspases (52). 
     Activation of initiator caspases by binding to cofactors and not by cleavage may play a role in the prevention 
of undesired activation of the cascade.  Due to the intrinsic activity possessed by pro-caspases, unexpected 
activation by cleavage could happen. Association instead is more controllable, and the ability of adapter 
molecules to activate the caspases can be regulated by other proteins that appear to directly interact with the 
adapter or with the caspases itself, as for example the inhibitor of apoptosis IAP. Zymogenicity data on initiator 
caspases supports this hypothesis (41). 
 
THE APOPTOTIC PHENOTYPE IS CAUSED BY SPECIFIC PROTEIN CLEAVAGE 
     What is surprising in apoptosis is that the caspase pathway takes place in the interior of a cell. The fact that 
proteolytic activity inside the cell is responsible for its demise suggests that the main role of caspases is to 
destroy intracellular proteins in such a way that the cell would not be able to function (53). In fact, one of the 
roles of caspases is to inactivate proteins that protect living cells from apoptosis. Cleavage of DNA-Protein 
Kinase, U1 snRNP-70K, ATM, PARP, proteins involved in DNA repair, splicing and replication prevent the 
induction of repair in cells targeted to apoptosis (54, 55). Another example is the cleavage of ICAD/DFF 45, an 
inhibitor of the nuclease responsible for DNA fragmentation CAD (Caspase-Activated Deoxyribonuclease). CAD 
is usually present as an inactive complex with ICAD. During apoptosis, caspases cleave ICAD and release active 
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CAD enzyme, which promotes chromatin condensation (56, 57). Caspases also cleave structural proteins of the 
nucleus and cytoskeleton such as lamin, fodrin, keratin, and actin, thus promoting cellular packaging and 
subsequent engulfment and phagocytosis (58, 59). Also negative regulators of apoptosis are cleaved and 
inactivated, such as Bcl-2 family members (60). Cleavage appears not only to inactivate these proteins, but the 
products seem to promote apoptosis (61). 
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Figure 3  Extrinsic Pathway
Five death receptors have been characterized. This picture describes the most
common and best known mechanism leading to cell death, the Fas/Fas ligand
pathway. The ligand binds to the receptor, which trimerizes and gets activated.
Interaction with docking molecule FADD through Death Domains (DD), allows
activation of pro-caspase-8 by binding through Death Effector Domains (DED). Once
activated casapse-8 dimerizes and can activate the apoptotic cascade. The Death
Inducing Signaling Complex (DISC) was isolated with anti-Fas antibodies.
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 Caspases Activated by Signaling Events 
     Many signaling pathways leading to apoptosis have been described. Extracellular and intracellular roads 
inducing activation of caspases have been characterized. What is common for all these pathways is the 
requirement of a death signal that activates apoptosis, leading to cytochrome c release or Fas ligand activation 
to induce the apoptosome formation and the subsequent caspase cascade activation.  
 
THE RECEPTOR-MEDIATED EXTRINSIC PATHWAY 
     As an extrinsic pathway, it is considered activation going through signals coming from the outside of the cell. 
This is the best-understood cell death pathway and it involves the binding of ligands to death receptors. Most of 
the progress in defining the extracellular signaling mechanism regulating apoptosis has been made by studying 
hematopoietic cells. 
Five death receptors have been described so far in mammalian cells: Fas/CD95, TNFR1, DR3 (Apo-
3/WS1/TRAMP/LARD), DR4, and DR5 (Apo 2R/TRIAL-R2/TRICK-2/KILLER), of the Tumor Necrosis Factor 
(TNF) receptor family, characterized by cystein-rich pseudorepeats in the N-terminal extracellular domain. The 
death-inducing receptors share a related intracellular sequence known as the death domain (DD) (38). After 
ligand binding, the receptor trimerizes and associates with cytoplasmatic adapter molecules containing DD (62-
64). Three of these proteins are known: FADD, RIP (Receptor Interacting Protein), and TRADD (TNFR1-
Associated Death Domain). FADD and RIP interact directly with Fas, whereas TRADD appears to bind TNFR1. 
Overexpression of any of these proteins induces apoptosis. TNF engagement causes TNFR1 activation, binding 
to TRADD molecule and complex formation with FADD. FADD, as already mentioned, is able to activate 
caspase-8 (Figure 3) (65). Anti-Fas antibodies, which are able to trigger apoptosis, have been used to isolate 
the components of DISC (Death Inducing Signaling Complex), consisting of Fas receptor, FADD molecule and 
caspase-8 (43, 66). All these receptors, depending on the signals they receive from the environment, can 
determine whether to induce apoptosis or to send survival signals. For example, TNFR1/TRADD complex is 
able to induce NF-κB activation, which suppresses TNF-α-induced apoptosis (67). 
 
THE INTRINSIC PATHWAY 
     Similar to the extrinsic pathway, the intrinsic pathway requires a triggering event leading to caspase 
recruitment by the adapter molecule Apaf-1.  
This triggering event has been identified as the release of cytochrome c from the mitochondria. 
 
THE ESSENTIAL ROLE OF MITOCHONDRIA 
     The principal function of mitochondria is to generate energy in the form of ATP by oxidative phosphorylation 
(Figure 4). However, mitochondria play a very important role in apoptosis. The oxidative phosphorylation 
proteins are located in the inner membrane of mitochondria. Electron-transport chain proteins, ATP synthase 
and adenine nucleotide translocator (ANT) oxidizes hydrogen from organic acid to generate H2O. Several 
respiratory complexes mediate the reaction and as an end-product two molecules of water are produced from a 
molecule of O2. The energy released is used to pump H+ outside the inner membrane of the mitochondria to 
create a transmembrane potential (∆Ψm). This leads to acidification of the intermembrane space of 
mitochondria and alkalization of the mitochondrial matrix. Depolarization of the membrane through F0/F1 ATP 
synthase is used for the production of ATP. One of the components of this machinery is cytochrome c, located 
in the intermembrane space. Its function is to catalyze the electron transfer from complex III to complex IV in 
oxidative phosphorylation reaction (68). 
Under certain conditions, such as a consequence of specific stimuli, cytochrome c is released into the cytoplasm 
and this event is sufficient to trigger caspase recruitment by Apaf-1 and activation of the caspase cascade. The 
importance of mitochondria in apoptosis was suggested by studies with a cell-free system in which nuclear 
condensation and DNA fragmentation were found to be dependent on the presence of mitochondria (69). 
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The key role of cytochrome c in the induction of caspase was again demonstrated in a cell-free system, where 
activation of caspase was triggered by the presence of cytochrome c and of deoxyadenosine triphosphate (70). 
Cytosolic cytochrome c binds to Apaf-1 (a chaperon-like protein), inducing a conformational change, allowing 
the binding of dATP to Apaf-1 (71) that further induces a conformational reorganization of the Apaf-1 molecule 
allowing recruitment of procaspase-9 in the apoptosome complex. This led to dATP hydrolysis-dependent 
caspase-9 autoactivation by cleavage, and the cascade proceeds through cleavage of caspase-3 (Figure 5) 
(72). The importance of cytochrome c in the apoptotic pathway was recently confirmed in cell lines derived from 
cytochrome c knockouts mice, where caspase-3 failed to be activated by different stimuli, such as UV-
irradiation, serum starvation, and staurosporine (73). 
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Cytochrome c release also disrupts the electron transport chain with consequent impairment of the production of 
energy. Although a drop in ATP production has been observed during apoptosis, it often occurs late in the 
process (71). This same event will increase the generation of reactive oxygen species, which are potent 
cytotoxic agents (74). With cytochrome c, other molecules are released from mitochondria during apoptosis. 
Apoptosis Inducing Factor (AIF) translocates to the nucleus and induces chromatin macrocondensation (75). 
Also procaspase-2 and –9 have been shown to be released during mitochondria damage (76). 
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     Recently a novel molecule was found to be released from mitochondria during apoptosis, the so-called Smac 
(the Second Mitochondria-derived Activator of Caspases) (77) or DIABLO (Direct IAP Binding protein with low 
pI) (78). Smac/DIABLO is likely the functional equivalent of Drosophila Reaper, Hid, and Grim (79-81). It 
neutralizes the anti-apoptotic function of IAP molecules. 
 
RELEASE OF THE DEADLY CYTOCHROME C  
     Several mechanisms have been proposed for the release of cytochrome c from mitochondria. The main 
difference is the association of loss of membrane potential to the release of cytochrome c. Opening of the 
permeability transition (PT) pores and swelling produce a drop in the ∆Ψm, whereas Bax-pores allow the 
release of cytochrome c without affecting the ∆Ψm. 
     In general, small molecules can diffuse freely through the outer membrane of mitochondria. The inner 
membrane is impermeable to small ions. In many apoptotic scenarios, the mitochondrial inner transmembrane 
potential collapses, indicating the opening of the PT pores. The structure of the megachannels is still only 
partially defined. The PT pore is thought to be composed of several proteins, including hexokinases, 
mitochondrial creatine kinase, a voltage-dependent anion channel (VDAC) present on the outer membrane, and 
the inner membrane adenine nucleotide transferase (ANT) and the matrix cyclophillin D (CD). Finally, Bax was 
found to be part of this complex (Figure 4) (82). 
     Following PT pore opening, water and small solutes up to 1.5 kDa would enter the mitochondria. This allows 
a non selective movement of ions within matrix and intermembrane space of mitochondria, dissipating the H+ 
gradient, uncoupling the respiratory chain. The ∆Ψm and the oxygen consumption drop. PT pore formation 
results in a volume deregulation of mitochondria, due to the hyperosmolarity of the matrix, and in swelling. 
Because of the flexibility of the inner membrane compared to the stiff outer membrane, expansion can cause the 
rupture of the outer membrane, releasing apoptotic-activating proteins (83).  
     Recent studies have provided evidence that cytochrome c release and caspase activation can occur prior to 
detectable loss of ∆Ψm, implying that PT pore may open downstream of apoptosome-mediated caspase 
activation (84). Probably in these cells an excess of cytochrome c is present, so that enough cytochrome c 
remains docked to cytochrome c oxidase to maintain electron transport.  
     Cytochrome c release may also occur by a different mechanism. Bcl-2 family members have been 
demonstrated to insert in mitochondrial membranes (85). These molecules, with high structural affinity with 
some types of bacterial toxins, can form ion channels in membranes (86). Bax is a candidate for the formation of 
this channel in the outer membrane. Recently it was shown that addition of Bax or Bak to liposomes containing 
VDAC allows passage of cytochrome c through the VDAC channel (87). Mitochondrial ATP synthase was also 
shown to affect Bax activity. In addition oligomycin, an ATP synthase inhibitor, abrogates Bax killing. However it 
is not known if Bax induced cytochrome c release requires ATP synthase (88). Bax toxicity was reduced in yeast 
mutant strains lacking the ability to perform oxidative phosphorylation (89). Other molecules other than Bax and 
VDAC may constitute the putative cytochrome c channels. 
 
THE TWO PATHWAYS COOPERATE TO ENHANCE THE POWER OF KILLING 
     Intrinsic and extrinsic pathways are two distinct roads leading to cell death, but they can interact to increase 
the strength of apoptotic signals (Figure 6). It has been reported that caspase-8, once activated through Fas 
ligand binding to receptor, can cleave Bid, a Bcl-2 family member. Bid cleavage can directly induce cytochrome 
c release from mitochondria, activating caspase-9 (84). It has been demonstrated that in some experimental 
systems, the release of cytochrome c can be prevented with caspase inhibitors (90). It is controversial if the 
extrinsic pathway really requires the involvement of mitochondria. So the idea of two different cell types 
developed. In “type I” cells, death receptor signaling is not blocked by Bcl-2 and in “type II” cells it is (91). Bid is 
cleaved by active caspase-8, and the activated truncated Bid targets mitochondria to trigger Bax oligimerization 
and cytochrome c release (39). A new scenario was recently proposed where Bid induces the release of 
Smac/DIABLO molecule, which targets IAP and set the active caspase-3 free. Cytochrome c may not be 
relevant in this particular case (92). 
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Taking the Decision of Death 
     The extrinsic pathway can be triggered by any signal activating the death receptors. Intracellular mediators 
will decide if the cell has to undergo apoptosis or promote cell survival. The intrinsic pathway appears to be 
more complicated and is not fully understood. Several events may induce caspase activation within the cell. 
Growth factors, cytokines and DNA damage appear to signal cell death through the mitochondria, and this 
pathway is the target of many oncogenic mutations. 
 
A GENE INVOLVED IN THE TRIGGERING OF APOPTOSIS: p53 
     p53 was the first tumor suppressor gene related to apoptosis. p53 mutations occur in the majority of human 
tumors and are often associated with an advanced tumor stage and poor prognosis. p53 has a remarkable 
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number of biological activities including a central role in cell-cycle checkpoint, maintenance of genomic integrity, 
control of angiogenesis. However, p53 can also induce apoptosis (93). Growth arrest proceeds through 
induction of the cyclin-dependent kinase (Cdk) inhibitor p21 (94). In contrast, the mechanism by which p53 
promotes apoptosis is more obscure. Nevertheless genes involved in cell death differ from those implementing 
growth arrest. One of the p53 targets implicated in apoptosis could be the Bcl-2 antagonist Bax (95). 
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p53 is implicated in cell responses to a variety of cellular insults: DNA damage, heat shock and expression of 
oncogenes such as Myc and E1A (96-98). When DNA damage occurs (1), the cell must decide to repair the 
damage or to undergo apoptosis. In both cases, DNA-PK (99), ATM (100) and other kinases are activated by 
DNA damage (2), and phosphorylate p53 and HDM2 (3) (101). p53 is a constitutively expressed gene and p53 
protein is present at low levels in the nucleus of undamaged cells associated with HDM2, which targets p53 for 
proteasome degradation (102). After phosphorylation, p53 dissociates from HDM2, tetramerizes (4) and induces 
transcriptional activation of target genes, such as p21, HDM2 and GADD42 (5-7) (95, 99). One of these gene 
products, Bax, probably translocates to mitochondria and induces cytochrome c release (95). 
 
COULD OTHER CELLULAR SIGNALS INDUCE APOPTOSIS? 
     The extrinsic and the intrinsic pathways are the two most common routes leading to apoptosis. Nonetheless, 
in some cells different mechanisms could be used to activate apoptosis. Synthetic peptides containing the 
arginine-glycine-aspartate (RGD) motif used as an inhibitor of integrin-ligand interaction in studies of cell 
adhesion, migration, growth and differentiation, were shown to be able to directly induce apoptosis, without any 
requirement for integrin-mediated cell clustering or signals. RGD motif is an integrin-recognition motif found in 
many ligands. The peptides containing RGD enter cells and directly induce autoprocessing and enzymatic 
activity of procaspase-3. Procaspase-3 contains a potential RGD-binding motif, an aspartate-aspartate-
methionine near its processing site. RGD probably induces apoptosis by triggering conformational changes in 
procaspase-3. After binding of RGD, a “safety catch” sequence in the small domain of procaspase-3 moves 
from its natural position, allowing caspase-3 auto-activation. Requirement of caspase-3 in RGD-mediated cell 
death was demonstrated with functional deletions of caspase-3 gene (103).  
     A pH-dependent mechanism of activation of procaspase-3 was also recently postulated. Low acidic pH (6) 
might be able to induce a conformational change in the structure of procaspase-3 inducing a N-terminus 
intermediate, which leads to its cleavage and to activation of caspase-3 (104).  
Regulation of Apoptosis Prevents Undesired Surprises  
     Apoptosis is a very important mechanism that must be strictly controlled to avoid undesired cell death or 
unprogrammed cell overgrowth. For these reasons the cells have evolved different checkpoints to regulate this 
event. 
 
BCL-2 FAMILY MEMBERS 
     The cloning and characterization of the Bcl-2 oncogene helped to establish the importance of apoptosis in 
tumor development. The first mammalian death regulator to be identified, Bcl-2, was discovered as a proto-
oncogene in follicular B-cell lymphoma (105). A chromosome translocation affecting the Bcl-2 gene locus was 
found to allow cell survival of cytokine-dependent hematopoietic cells, in a quiescent state in the absence of 
cytokine (106). Further studies demonstrated that Bcl-2 promotes cell survival by blocking programmed cell 
death (107). Bcl-2 was found to be a functional and structural homologue to the C. elegans Ced-9 molecule 
(18). Bax (Bcl-2 Associated protein X) was the first pro-apoptotic member of the family discovered by 
coimmunoprecipitation with Bcl-2 (108). These genes were subsequently found to be part of a larger family, 
positively and negatively affecting apoptosis. The Bcl-2 family proteins constitute a critical intracellular 
checkpoint of apoptosis. The anti-apoptotic members of this family are Bcl-2, Bcl-XL, Mcl-1, Bcl-w, Boo, Baf, Bag 
and A1. The pro-apoptotic members so far identified are Bax, Bcl-XS, Bak, Bad, Bid, Bim, Bik, Bok, Blk, EGL-1, 
BNIP3, Noxa, and Harakiri. The Bcl-2 family has also homologues in DNA viruses: E1B-19K gene of 
adenovirus, BHRF1 gene of EBV, LMVS-HL genes of the African swine fever virus. The amino acid sequence 
homology between the Bcl-2 family members is low, and only confined to four specific regions called the Bcl-2 
Homology (BH) domains. These domains control the ability to homodimerize and heterodimerize, which is an 
important feature in regulation of apoptosis (Figure 8) (108, 109). BH1 and BH2 are required for Bcl-2 and Bcl-
XL interaction with Bax to suppress apoptosis (110). BH3 domain of pro-apoptotic proteins is sufficient for the 
binding to anti-apoptotic Bcl-2 and Bcl-XL to promote apoptosis (111). BH4 is found in the N-terminal region of 
anti-apoptotic proteins only. Mutants lacking BH4 loose their anti-apoptotic ability and also gain pro-apoptotic 
functions. Some of the Bcl-2 family members display a hydrophobic amino acid sequence at the C-terminus, 
probably involved in membrane interaction (61). The tri-dimensional structure of Bcl-XL and Bid has been 
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elucidated. It showed a structural homology to pore-forming domains of certain bacterial toxins, as colicins A 
and E1 (112-114). These bacteria toxins are pore-forming proteins that function as channels for ion and small 
proteins. As predicted by their structures, Bcl-2, Bcl-XL, and Bax can form ion-channels when they are added to 
synthetic membranes (85, 86, 115).  
     There is a pretty good evidence that Bcl-2 family proteins may play a role directly in the formation of the 
channels in mitochondrial membrane leading to release of cytochrome c, and this may explain their role in the 
regulation of apoptotic events (unpublished data). These proteins act as a checkpoint upstream of caspases and 
mitochondrial dysfunction. The multiconductive channels formed by Bcl-2 family proteins are pH sensitive, 
voltage-dependent, with poor ion selectivity. Bcl-2 and Bcl-XL channels are more prone to be cation selective 
and Bax channels anion selective at physiological pH. Bax can form pores at physiological pH, whereas Bcl-2 
requires low pH. Bax pore forming ability depends on the membrane’s lipid composition, and this could serve as 
a regulatory mechanism (116). (117) 
Figure 8  Bcl-2 family members, BH domains
Several Bcl-2 family members have been discovered and their structure has been
characterized. The family has been divided in two major subfamilies, pro- and anti-
apoptotic members. We can further divide the pro-apoptotic in Bax and BH3
subgroups. Bcl-2 homologous (BH) domains are characteristic for each subfamily. BH
domains of Bcl-XL are represented in the 3D structure (117).
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Bax can only form channels as an oligomer. Oligomerization results after a conformational change possibly 
triggered by Bid or by other BH3 domain containing proteins (116, 118, 119). Bax can directly induce 
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cytochrome c release from mitochondria, which can be prevented by Bcl-2. Bcl-2 may inhibit Bax insertion in 
mitochondria or may directly inhibit the Bax channel activity (120). Bcl-2 can also prevent PT pore opening by 
increasing proton efflux from matrix, inhibiting mitochondria respiration, which prevents free radical formation 
(121). This would explain the anti-toxicity properties attributed to Bcl-2 (122, 123). Because Bax 
homodimerization can lead to apoptotic death and Bcl-2 overexpression induces heterodimerization with Bax 
and death repression (108), the ratio Bcl-2/Bax is important in the determination of apoptosis susceptibility. 
Compartmentalization may also play a role in this process. Bcl-2 family members have been shown to be both 
membrane associated and cytosolic. A few years ago, the C-terminal domain of Bcl-2 family members, was 
thought to be responsible for the attachment to membranes, so that proteins containing this hydrophobic 
sequence were supposed to be membrane associated. New research demonstrated that this does not appear to 
be an absolute rule (124). Bcl-2 may also associated with ER, nuclear envelope and mitochondrial membranes, 
and Bcl-XL and Bax with C-terminal domains are found in the cytosol. Localization of Bcl-2 family proteins 
changes during apoptosis. It is possible that under normal conditions the hydrophobic domain is protected, 
localizing the molecule in the cytosol and after conformational change and exposure of the domain the protein 
translocate to mitochondrial membrane (118). Other modifications could induce relocalization of these proteins. 
Phosphorylation and proteolysis regulate the activity of some Bcl-2 family members. Bcl-2 has been reported to 
undergo extensive phosphorylation, affecting its relocalization and proteasome degradation in many occasions 
(125, 126). The kinase responsible for Bcl-2 phosphorylation has not been fully identified. A good candidate 
could be c-Jun N-terminal Kinase/stress-activated protein kinase (JNK), which is activated by several known 
stimuli (127). Other kinases such as Raf, ASK1, and ERK1/2, have been shown to phosphorylate Bcl-2 (128).  
     Bcl-2 family members can regulate apoptosis also at levels other than the mitochondria. For example, Bcl- XL 
may inhibit the association of Apaf-1 to procaspase-9 and prevent caspase-9 activation (129). Pro-apoptotic 
molecules like Bik may release Apaf-1 from the inhibition (130). Bcl-2 was also shown to protect cells after 
cytochrome c microinjection suggesting an inhibitory event at Apaf-1/procaspase-9 level (131).  
 
IAPs 
     IAPs are proteins that work as direct caspase inhibitors. IAPs were discovered during work on viruses. Very 
often, viruses attenuate apoptosis to circumvent the normal infection response. Three classes of viral inhibitors 
have been described: Crm A (132), p35 (124), and IAP family (Inhibitors of Apoptosis) (18). Crm A is a member 
of the serpin family that is a potent inhibitor of active initiator caspases involved in inflammation. The baculovirus 
p35 has no known homologies and its selectivity for caspases is not clearly defined (133). The IAP proteins are 
a large family that also has mammalian homologues. IAPs were first discovered in baculoviruses, a group of 
insect viruses. The IAP family is characterized by a novel ~70 amino acid domain containing Baculoviral IAP 
Repeat (BIR), up to three tandem copies (134). Another region of IAP, the RING domain, acts as a ubiquitin 
ligase, promoting the degradation of XIAP (135) and possibly any caspase it is bound to (92). The human c-
IAP1 and c-IAP2 contain a CARD domain. Six IAP relatives have been defined in humans: XIAP, c-IAP1, c-
IAP2, NAIP, Survivin, and BRUCE. Overexpression of IAPs has been shown to suppress apoptosis induced by 
a variety of stimuli, including TNF, staurosporin, taxol, and growth factor withdrawal. Several human IAPs 
directly inhibit caspases (136). Inhibition by IAPs may work by increasing the threshold that determines the 
concentration of active effector caspases required to initiate the cascade, thus preventing the consequence of 
accidental or spontaneous proenzyme activation (137), they may serve as endogenous “brakes” of apoptosis. 
 
AKT 
Phosphorylation, which plays an important role in the regulation of Bcl-2 family members, may be involved in the 
regulation of the caspase cascade directly (1). The ability of endogenous factors to promote survival, for 
example nerve growth factor in sympathetic neurons, has been attributed partly to the phosphatidyl-inositide 3'-
OH Kinase (PI3K)/c-Akt kinase cascade (138). Recent data have implicated PI3 kinases and their phospholipid 
products in promoting survival downstream of extracellular stimuli (139). PI3K was first implicated in the 
suppression of apoptosis in a study by Yao (140) in which Akt was identified as the general mediator of survival 
signals. Akt itself requires phosphorylation for its activity (141). Akt may target directly apoptotic molecules as 
caspase-9 and Bad inhibiting their pro-apoptotic activity (142, 143). 
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CLL: A Beautiful Primary System To Study Apoptosis 
     Chronic lymphocytic leukemia (CLL) is a neoplasm of B-lymphocytes occurring predominantly in older 
persons with an average age between 60 and 70 years. In some cases (about 10 %) it has occurred in younger 
patients. B-CLL is classified along with indolent lymphoma. It is the most common leukemia in the Western 
World. Non-Hodgkin's lymphoma is a malignant (cancerous) growth of B or T cells in the lymph system. The 
Non-Hodgkin's lymphomas encompass over 29 types of lymphoma. The distinctions are based on the type of 
cancer cells. There are classification systems that group lymphomas by cell type and rate of growth. The US 
National Cancer Institute now splits lymphomas into aggressive (fast growing) and indolent (slow growing).     / 
G1
     CLL represents a perfect example of a human malignancy, which is caused primarily by defects in 
programmed cell death, rather than cell cycle deregulation. CLL patients typically accumulate CD5+, non-
responsive, growth-arrested B-cells that express little or no surface IgG. These mature circulating B-
lymphocytes are largely quiescent G0/ G1 phase cells, which accumulate not because they are dividing more 
rapidly than normal, but because they survive longer (144). Studies of apoptosis regulation in CLL may serve as 
a model not only for B-CLL, but also for eventually overcoming chemoresistance and inhibiting cancer cell 
survival in more common types of malignancies, including solid tumors.  
     The advantage of CLL is that the cells are essentially quiescent or very slowly proliferating. Therefore the cell 
cycle machinery, which is usually the conventional target of anti-cancer drugs, does not affect the study of drug-
induced apoptosis. Primary B-CLL lymphocytes are used in our experiments as the system to analyze the 
apoptotic process.  
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DESCRIPTION AND SIGNIFICANCE OF THE PERSONAL CONTRIBUTIONS 
 
     In this thesis we tried to characterize the mechanism of action of newly synthesized drugs, of old drugs 
whose mechanism was unknown or applied for the treatment of other diseases. 
The system we used is B-CLL, because these cells are a slowly proliferating primary system and because of the 
availability of millions of cells from a single patient. 
 
     The first set of drugs we started to analyze were the purine nucleoside analogs. For years cladribine and 
fludarabine were used for the clinical treatment of B-CLL, but their detailed mechanism of action was not fully 
understood. In a series of articles that were first published in 1995, Xiaodong Wang proposed a novel 
mechanism for the initiation and execution of apoptosis. He identified the partners forming the apoptosome 
complex (Apaf-1 / cytochrome c / caspase-9) and demonstrated that dATP or ATP was absolutely required for 
the activation of this apoptotic cascade (70). In our research, we demonstrated that 2CdATP was also able to 
activate in a cell-free system the apoptosome complex, substituting dATP, and that this activity is essential in 
the mechanism of action of cladribine in B-CLL cells [Paper 1]. We further investigated if other clinically relevant 
tri-phosphate versions of nucleoside analogs had the same ability to activate caspases in a cell free-system. We 
ranked several of these drugs for their “apoptosome activation” potency, determining their enzymatic kinetics for 
caspase activation. Interestingly we also found ADP and ATP to be inhibitors of the dATP-induced activation of 
the apoptosome complex [Paper 2]. To understand the mechanism of the ADP/ATP inhibition, we investigated 
the possible role of caspase-9 phosphorylation by Akt kinase (142). We determined, using 35S-in vitro translation 
of caspase-9 experiments, that ATP acted exclusively as competitive inhibitor of the complex Apaf-1 / 
cytochrome c / caspase-9 and did not affect the Akt kinase. We also demonstrated that phosphorylation of 
caspase-9 protected the autocatalytic processing of caspase-9 but not the feed-back cleavage by caspase-3. 
We concluded that the phosphorylation of caspase-9 has no relevant effect on its activation, because the 
binding to Apaf-1 (and not its proteolytic cleavage) is the only essential step required for its activation [Paper 3]. 
Our interest in the mechanism of action of the nucleoside analogs didn’t stop there. We were intrigued by the 
fact that, in whole cell assays, 2CdA was much more cytotoxic than fludarabine, whereas in a cell-free system, 
F-Ara-ATP was a more potent caspase activator. In order to understand this discrepancy, we measured the 
ability of several of purine deoxynucleoside analogs to induce DNA strand breaks by two methods: an alkaline 
unwinding assay to measure the total DNA strand breaks and the comet assay to measure single cell damage. 
We discovered that the DNA-damage activity of the drugs tested was comparable. We then compared their 
toxicity toward mitochondria by cytochrome c and AIF release assays, by mitochondrial membrane potential 
measurement in whole cells and in isolated mitochondria, and by immunohistochemical assays for cytochrome c 
release. We discovered that the two chlorinated analogs, 2CdA and CaFdA, were able to damage directly 
mitochondria. Direct microinjection of the nucleotide analogs in fibroblasts confirmed the mitochondria toxicity of 
the chlorinated analogs [Paper 4]. If F-Ara-A was killing the cells mainly through DNA damage, p53 had to be 
involved in its toxicity. Previous reports correlated multidrug-resistance of several cancers for DNA-damaging 
drugs to p53 status (145). In a further study, we identified a B-CLL sampler not expressing p53. We 
demonstrated that these cells were resistant to F-ara-A treatment. Further analysis confirmed that p53 appears 
to play a major role in B-CLL chemotherapy. In fact, not only is p53 required for an efficient response to F-ara-A 
treatment, but also its turnover in the cell appears to be distinct. We observed an unusual ubiquitous p53 
localization in B-CLL cells, and this might be involved in the difference response to treatments compared to 
normal PBL [Paper 5]. 
 
     Indanocine is a novel microtubule-binding drug synthesized in our lab. Indanocine showed high affinity to 
colchicine, competing for its binding site on microtubule filaments. Indanocine showed higher toxicity for 
multidrug-resistant cell lines compared to the relative wild type [Paper 6]. Similar to colchicine, indanocine also 
was able to induce apoptosis in B-CLL cells. The study of indanocine-induced apoptosis revealed the activation 
of an intrinsic pathway, with a central role for mitochondria. The triggering event appeared to be the 
phosphorylation of the anti-apoptotic protein Bcl-2, resulting in its dimerization, subcellular relocalization, and 
inactivation. In addition, pro-apoptotic molecule Bax showed relocalization from cytosol to the membrane, 
release of cytochrome c, and consequent caspases cascade activation. Simultaneously with Bcl-2 
phosphorylation, the activation of JNK kinase was observed. The kinase might be responsible for Bcl-2 
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phosphorylation [Paper 7]. To elucidate the mechanism of action of indanocine, we selected an indanocine-
resistant clone (CEM-178), from a T lymphoblastoid CEM cell line. From polymerization and depolymerization 
assays it appeared that CEM-178 had mutated tubulin. In fact the resistant cell line presented cross-resistance 
to microtubule-disrupting agents such as colchicine and vinblastine. Fusion assays proved that the mutation was 
a codominant phenotype [Paper 8]. 
 
     The non-steroidal anti-inflammatory drug etodolac, commonly used for the treatment of rheumatoid arthritis 
resulted to give relief to B-CLL patients. In vivo data showed the reduction of the circulating leukemic cell 
number when etodolac was administered to B-CLL patients. Additional study revealed that etodolac was able to 
induce apoptosis in vitro in B-CLL cells. Analysis of the pro-apoptotic mechanism of etodolac in B-CLL 
demonstrated that the nuclear receptor PPAR-γ, expressed at unexpected high levels in B-CLL cells as 
compared to normal lymphocytes, was activated by etodolac. In addition, the anti-apoptotic molecule Mcl-1 was 
rapidly down-regulated in etodolac-treated B-CLL cells. This resulted in the activation of the intrinsic pathway of 
apoptosis. Etodolac is right now in a phase II clinical trial for the treatment of B-CLL, and the results are 
extremely promising [Paper 9].   
 
     HIV virus induces the depletion of CD4+ T lymphocytes in infected patients. The mechanism used by the 
virus to kill these cells was not clear. In particular, it was not clear whether the intrinsic pathway of apoptosis or 
the extrinsic Fas-mediated activation of apoptosis were responsible for the depletion of CD4+ cells. The 
enzymatic activity of caspases suggested the activation of the intrinsic pathway. We assessed if mitochondria 
were involved, by detecting cytochrome c and AIF release by immunohistochemistry and by measuring the 
mitochondrial membrane potential. After concluding that the intrinsic pathway was activated, the next step was 
to discover which triggering event was leading to mitochondria damage. The infection of the virus and its 
integration into the DNA suggested us that p53 could be involved in the activation. In fact, p53 was activated 
and this resulted in the up-regulation of pro-apoptotic molecule Bax. Bax has already been correlated with p53-
mediated release of cytochrome c from mitochondria in different systems (95) [Paper 10]. In a collaborative 
study, we analyzed the HIV-induced gene expression of the infected cells using gene arrays. This novel 
technology allowed us to measure quantitatively and simultaneously the mRNA levels of more than 5,000 
genes. The results confirmed our biochemical data, and indicated that HIV is capable of activating the p53-
signaling pathway, and regulates mitochondrial-related genes that may be involved in apoptosis [Paper 11]. 
 
     This thesis also contains other papers resulting from collaborations not directly related to the theme of the 
thesis.  
     The first publication is in the immunology field. Dr. Albani’s group developed artificial antigen presenting cells 
(aAPC) to modulate immune response. Liposomes exposing MHC class II molecules were used to induce a 
response in T cells. Our expertise was essential in the imaging of the interaction between the aAPC and the 
target cells expressing the T cell receptor [Paper 12].  
     In another collaboration with the department of Bioengineering of UCSD, we analyzed the biological activity 
of particles released from orthopedic implants that play an essential role in the aseptic loosening of the 
prosthesis. Different materials are used for orthopedic implants, and the particles released can induce different 
response. We discovered that particles from different materials have an effect on the modulation of genes that 
code for inflammatory cytokines and for nucleus architecture. We also demonstrated that some of them can 
cause apoptosis in cells from bones (osteoblasts) [Paper 13]. 
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ABSTRACT Adenine deoxynucleosides, such as 2-chloro-2*-
deoxyadenosine (2CdA) induce apoptosis in quiescent lympho-
cytes, and are thus useful drugs for the treatment of indolent
lymphoproliferative diseases. However, it has remained puzzling
why deoxyadenosine and its analogs are toxic to a cell that is not
undergoing replicative DNA synthesis. The present experiments
demonstrate that the 5*-triphosphate metabolite of 2CdA (2CdA-
5*-triphosphate), similar to dATP, can cooperate with cyto-
chrome c and Apaf-1 to activate caspase-3 in a cell free system.
Chronic lymphocytic leukemia cells and normal peripheral
blood lymphocytes expressed both caspase-3 and apoptotic pro-
tease activating factor 1. Incubation of the lymphocytes with
2CdA induced caspase-3 activation prior to DNA degradation
and cell death. Stimulation of the caspase proteolytic cascade by
2CdA-5*-triphosphate, in the context of DNA strand break
formation, may provide an explanation for the potent cytotoxic
effects of 2CdA toward nondividing lymphocytes.
The effectiveness of cancer chemotherapy often depends upon
the induction of apoptosis in malignant cells. Among antime-
tabolites, the 29-deoxyadenosine congeners 2-chloro-29-
deoxyadenosine (2CdA, cladribine) and 9-b-D-arabinofuranosyl-
2-fluoroadenine (fludarabine) have the ability to induce apopto-
sis in nondividing lymphocytes, at concentrations that spare other
cell types (1). For this reason, the deoxyadenosine analogs have
achieved an important place in the treatment of indolent lym-
phoid malignancies, including hairy cell leukemia, chronic lym-
phocytic leukemia (CLL), and low grade lymphoma (2, 3).
The cytotoxicity of 2CdA depends mainly upon the selective
and progressive accumulation of its 59-triphosphate metabolite
(2CdATP) in lymphocytes that have a high ratio of deoxycytidine
kinase (EC 2.7.1.74) to cytosolic 59-nucleotidase (EC 3.1.3.5),
compared with other cell types (1, 4). However, why 2CdATP
triggers apoptosis in non-dividing cells is unclear.
Various stimuli of apoptosis lead to the activation in the
cytoplasm of cysteine proteases with specificity for aspartic
acid residues, referred to as caspases. The activated caspases
can cleave structural proteins and enzymes necessary for the
survival of both proliferating and resting cells (reviewed in
refs. 5–7). In addition, caspases have been shown to activate
the endonuclease responsible for the internucleosomal cleav-
age of genomic DNA, a hallmark of apoptosis (8, 9).
One important component of the caspase cascade is caspase-3,
which is activated by two sequential proteolytic events that cleave
the 32-kDa precursor at aspartic acid residues to generate an
active heterodimer of 20- and 12-kDa subunits (10). The activa-
tion can either be autocatalytic, or occur via a caspase cascade,
similar to the serine protease cascade in the blood clotting process
(7). In susceptible cells, caspase activation might amplify preex-
isting but sublethal apoptotic signals, leading to rapid and irre-
versible proteolysis.
Recently, Wang and coworkers established a cell free system in
which caspase-3 activation in the cytosol is induced by the
addition of dATP and cytochrome c (11–13). Three protein
factors, designated apoptotic protease activating factors (Apafs),
are necessary and sufficient to reconstitute dATP-dependent
caspase-3 activation. Apaf-2 has been identified as cytochrome c,
and Apaf-3 as caspase-9. Caspase-3 activation begins when
caspase-9 (Apaf-3) binds to Apaf-1 in a reaction stimulated by
cytochrome c and dATP (11). Because of the structural similarity
between dATP and 2CdATP, and the important role of 2CdA in
the treatment of indolent lymphoid malignancies, we designed
experiments to address the possibility that 2CdATP directly
induces caspase-3 proteolysis in a cell free system, and to verify
that caspase-3 proteolytic activation occurs in viable lymphocytes
and CLL cells exposed to 2CdA in vitro.
MATERIALS AND METHODS
Synthesis of 2CdATP. 2-Chloro-29-deoxyadenosine-59-
triphosphate (2CdATP) was prepared by a modification of the
general procedure for nucleoside triphosphate synthesis (14).
Briefly, unprotected (2-CdA) was phosphorylated with POCl3 in
trimethyl phosphate, followed by treatment of the 59-
phosphorodichloridate intermediate with tri-n-butylammonium
pyrophosphate in dimethyl formamide. The reaction mixture was
neutralized with cold 1.0 M of triethylammonium bicarbonate
(pH 8.5) and was chromatographed on a DEAE-Sephadex A-25
column with water and then a linear gradient of triethylammo-
nium bicarbonate. The 2-CdATP was eluted at about 0.8 M of
triethylammonium bicarbonate, dried, and stored at 220°C.
Cell Isolation and Analysis. Heparinized peripheral blood
samples from normal subjects, or patients with CLL containing
at least 80% malignant cells, were fractionated by Ficolly
Hypaque sedimentation. Nonadherent mononuclear cells were
resuspended in complete medium (RPMI 1640 medium supple-
mented with 10% fetal bovine serum) at a density of 1 to 2 3 106
per ml. Cells were incubated at 37°C in an atmosphere of 5% CO2
with 1 mM of 2CdA or 10 mM of dexamethasone for up to 24 hr,
as indicated.
Preparation of HeLa and CLL Extracts. Human HeLa S3 cells
(American Type Culture Collection, Manassas, VA; CCL 2.2)
were grown in complete medium (DMEM supplemented with
10% fetal bovine serum) at 37°C in an atmosphere of 5% CO2
95% air. At 80% confluence, the culture flasks were placed on
ice, washed twice with ice-cold isotonic PBS (pH 7.4), and
harvested using a cell scraper. CLL cells were isolated as de-
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scribed above. Cells were then washed at 4°C and resuspended in
a hypotonic extraction buffer (HEB; containing 50 mM Pipesy50
mM KCly5 mM EGTAy2 mM MgCl2y1 mM DTTy0.1 mM
phenylmethanesulfonyl fluoride). The cells were centrifuged at
1,000 3 g to form a tight pellet, and the volume of the cell pellet
was approximated. The supernatant was discarded and HEB
buffer was added to a volume between 0.5 and 13 the pellet
volume. The cells were allowed to swell for 20–30 min on ice and
then lysed in a Dounce homogenizer with 100 strokes of a B-type
pestle. The extent of lysis was monitored under the microscope by
erythrosin B staining. The cell lysate was centrifuged for 30 min
at 100,000 3 g. The clarified supernatant was used immediately
or stored in aliquots at 280°C. The cytoplasmic fraction did not
contain microscopically visible whole cells, nuclei, or mitochon-
dria.
Immunoblot assay for Nucleotide-Induced Caspase-3 Activa-
tion. HeLa and CLL extracts were prepared as described above.
Ten microliter aliquots (100 mg of protein) were incubated with
the indicated nucleotides, and 10 mM of cytochrome c from
bovine heart, at 30°C for 1 h in 15 ml with HEB buffer. At the end
of the incubation, 5 ml of 43 SDS sample buffer were added to
each reaction. After boiling for 5 min, each sample was subjected
to 14% Triszglycine SDSyPAGE. Caspase-3 was revealed by
immunoblotting as described below.
Colorimetric Assay for Nucleotide-Induced Caspase-3 Ac-
tivation. HeLa extracts were clarified by 0.2 mm filtration, then
10 ml of extracts (100 mg protein) were incubated in a 96-well
plate with the indicated nucleotides, 10 mM of cytochrome c,
and 100 mM of DEVD-p-nitroanilide (pNA), at 37°C for 30–60
min, in 50 ml with HEB buffer. The hydrolysis of the substrate
was followed spectrophotometrically at 405 nm, in a Molecular
Devices MAXline Microplate Spectrophotometer (Menlo
Park, CA). Baseline absorbance values from reactions without
nucleotides were substracted from each data point. The spec-
ificity of the assay was validated by using the caspase-3
inhibitor Ac-DEVD-CHO at 1 mM. DEVD-pNA [sequence;
N-acetyl-Asp-Glu-Val-Asp-pNA (15)] and Ac-DEVD-CHO
(16) were purchased from Calbiochem.
Immunoblotting. Washed cell pellets were lysed in 23
SDSyPAGE sample buffer containing 10 mM DTT, for 5 min
at 100°C. Alternatively, washed cells were lysed in RIPA buffer
[50 mM TriszHCly50 mM NaCl, pH 7.4y1 mM EGTAy0.5%
(volyvol) Nonidet P-40y1 mg/ml aprotininy1 mg/ml leupep-
tiny1 mM phenylmethanesulfonyl f luoride]. Lysates were cen-
trifuged at 15,000 3 g for 10 min to remove nuclei and the
protein content of supernatants was measured by using a
modified Coomassie blue assay (Pierce). Proteins were re-
solved at 125 V on 14% gels and electrophoretically trans-
ferred to 0.2 mm of polyvinylidene fluoride membranes (Mil-
lipore) for 2 h at 125 V. Membranes were blocked overnight
in I-Block blocking buffer (Tropix, Bedford, MA). Blots were
then probed for 1 h with antibodies to caspase-3 (Transduction
Laboratories, Lexington, KY), or to Apaf-1 (11). The blots
were developed with species-specific antisera, and visualized
by alkaline phosphatase-based enhanced chemiluminescence
(Tropix, Bedford, MA), according to the manufacturer’s in-
structions. The x-ray films were scanned, acquired in Adobe
Systems (Mountain View, CA) PHOTOSHOP, and analyzed with
National Institutes of Health IMAGE software.
Measurement of DNA Fragmentation. DNA fragmentation
was assessed by flow cytometry and electrophoresis. Prior to
analysis by flow cytometry, cells were fixed in ice-cold 70%
ethanol, and incubated with 100 mgyml of RNAse A and 50
mgyml PI for 1 h at 37°C. Hypodiploid cells were visualized
using a Becton Dickinson FACScalibur, and the program
MODFIT LT 2.0 (Verity Software House, Topsham, TX).
Prior to electrophoresis, cells were resuspended for 20 min
in hypotonic lysis buffer containing 10 mM TriszHCl, 50 mM
NaCl, 10 mM EDTA and 0.2% Triton X-100 (pH 7.5). After
centrifugation at 14,000 3 g for 10 min, and proteinase K
digestion, DNA was precipitated at 220°C in 2 volumes of
isopropanol and 0.5 M of NaCl. The pellet was washed and
resuspended in 10 mM of TriszHCl, 10 mM of EDTA, and the
samples were then electrophoresed for 2 h at 60 V in 2%
agarose with 0.5 mgyml ethidium bromide. An HaeIII digest of
fX174 provided molecular mass standards. After electro-
phoresis, the gels were photographed on a UV transluminator.
Cytof luorimetric Analysis of Mitochondrial Transmem-
brane Potential (Dcm) by 3,3* Dihexyloxacarbocyanine Iodide
(DiOC6) and Cell Membrane Permeability by PI. Cells were
treated with the indicated amount of 2CdA and 10 mM of the
cell-permeable caspase-3ycaspase-7-selective inhibitor Ac-
DEVD-fmk (sequence; N-acetyl-Asp-Glu-Val-Asp-fluorom-
ethylketone, Enzyme Systems Products, Livermore, CA). Cells
were then incubated for 10 min at 37°C in culture medium
containing 40 nM of DiOC6 (Molecular Probes, Eugene, OR)
and 5 mgyml PI (Molecular Probes), followed by analysis
within 30 min of fluorochrome in a Becton Dickinson FAC-
Scalibur cytofluorometer. After suitable compensation, f luo-
rescence was recorded at different wavelengths: DiOC6 at 525
nm (FL-1) and PI at 600 nm (FL-3).
RESULTS
Caspase-3 Activation by 2CdATP. Liu et al. have reported
that the addition of cytochrome c and dATP to cytosolic
extracts induces the processing of caspase-3 to active forms
capable of inducing apoptotic cell death (12). To determine if
2CdATP was able to replace dATP, a similar cell free system
was established using HeLa cells and CLL cells. The addition
of cytochrome c (0.2 mg per reaction) and dATP was required
for the activation of caspase-3 in both HeLa and CLL extracts
(Fig. 1 A and B), as demonstrated by the disappearance of the
32-kDa band and the appearance of a 20-kDa band, which
represent the cleaved active fragment of caspase-3. dATP
alone was not enough to activate caspase-3, probably because
during the preparation of the cytosolic extract, the mitochon-
dria were not damaged and did not release sufficient cyto-
FIG. 1. Nucleotide-induced caspase-3 cleavage in cell free extracts.
(A). Aliquots (10 ml) of HeLa cell extracts (100 mg) were incubated in the
presence (lanes 1, 2, 4, 6, and 8) or absence (lanes 3, 5, and 7) of
cytochrome c (10 mM) and various nucleotides (1 mM). Control lane
(lane 1), dATP (lane 2), 2CdA (lane 3 and 4), 2CdAMP (lane 5 and 6),
and 2CdATP (lane 7 and 8). (B) Aliquots (10 ml) of CLL cell extracts (100
mg) were incubated in absence (Control) or in the presence of cytochrome
c (10 mM) and various nucleotides (1 mM), as indicated. Samples were
subjected to SDSyPAGE, transferred to a polyvinylidene fluoride mem-
brane, and probed with an anti-caspase-3 antibody.
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chrome c. In the presence of cytochrome c, 2CdATP also
induced caspase-3 cleavage, while 2CdA had no effect. The
minimal activation of caspase-3 by 2CdAMP may be due to its
conversion to 2CdATP by kinases present in the cell-free
extracts, thus mimicking the process that occurs in vivo in cells
exposed to 2CdA. Other nucleotides were also tested in the
CLL extracts (Fig. 1B). 9-b-D-Arabinofuranosyl ATP ap-
peared to be the most potent inducer of caspase-3 activation,
followed by dATP and 2CdATP. Under these conditions no
caspase-3 cleavage was observed in extracts containing ATP,
2CdA, 9-b-D-arabinofuranosyl-CTP and 29,39-dideoxy ATP.
The quantification of caspase-3 activation by the colorimetric
enzyme assay (Fig. 2) showed that dATP is more potent than
2CdATP, especially at concentrations below 100 mM. At
concentrations of 1 mM and above, both nucleotides showed
similar activities, and were more potent than ATP. The
maximal caspase-3 activity induced by ATP was '60% of the
maximal activity induced by dATP and 2CdATP.
Caspase-3 and Apaf-1 in Normal Lymphocytes and CLL. In
light of the results obtained in the cell free system, it was
important to determine if caspase-3 and Apaf-1 were expressed
in CLL cells and normal lymphocytes. Immunoblotting revealed
that both components of the caspase cascade were detectable.
The expression levels of Apaf-1 were approximately equivalent in
the normal and malignant lymphocytes (Fig. 3B). In contrast, the
expression level of caspase-3 was higher in CLL cells than in
normal cells (Fig. 3A). Densitometric quantitation showed that
the mean caspase-3 level in CLL cells was about twice that of
normal peripheral blood lymphocytes.
Caspase Activation by 2CdA in Normal Lymphocytes and
CLL. Previous work has shown that 2CdA induces internu-
cleosomal DNA cleavage characteristic of apoptosis in sensi-
tive CLL cells (17–19). To determine if the fragmentation was
preceded by caspase-3 activation, cells from CLL patients were
treated for 24 h with 1 mM 2CdA, and the time courses of
caspase-3 and DNA degradation were compared. Leukemic
lymphocytes treated with 1 mM 2CdA showed a gradual
appearance of cells with a hypodiploid DNA content (Fig. 4).
Agarose gel electrophoresis similarly demonstrated increasing
amounts of the DNA fragments in an oligonucleosomal pat-
tern (data not shown). Internucleosomal cleavage did not
become prominent until 16 h of exposure. Untreated CLL cells
also developed some spontaneous apoptosis after 24 h culture.
Immunoblotting experiments showed that freshly isolated
CLL cells have already a small amount of cleaved caspase-3
(Fig. 4), as opposed to lymphocytes from normal donors, which
did not shown any detectable cleavage products (data not
shown). 2CdA incubation substantially increased the caspase
activation between 4 and 8 h of incubation, after the induction
of DNA single strand breaks (20), but before endonuclease
activation became prominent. Thus, significant cytoplasmic
caspase-3 activation preceded nucleosomal degradation and
cell death by 8 h in 2CdA-treated CLL cells.
Effect of 2CdA on Mitochondria. To determine the effect of
2CdA treatment on the Dcm of freshly isolated CLL cells, the
fluorochrome DiOC6 was used. The reduction of Dcm has been
shown (21) to precede nuclear DNA fragmentation in lym-
phocyte apoptosis induced by dexamethasone. Either short-
term treatment (24 h) of CLL cells with 1 mM 2CdA or
long-term (72 h) treatment with 50 nM 2CdA reduced the
DiOC6 f luorescence (Fig. 5 C and D). There was a concom-
itant increase in PI binding to DNA, reflecting a loss of
membrane permeability and in the percentage of hypodiploid
apoptotic cells. Untreated CLL cells incubated for 24 h had
only 1% apoptotic cells, but 13% of low Dcm cells and 8%
FIG. 2. Induction of caspase-3-like activity by nucleotides.
Caspase-3-like activity was measured spectrophometrically at 405 nm
by hydrolysis of the colorimetric substrate DEVD-pNA. Aliquots (10
ml) of HeLa cell extracts (100 mg) were incubated at 37°C for 30 min,
in the presence of DEVD-pNA (100 mM), cytochrome c (10 mM), and
the indicated concentration of nucleotide. The data are representative
of at least three independent experiments.
FIG. 3. Caspase-3 and Apaf-1 in normal and CLL lymphocytes.
Extracts of CLL and normal lymphocytes were lysed in RIPA buffer
for 1 h at 4°C, and lysates were centrifuged at 15,000 3 g for 10 min.
Equal amounts (50 mg) of protein supernatants were electrophoresed
on 14% Tris-glycine gels, subjected to SDSyPAGE, and transferred to
polyvinylidene fluoride membranes. Caspase-3 and Apaf-1 were re-
vealed by immunoblotting with enhanced chemiluminescent detection.
FIG. 4. Kinetics of caspase-3 activation and DNA fragmentation
induced by 2CdA in CLL cells. Freshly isolated CLL cells were
incubated for the times indicated with 1 mM 2CdA, after which
caspase-3 activation and DNA fragmentation were measured.
Caspase-3 cleavage (n) was quantified by densitometry after immu-
noblotting, by comparing the relative intensities of the p32 caspase-3
precursor and the p20 cleaved product. DNA fragmentation (p) was
estimated by PI staining of ethanol-fixed cells and subsequent flow
cytometry analysis. The results are representative of three indepen-
dent replicates with different patient isolates.
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PI-positive cells (Fig. 5A). After 72 h of incubation, 20% of the
untreated cells were apoptotic, 19% were PI-positive, and 8%
showed a reduced Dcm (Fig. 5B). Thus, a fall in DiOC6 staining
was a sensitive early marker of both drug-induced and spon-
taneous apoptosis in cultured CLL cells. The incubation of the
cells with the cell-permeable caspase-3ycaspase-7-selective
inhibitor Ac-DEVD-fmk at 10 mM inhibited completely the
appearance of apoptotic cells (Fig. 5 E and F). The loss of Dcm
was also noticeably reduced, but not blocked completely.
Approximately 10% of cells treated with 50 nM 2CdA and with
the caspase inhibitor still displayed a low Dcm.
DISCUSSION
The toxicity of 2CdA depends on its intracellular phosphorylation
to CdATP by the tandem action of deoxycytidine kinase, AMP
kinase, and nucleoside diphosphate kinase (22, 23). Because
2CdAMP is dephosphorylated back to the nucleoside by a
cytosolic 59-nucleotidase, both the in vitro sensitivity of cultured
leukemic cells (1) and the in vivo response of patients with CLL
to 2CdA (4) correlate with the ratio of deoxycytidine kinase to
59-nucleotidase activities. Because CLL cells divide very slowly,
and cell volume remains stable, 2CdATP accumulates in cells
with a high kinase to nucleotidase ratio until a new equilibrium
is achieved, or death ensues. In patients given 2CdA orally (10
mgym2) intracellular 2CdATP levels reached 10 mM after 3 h,
within cells cultured with 1 mM 2CdA the intracellular 2CdATP
levels reached 70 mM (24).
How 2CdATP induces apoptosis in nondividing cells is not
yet known. The nucleotide inhibits ribonucleoside diphosphate
reductase (25), DNA polymerases a and b (26), DNA ligase,
and is incorporated into DNA (27). Together, these actions
lead to the progressive accumulation of DNA single-strand
breaks (20). The strand break formation by itself would not be
expected to kill a noncycling cell. However, DNA strand
breaks induce the activation of poly(ADP ribose)polymerase,
with resultant consumption of NAD, and of total adenine
nucleotides. The addition of nicotinamide to lymphocyte
cultures exposed to 2CdA can delay the onset of cell death, by
inhibiting poly(ADP ribose) formation, maintaining adenosine
nucleotides, and replenishing NAD (20, 28).
In the present study, 2CdATP and cytochrome c initiated an
apoptotic program in cell free cytosolic extracts, from both
HeLa and CLL cells, as measured by the activation of
caspase-3. Exposure of viable normal or CLL lymphocytes to
2CdA also induced caspase-3 activation. Time course analysis
indicated that caspase activation occurred early, at the same
time as DNA strand break formation, but before internucleo-
somal cleavage became prominent. The inhibition of caspase
enzymatic activity by the cell-permeable caspase-3ycaspase-
7-selective inhibitor Ac-DEVD-fmk blocked 2CdA-induced
apoptosis and partially prevented the 2CdA-induced reduction
of the (Dcm) of freshly isolated CLL cells.
Recently, Liu and coworkers (8) identified in HeLa cytosol
an heterodimeric protein of 45 kDa and 40 kDa, termed DNA
fragmentation factor (DFF) that functions downstream of
caspase-3 to trigger DNA fragmentation. A similar protein was
found in the cytoplasm of mouse lymphocytes by Enari et al.
(9). By cleavage of this inhibitor of caspase-activated DNase
(ICAD), caspase-3 activates the caspase-activated DNase
(CAD), enabling it to migrate to the nucleus and degrade
DNA.
In most cell types, DNA strand break formation causes the
activation of both poly(ADP ribose)polymerase and p53 de-
pendent pathways (reviewed in refs. 29–32). In quiescent cells
poly(ADP ribose)polymerase activation can induce an abrupt
drop in NAD and in total adenine nucleotide pools (20). The
activation of p53 has been shown to increase the synthesis of
enzymes that generate or respond to oxidative stress (33). The
combination of reduced adenine nucleotides and increased
oxidative stress may impair the function of the F1F0-ATPase
in the inner mitochondrial membrane, thereby promoting the
release of cytochrome c into the cytoplasm (34, 35). The
released cytochrome c could work together with Apaf-1,
caspase-9, and increasing concentrations of adenine de-
oxynuclesoside 59-triphosphates to start a feed forward am-
plification cascade of caspase activation.
In summary, the data are consistent with the following
mechanism of action of adenine deoxynucleosides in resting
lymphocytes (Fig. 6). The deoxynucleoside enters cells and is
converted progressively to its active 59-triphosphate form,
which causes DNA strand break formation, activating poly-
(ADP ribose)polymerase and p53. In consequence, NAD and
total adenine nucleotides decrease, oxidative stress increases,
and mitochondrial integrity wanes. In untreated cells, the
concentrations of ATP and cytochrome c in the cytoplasm are
insufficient to trigger the caspase cascade. However, the
binding of Apaf-1 to caspase-9, and caspase-3, in the presence
of high concentrations of adenine deoxynucleoside 59-
triphosphates and small amounts of released cytochrome c,
leads to the cleavage of caspase-3, converting it to an active
autocatalytic protease, in a process analogous to blood clot-
FIG. 5. Effect of 2CdA and caspase inhibitors on mitochondrial
transmembrane potential and apoptosis. Freshly isolated CLL cells were
incubated for the times indicated with 50 nM or 1 mM 2CdA in the
presence or absence of 10 mM of the cell-permeable caspase-3ycaspase-
7-selective inhibitor Ac-DEVD-fmk. Cell membrane permeability and
Dcm were then assayed by incubating the unfixed cells for 10 min at 37°C
in presence of 5 mgyml PI and 40 nM DiOC6. DNA fragmentation was
estimated by flow cytometry after PI staining of fixed cells. In the large
graphs, the x-axis is DiOC6 (FL-1) fluorescence, and the y-axis is PI
(FL-3) fluorescence. Numbers refer to the percentages of cells in the
upper-left quadrant (dead cells), the lower-left quadrant (low Dcm), and
the lower-right quadrant (normal cells). The small graphs (Insets) rep-
resent the DNA content of the cells from parallel cultures determined by
PI staining of permeabilized cells, and the numbers refer to the percent-
ages of hypodiploid (apoptotic) cells.
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ting. The active caspase-3 then stimulates, in turn, the CAD
endonuclease that irreversibly degrades DNA. This model
suggests that the baseline levels of caspase activation, in
addition to the rate of adenine deoxynucleoside 59-
triphosphate formation, may be a factor that influences sen-
sitivity to 2CdA, fludarabine, and deoxycoformycin chemo-
therapy. Malignant lymphocytes that display greatest sensitiv-
ity to the 2CdA, such as hairy cell leukemia cells, may undergo
spontaneous apoptosis, due to a subthreshold level of
caspase-3 activation in unmanipulated cells.
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Adenine deoxynucleosides, such as 2-chlorodeoxyade-
nosine (2CdA) and fludarabine, induce apoptosis in qui-
escent lymphocytes, and are thus useful drugs for the
treatment of indolent lymphoproliferative diseases. We
previously demonstrated that that the 5*-triphosphate
metabolite of 2CdA (2CdATP), similar to dATP, can co-
operate with cytochrome c and apoptosis protein-acti-
vating factor-1 (APAF-1) to trigger a caspase pathway in
a HeLa cell-free system. We used a fluorometry-based
assay of caspase activation to extend the analysis to
several other clinically relevant adenine deoxynucleo-
tides in B-chronic lymphocytic leukemia extracts. The
nucleotide-induced caspase activation displayed typical
Michaelis-Menten kinetics. As estimated by the Vmax/Km
ratios, the relative efficiencies of different nucleotides
were Ara-ATP > 9-fluoro-9-b-D-arabinofuranosyladenine
5*-triphosphate > dATP > 2CdATP > 9-b-D-arabino-
furanosylguanine 5*-triphosphate > dADP > ATP. In
contrast to dADP, both ADP and its nonhydrolyzable
a,b-methylphosphonate analog were strong inhibitors
of APAF-1-dependent caspase activation. The hierarchy
of nucleotide activation was confirmed in a fully recon-
stituted system using recombinant APAF-1 and recom-
binant procaspase-9. These results suggest that the po-
tency of adenine deoxynucleotides as co-factors for
APAF-1-dependent caspase activation is due both to
stimulation by the 5*-triphosphates and lack of inhibi-
tion by the 5*-diphosphates. The capacity of adenine
deoxynucleoside metabolites to activate the apopto-
some pathway may be an additional biochemical mech-
anism that plays a role in the chemotherapy of indolent
lymphoproliferative diseases.
The purine nucleoside analogs 9-b-D-arabinofuranosyl-2-
fluoradenine (fludarabine or F-Ara-A),1 2-chlorodeoxyaden-
osine (cladribine or 2CdA), and 29-deoxycoformycin are active to
varying degrees in indolent lymphoproliferative diseases, includ-
ing chronic lymphocytic leukemia (CLL), hairy cell leukemia,
Waldenstrom’s macroglobulinemia, and low grade lymphomas (1,
2). They are unique among nucleoside antimetabolites by virtue
of their ability to induce apoptosis in nonproliferating cells.
The regulation of cell death by apoptosis is thought to play a
fundamental role in the natural evolution of malignancy and in
the response of tumors to chemotherapy. CLL is an attractive
model to investigate the regulation of apoptosis, independent of
cell cycle progression, because of its slow population doubling
time and the ready accessibility of malignant cells. Previous
studies have documented abnormalities in the expression of
certain Bcl-2 family proteins in CLL (3–6). This family of
proteins plays a critical role in controlling cellular responses to
apoptotic stimuli, including those induced by many chemother-
apeutic drugs (7). Some of the actions of Bcl-2 are mediated by
its ability to control the response of mitochondria to factors in
the cytoplasm that induce the release of cytochrome c.
The molecular details of the activation of the final steps of
the apoptotic pathway have been recently investigated (8, 9).
The cascade is initiated by cytochrome c binding to the apo-
ptosis protein-activating factor APAF-1, which induces it to
undergo a conformational change leading to the formation of
APAF-1 multimers and to the recruitment of procaspase-9. The
subsequent autocatalysis of procaspase-9 is followed by proteo-
lytic activation of procaspase-3 and possibly procaspase-7. The
entire multimeric complex has been defined as the functional
apoptosome. Cytochrome c is normally sequestered inside mi-
tochondria, between the inner and outer membranes of these
organelles. However, it becomes released into the cytosol fol-
lowing exposure of cells to a variety of proapoptotic stimuli (10)
(11–13). In addition to cytochrome c, the APAF-1-mediated in
vitro activation of procaspase-9 and procaspase-3 requires
dATP. Although ATP can supplant dATP, the deoxynucleotide
is more active (12, 14). The peculiar preference of APAF-1 for
dATP is unusual for energy-requiring processes not directly
connected to DNA synthesis. In the present study, therefore,
we designed experiments to compare the abilities of the purine
deoxynucleoside analogs commonly used in the treatment of
indolent lymphoproliferative diseases to activate the APAF-1-
dependent apoptotic pathway and to define the kinetic param-
eters of the process.
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MATERIALS AND METHODS
Nucleotides—Nucleosides were purchased from Sigma or Calbio-
chem. When nucleotides were unavailable commercially, they were
synthesized by standard methods (15, 16) and checked for purity by
TLC or high pressure liquid chromatography. The triphosphates stud-
ied included those of 9-b-D-arabinofuranosyladenine 59-triphosphate
(Ara-ATP), 2-fluoro-9-b-D-arabinofuranosyladenine 59-triphosphate (F-
Ara-ATP), 2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine
59-triphosphate (CAFdATP), 2-chloro-29-deoxyadenosine (2CdATP),
9-b-D-arabinofuranosylguanine 59-triphosphate (Ara-GTP), and 8-chlo-
roadenosine 59-triphosphate (8-Cl-ATP).
Cell Isolation—Heparinized peripheral blood samples from patients
with CLL containing at least 80% malignant cells, were fractionated by
Ficoll/Hypaque sedimentation. Nonadherent mononuclear cells were
resuspended in complete medium (RPMI 1640 supplemented with 10%
fetal bovine serum) at a density of 1–2 3 106 cells/ml.
Cell-free Extract Preparation—CLL cells were isolated as described
above. Cells were then washed at 4 °C and resuspended in a hypotonic
extraction buffer (HEB; containing 50 mM PIPES, 50 mM KCl, 5 mM
EGTA, 2 mM MgCl2, 1 mM dithiothreitol, 0.1 phenylmethanesulfonyl
fluoride). The cells were centrifuged at 1000 3 g to form a tight pellet,
and the volume of the cell pellet was approximated. The supernatant
was discarded, and HEB buffer was added to a volume between 0.5 and
1 times the pellet volume. The cells were allowed to swell for 20–30 min
on ice and then lysed in a Dounce homogenizer with 100 strokes of a
B-type pestle. The extent of lysis was monitored under the microscope
by erythrosin B staining. The cell lysates were centrifuged for 60 min at
100,000 3 g. The clarified supernatants were used immediately or
stored in aliquots at 280 °C. The cytoplasmic fractions did not contain
microscopically visible whole cells, nuclei, or mitochondria.
Cell-free Assays for Caspase Activity—CLL extracts were clarified by
0.2-mm filtration, and then 5–10 ml of extracts (100–200 mg of protein)
were incubated in a 96-well plate with the indicated nucleotides, 2 mM
of cytochrome c from bovine heart, and either 50 mM Ac-DEVD-7-amino-
4-methylcoumarin (AMC) or 50 mM of Ac-LEHD-7-amino-4-trifluoro-
methylcoumarin (AFC) at 37 °C for 30–60 min in 50 ml with HEB
buffer. The hydrolysis of the substrate was followed fluorometrically at
380 nm (excitation) and 460 nm (emission) for the caspase-3 substrate
Ac-DEVD-AMC and at 400 nm and 505 nm for the caspase-9 substrate
Ac-LEHD-AFC in a CytoFluor fluorescence plate reader (PerSeptive
Biosystems, Framingham, MA). Base-line fluorescence values from re-
actions without nucleotides were subtracted from each data point. The
specificity of the assay was validated using the caspase-3 inhibitor
Ac-DEVD-CHO (aldehyde) at 1 mM. Ac-DEVD-AMC (sequence,
N-acetyl-Asp-Glu-Val-Asp-AMC (17)), Ac-DEVD-CHO (18), and Ac-
LEHD-AFC (sequence, N-acetyl-Leu-Glu-His-Asp-AFC (19)) were pur-
chased from Calbiochem.
Immunoblotting—10 ml of CLL extracts were incubated at the indi-
cated time points with the nucleotides and cytochrome c (2 mM) in a
volume of 20 ml in HEB buffer at 37 °C. Proteins were resolved at 125
V on 14% gels and electrophoretically transferred to 0.2-mm polyvinyli-
dene fluoride membranes (Millipore Corp., Bedford, MA) for 2 h at 125
V. Membranes were blocked overnight in I-Block blocking buffer
(Tropix, Bedford, MA). Blots were then probed for 1 h with antibodies to
procaspase-3 (Transduction Laboratories, Lexington, KY) or to
caspase-9 (provided by X. Wang). The blots were developed with spe-
cies-specific antisera and visualized by alkaline phosphatase-based en-
hanced chemiluminescence (ECL; Tropix), according to the manufac-
turer’s instructions. The x-ray films were scanned, acquired in Adobe
Photoshop, and analyzed with NIH Image software.
In Vitro Caspase-9 and Caspase-3 Assay—Cytosolic extracts were
prepared as described above and stored at 280 °C. Human caspase-9
and caspase-3 expression plasmids were kindly provided by Dr. John
Reed (Burnham Institute, La Jolla, CA). The respective procaspases
were translated in vitro in the presence of [35S]methionine with a
Promega (Madison, WI) TNT transcription/translation kit and purified
from radioactive methionine and ATP through a desalting column
(Bio-Rad).
Reconstituted System—The APAF-1/caspase-9 reconstituted system
was recently described (20). Briefly, aliquots of 0.5 ml (0.2 mg) of His-
tagged baculovirus-expressed recombinant procaspase-9 and 5 ml (0.8
mg) of baculovirus-expressed recombinant APAF-1 were incubated in
the presence or absence of 10 ng/ml cytochrome c and the indicated
nucleotides and 1 mM additional MgCl2 at 30 °C for 1 h in a final volume
of 20 ml of buffer A (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM
MgCl2, 1 mM NaEDTA, 1 mM NaEGTA, 1 mM dithiothreitol, 0.1 mM
phenylmethylsulfonyl fluoride) (20). After incubation, the samples were
subjected to a 15% SDS-PAGE and transferred to a nitrocellulose filter,
which was blotted with anticaspase-9 antibody. Procaspase-3 was
translated and purified as described above. A 1-ml aliquot of in vitro
translated caspase-3 was incubated with the mixture of procaspase-9
activation reaction as described above. The samples were subjected to a
15% SDS-PAGE, and then the gel was transferred to a nitrocellulose
filter, which was subsequently exposed to a phosphor imaging plate and
visualized in a Fuji BAS-1500 phosphor imager.
RESULTS
Characterization of the Assay Conditions—We have previ-
ously demonstrated that the addition of cytochrome c and pu-
rine nucleotide analogs to HeLa and B-CLL cytosolic extracts
induces the processing of procaspase-3 to active forms capable
of inducing apoptotic cell death (14). To further investigate the
details of this nucleotide-induced apoptotic pathway, the ki-
netic parameters were determined using a caspase-3-specific
fluorigenic Ac-DEVD-AMC substrate. The results obtained us-
ing the Ac-LEHD-AFC substrate, which has a better affinity for
caspase-9 (19), were very similar to those obtained with Ac-
DEVD-AMC (data not shown). No cleavage of the caspase-1
substrate Ac-YVAD-AFC was observed in our experimental
system (data not shown), thus confirming that caspase-1 is not
activated by cytochrome c and nucleotides (21).
Nucleotide-induced caspase activation was optimal at pH 7.0
(Fig. 1A). This finding is in agreement with previous results
showing that intracellular acidification is an early event in the
apoptosis program in a variety of systems (22, 23). The opti-
mum pH for caspase-3 activity has been reported to be pH 7.5
(24), indicating that the observed acidic optimum pH is deter-
mined by either caspase-9 activity or by cytochrome c and
nucleotide-induced APAF-1 activation.
We used KCl in the range of 0–0.5 M in HEB buffer to
FIG. 1. Characterization of nucleotide and cytochrome c-in-
duced caspase activation in cell-free extracts: pH and salt de-
pendence. Caspase-3-like activity was measured fluorometrically by
hydrolysis of the fluorigenic substrate DEVD-AMC (excitation, 380 nm;
emission, 460 nm). Aliquots (10 ml) of HeLa cell extracts (100 mg) were
incubated at 37 °C for 30 min, in the presence of DEVD-AMC (100 mM),
cytochrome c (2 mM), and 0.5 mM dATP. HEB buffer was prepared for
each of the indicated pH and KCl conditions. The y axis represents the
percentage of caspase activity from the controls without dATP. The data
are representative of at least three independent experiments.
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address the effect of ionic strength on nucleotide-induced
caspase activation. Interestingly, although caspase-3 activity is
not affected by high salt concentrations (24), nucleotide-in-
duced caspase activity was maximal at 20 mM KCl (Fig. 1B) and
was 20% of maximal activity at 150 mM KCl. These results
indicate that the intracellular ionic strength may play an impor-
tant role in restraining APAF-1-mediated caspase activation.
Time Course of Nucleotide and Cytochrome c-Induced
Caspase Activation—In the presence of 2 mM cytochrome c, but
without the exogenous addition of dATP, no activation of
caspase-3 pathway in CLL extracts was detectable (Fig. 2). In
contrast, 12.5 mM of dATP was sufficient to trigger the activa-
tion of the caspase after 15 min of incubation. The immu-
nodepletion of caspase-9, APAF-1, or both, using specific poly-
clonal antibodies, completely abolished the nucleotide/
cytochrome c-induced caspase activation (data not shown).
These results indicate that caspase-9 and APAF-1 are critical
for nucleotide/cytochrome c-initiated caspase-3 activation and
cannot be substituted for by other caspases or CED-4 homologs
present in the CLL extract.
In order to determine the possible role of intracellular nucle-
otides and low molecular weight compounds present in the CLL
cell-free extracts, we dialyzed the extracts and repeated the
caspase assays in the presence of exogenous cytochrome c and
various concentrations of nucleotides. Dialysis did not prevent
cytochrome c and nucleotide-induced caspase activation. How-
ever, the preparation of CLL and HeLa cell-free extracts by
manual homogenization led predictably to the release of small
amounts of cytochrome c from mitochondria that could be vis-
ualized by immunoblotting (data not shown). In order to ad-
dress the role of the released cytochrome c, immunodepletion
experiments using anticytochrome c (native form) antibodies
were carried out. The removal of the endogenous cytochrome c
did not alter the observed nucleotide kinetics. In the immu-
nodepleted extracts, exogenous cytochrome c was required
to initiate procaspase-9 and procaspase-3 cleavage (results
FIG. 2. Time course of nucleotide and cytochrome c-induced
caspase activation in CLL extracts. Caspase-3-like activity was
measured fluorometrically as described in Fig. 1. Various concentra-
tions of dATP were used (12.5 mM (), 25 mM (), 37.5 mM (l), 50 mM (l),
100 mM (M), and no ATP (f)), and the fluorometric values at the
indicated times were converted to nmol/mg using a standard curve of
AMC.
FIG. 3. Kinetics of nucleotides and cytochrome c-induced
caspase activation in CLL extracts. Caspase-3-like activity was
measured fluorometrically as described in the legends to Figs. 1 and 2
using DEVD-AMC. The nucleotides (F-Ara-ATP (), dADP (), Ara-
ATP (), dATP (), 2CdATP (l), ATP (l), and ADP (M)) were added at
the indicated concentrations in the presence of 2 mM cytochrome c in
HEB buffer, and fluorescence was then measured after a 30-min incu-
bation at 37 °C. Caspase-3-like activity was then expressed as nmol of
AMC cleaved from the DEVD substrate per mg of CLL extract per 1 h
of incubation (nmol/mg/h) using an AMC standard curve.
FIG. 4. Nucleotide inhibition of dATP and cytochrome c-in-
duced caspase activation. A, CLL extracts were incubated in HEB
buffer with DEVD-AMC, 250 mM dATP, and 2 mM cytochrome c and with
the indicated concentrations of competing nucleotides (ADPcP (M),
AMPcP (), ADP (f), and ATP ()). After 30 min at 37 °C, fluorescence
was measured. B, “primary” double reciprocal plot (Lineweaver-Burk
plot) for dATP and cytochrome c-induced caspase activation in HeLa
extracts. dATP concentrations were varied between 50 and 500 mM,
while ADP was at different fixed concentrations (0 mM (f), 25 mM (), 50
mM (), and 200 mM (l)). Each line was obtained by an unweighted
least-squares fit to a hyperbola (Prism, GraphPad).
TABLE I
Kinetic parameters of cytochrome c and nucleotide-induced caspase-3
activation in a CLL cell-free system
B-CLL extracts (100 mg) were incubated at 37 °C with 2 mM cyto-
chrome c and concentrations of nucleotides ranging from 10 to 1000 mM.
A fluorometric based assay was used to monitor caspase-3 enzymatic
activity at 20, 30, 40, and 60 min of incubation. The data collected were
analyzed using nonparametric curve fitting to obtain the enzymatic
kinetic values (Prism, GraphPad Software, San Diego, CA).
Nucleotide Km Vmax
Efficiency
(Vmax/Km)
Relative
efficiency
mM nmol/mg/h
Ara-ATP 30 6 13 53 6 9 1.767 50
F-Ara-ATP 39 6 11 54 6 2 1.385 39
CaFdATP 59 6 15 54 6 8 0.915 26
dATP 65 6 18 52 6 4 0.897 25
2CdATP 199 6 30 56 6 5 0.281 8
Ara-GTP 220 6 30 59 6 7 0.268 8
8-Cl-ATP 252 6 25 50 6 5 0.198 6
dADP 298 6 35 49 6 11 0.164 5
ATP 374 6 89 13 6 5 0.035 1
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not shown).
Kinetic Parameters of Nucleotide Activators in CLL Ex-
tracts—A fluorometry-based assay was used to compare the
effects of different nucleotides on APAF-1-dependent caspase
activation in B-CLL cell extracts (Fig. 3). Caspase activation
followed Michaelis-Menten kinetics, with a hyperbolic relation-
ship between initial velocity and nucleotide concentrations.
The ratio of Km to Vmax, calculated by a nonlinear least-squares
fit method, revealed the relative efficiencies of the different
nucleotides (Table I). The most active compounds were as fol-
lows: Ara-ATP . F-Ara-ATP . CAFdATP. dATP .
2CdATP . Ara-GTP . dADP . ATP. ATP was a very weak
activator, with a relative efficiency 25-fold smaller than dATP
and 50-fold smaller than Ara-ATP. We also tested nucleotides
and deoxynucleotides based on other bases (C, G, U, T, and I),
but none activated caspases in CLL extracts, with the notable
exception of Ara-GTP (Table I). These results confirmed the
energetic requirement for APAF-1-mediated caspase activation
and indicated that arabinofuranosyl nucleotides are more ac-
tive than deoxynucleotides.
Kinetic Parameters of Nucleotide Inhibitors in CLL Ex-
tracts—In addition to studying the activation of APAF-1 by
purine nucleoside 59-triphosphate substrates, it also was im-
portant to determine if the 59-diphosphates were product in-
hibitors. Both ADP and ATP dose-dependently inhibited dATP-
induced caspase activation in CLL extracts (Fig. 4). The
determination of the Ki values (Table II) showed ADP (Ki 5 133
mM) and ATP (Ki 5 163) to be nearly equipotent inhibitors.
However, while a nonhydrolyzable a,b-methylphosphonate an-
alog of ADP (AMPcP) was also an inhibitor, a nonhydrolyzable
analog of ATP (ADPcP) was ineffective (Fig. 4A). Hence, it is
likely that the inhibitory action of ATP is due partly to its rapid
conversion into ADP. It is noteworthy that dADP at concentra-
tions up to 1 mM had no significant inhibitory effect on optimal
dATP-induced caspase activation. The nonphysiological nucle-
otides 29,39-ddATP and cordycepin (39-dATP) showed an inhib-
itory capacity toward dATP-induced caspase activation.
Immunoblotting—Immunoblotting with anticaspase-3 and
anticaspase-9 antibodies verified the time course of the nucle-
otide and cytochrome c-induced proteolytic activation of the
procaspases in B-CLL extracts (Fig. 5). The results demon-
strated that maximal procaspase-9 cleavage preceded maximal
procaspase-3 proteolytic processing. Similarly, the depletion of
caspase-9 was more rapid than that of caspase-3. After 20 min
of incubation with 2 mM cytochrome c and 0.25 mM dATP (lane
2) both caspase-3 and caspase-9 appeared to be cleaved. After
40 min, no visible procaspase-9 was detectable in the extract.
In contrast, 120 min of incubation were needed to fully deplete
procaspase-3. The immunoblotting also confirmed the ATP/
ADP inhibition. The addition of 0.5 mM ATP reduced the inten-
sity of the dATP-activated procaspase-3 band (lane 7). The
inhibitory effect of ATP/ADP on dATP-induced procaspase-9
activation was less visible, but the intensity of the lower band
that corresponded to the activated caspase-9 was also reduced.
The immunoblotting of caspase-9 showed two bands of cleaved
products, which probably correspond to the p35 and p37 frag-
ments resulting from cleavage at the processing sites D315
(p35) and D330 (p37). The p35 fragment, which is the result of
the autocatalytic cleavage of procaspase-9, was more abundant in
the immunoblot than the p37 fragment, which is thought to be
the result of feedback cleavage of caspase-9 by caspase-3 (25).
Cleavage of in Vitro Translated Caspase-9 and Caspase-
3—To support further the data obtained by immunoblotting,
the proteolysis of in vitro translated procaspase-9 was studied
(Fig. 6). The results confirmed the dose dependence of dATP-
induced procaspase-9 degradation. In agreement with the fluoro-
metric assays, F-Ara-ATP and Ara-ATP were more potent than
dATP, while 2CdATP was slightly less effective. These data also
confirmed the inhibitory properties of ADP, which almost com-
pletely inhibited dATP-induced procaspase-9 cleavage.
Nucleotide Effects in a Reconstituted System—To rule out
any possible effects of contaminants on nucleotide-induced
caspase activation, we utilized a recently described reconsti-
tuted system, based on highly purified cytochrome c, recombi-
nant APAF-1, and recombinant procaspase-9 and -3 (20). The
results were similar to those obtained with CLL extracts (Fig.
7). Visible procaspase-3 and procaspase-9 cleavage was ob-
served with as little as 10 mM of F-Ara-ATP and dATP. The
ranking of the tested nucleotides was the same as shown in
Table I: F-Ara-ATP . CAFdATP . dATP . 2CdATP . ATP.
DISCUSSION
These results indicate that various nucleotides can have
markedly different effects on APAF-1-mediated caspase activa-
tion. Although other reports have elucidated carefully the
mechanism of activation of caspase-9 by APAF-1, the role of the
nucleotides in the process has not been quantified (9, 20, 21,
25). It is important to address this issue because of the known
ability of certain purine deoxynucleoside analogs to induce
apoptosis in nondividing cells.
The purine analogues fludarabine or cladribine are active in
CLL patients resistant to classical alkylating agents (2, 26).
Other nucleosides that are capable of killing nondividing
TABLE II
Inhibition constants of nucleotides for cytochrome c- and dATP-
induced caspase-3 activation in a CLL cell-free system (100 ng)
CLL extracts were incubated at 37 °C with 2 mM cytochrome c and 250
mM dATP, and the activation of caspase-3 was assessed at nucleotide
concentrations from 50 to 1000 mM. The calculated Ki values are shown.
Nucleotide Ki
mM
29,39-ddATP 89 6 6
ADP 133 6 5
ATP 163 6 16
AMPcP 1536 6 250
39-dATP (cordycepin) 1685 6 302
ADPcP NAa
dADP NA
a NA, no inhibitory activity.
FIG. 5. Nucleotide-induced procaspase-9 and procaspase-3
cleavage in cell-free CLL extracts. Aliquots (10 ml) of CLL cell
extracts (100 mg) were incubated in the presence of cytochrome c (2 mM)
and 250 mM dATP (lanes 2–7) or 250 mM Ara-ATP. Lane 1, control
without any nucleotide; lanes 6 and 7, 100 and 500 mM ATP. Lanes 1, 4,
6, 7, and 8 were incubated for 60 min, lane 2 for 20 min, lane 3 for 40
min, and lane 5 for 120 min at 37 °C. Samples were subjected to
SDS-PAGE, transferred to a polyvinylidene difluoride membrane, and
probed with an anticaspase-3 antibody (top) and an anticaspase-9 an-
tibody (bottom).
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lymphoid cells include 29-deoxyadenosine, 29-b-D-arabino-
furanosyladenine (27), 2-chloro-29-b-D-arabinofluoro-29-de-
oxyadenosine (28), and 29-b-D-arabinofuranosylguanine (29).
The cytotoxicity of these nucleoside analogs in lymphocytes
depends mainly upon the selective and progressive accumula-
tion of the 59-triphosphate metabolites because of the high ratio
of deoxycytidine kinase (EC 2.7.1.74) to cytosolic 59-nucleotid-
ase (EC 3.1.3.5) in lymphocytes, compared with other cell types
(30, 31). The nucleoside 59-triphosphates inhibit DNA polym-
erization and ligation and are incorporated into DNA (32). This
leads to the progressive accumulation of DNA single strand
breaks (33), followed by the activation of poly(ADP-ribose) po-
lymerase, with resultant consumption of NAD and depletion of
total adenine nucleotides.
Recently, we reported that 2CdATP was able to replace
dATP in the activation of the procaspase-9/APAF-1 death path-
way in HeLa cell extracts (14). In this paper, we demonstrate
that 59-triphosphate metabolites of the same nucleosides with
in vitro and in vivo cytotoxicity against indolent lymphoprolif-
erative diseases are able to promote apoptosome activation
both in CLL extracts and in a reconstituted “pure” system. The
kinetics of nucleotide activation suggest that the apoptosome
apoptotic pathway may play a relevant role in vivo. In fact, the
concentrations of F-Ara-ATP in CLL lymphocytes of leukemic
patients undergoing chemotherapy reach 30–60 mM (34), near
or above the Km for the F-Ara-ATP-induced caspase cleavage
(39 mM).
In the CLL extracts, the arabinofuranosyl-based adenine
nucleotides were the most potent activators, although Ara-GTP
also had some activity (Table I). Furthermore, dATP was 25
times more effective than ATP in promoting apoptosome acti-
vation. A 29-fluoro substitution of Ara-ATP slightly reduced its
potency as compared with Ara-ATP, whereas the 29-arafluoro
substitution of CAFdATP increased its caspase activating ca-
pacity compared with 2CdATP. In other experiments, 8-Cl-ATP
had 2-fold greater efficiency than ATP, whereas 29,39-ddATP
was devoid of caspase activating ability. Fig. 8 shows the struc-
tural features of nucleotides that appear to be optimal for
APAF-1 activation of the apoptosome pathway: 1) a purine base
(adenine . guanine), possibly with an 8-chloro substitution
(R3), but without 2-halogenic substitutions (R2); 2) a ribo-
furanoside sugar with either no 29-hydroxy group (R1) or a
29-hydroxy or 29-fluoro group in the “up” position and a 39-
hydroxy group in the “down” position; and 3) three 59-hydro-
lyzable phosphate groups. Only a few proteins have been re-
ported to show a preference for dATP as compared with ATP.
These include DNA polymerases a, b, and g as well as DNA
primase (35, 36). Interestingly, 2-fluoro-29-deoxyadenosine 59-
triphosphate was able to completely substitute for dATP using
DNA polymerases a and g, whereas the 2-chloro and 2-bromo
analogs substituted poorly (35).
Recent evidence suggests that the intracellular levels of pu-
rine nucleotides may play an important role in the modulation
of apoptotic and necrotic cell death signals (37). Adenine nu-
cleotide depletion has been shown to induce apoptosis, which
was prevented by the antiapoptotic protein Bcl-2 (38). In our
system, ADP was a good inhibitor of APAF-1-dependent
caspase activation, with a Ki of 133 mM. Thus, earlier reports
showing that ATP was an inefficient activator of the APAF-1-
mediated caspase pathway are difficult to interpret due to its
progressive conversion into ADP. In addition, our findings
showed that a nonhydrolyzable analog of ADP (AMPcP) was a
good inhibitor, while a nonhydrolyzable analog of ATP (ADPcP)
was not. Normal lymphocytes and CLL cells have been re-
ported to have average cell volumes of 200 and 160 femtoliters
FIG. 6. Aliquots (10 ml) of CLL cell extracts (100 mg) were in-
cubated in the presence of in vitro translated (rabbit reticulo-
cyte) 35S-labeled procaspase-9 (3 ml) and cytochrome c (2 mM)
and the indicated concentrations of nucleotides. Lane 1, control
without any nucleotides; lanes 2–5, 10–250 mM dATP; lanes 6–8, 100 mM
F-Ara-ATP, Ara-ATP, and 2CdATP; lane 9, 100 mM dATP and 250 mM
ADP. Samples were subjected to SDS-PAGE, transferred to a polyvi-
nylidene fluoride membrane, and exposed to x-ray films using an am-
plifying screen (Biomax Transcreen LE, Eastman Kodak Co.).
FIG. 7. Reconstituted purified recombinant APAF-1 and pro-
caspase-9 system for nucleotide-induced activation of caspase-3
and -9. Top panel, caspase-3. Recombinant APAF-1 and procaspase-9
were prepared as described under “Materials and Methods.” Aliquots of
recombinant procaspase-9 (2 mg), recombinant APAF-1 (0.8 mg), and
cytochrome c (0.2 mg) were incubated in the presence (lanes 2 and 6, 10
mM; lanes 3 and 7, 50 mM; lanes 4 and 8, 100 mM; lanes 5 and 9, 1000 mM)
or absence (lane 1) of the indicated nucleotides with 1 ml of 35S-labeled
affinity-purified procaspase-3 at 30 °C for 1 h in a final volume of 20 ml
of buffer A. The samples were then subjected to 15% SDS-PAGE,
transferred to a nitrocellulose filter, and exposed to a phosphor imaging
plate for 12 h at room temperature. Lower panel, caspase-9. The same
procedure and conditions were used in the lower panel, except for the
addition of the labeled procaspase-3. After the nucleotide incubation,
the samples were subjected to 15% SDS-PAGE and transferred to a
nitrocellulose filter. The filter was probed with a rabbit antibody
against caspase-9. The antigen-antibody complexes were visualized by
an ECL method.
FIG. 8. Structure activity relationship for nucleotide-induced
caspase activation. Schematic representation of the prototypic nucle-
otide activator of the apoptosome.
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and ADP contents of 1127 and 873 pmol/107 cells, respectively
(39–41). These values yield an estimated ADP concentration of
about 400 mM, 3-fold higher than the Ki of ADP for apoptosome
activation. Taken together, The data appear to indicate that
ADP may work as a physiological intracellular inhibitor of the
cytochrome c and APAF-1-mediated caspase pathway in both
normal lymphocytes and CLL cells.
The correlation between the clinical relevance of the nucleo-
sides and the capacities of their corresponding 5-triphosphate
derivatives to activate the apoptosome pathway underscores
the relevance of these effects in the chemotherapy of indolent
lymphoproliferative diseases. However, the capacity of nucleo-
tide analogs to activate directly the apoptosome pathway does
not fully explain their diverse cytotoxicities toward CLL cells,
both in vitro and in vivo. It is well known that 2CdA is more
toxic than F-Ara-A when tested in purified CLL cells (42), and
the in vivo dosage of F-Ara-A is approximately 5 times higher
than 2CdA (43). In contrast, our results showed that F-Ara-
ATP was more effective than 2CdATP in activating caspases.
Therefore, there must be additional mechanisms involved in
the nucleoside cytotoxicity toward CLL cells. One contributing
parameter may be DNA strand break formation, which triggers
the consumption of adenine nucleotide pools for poly(ADP-
ribose) synthesis and reduces ADP constraints on caspase ac-
tivation. It is also possible that various nucleotide analogs may
interfere with adenine nucleotide translocation in mitochon-
dria, leading to the release of cytochrome c. Thus, deoxynucle-
otides may be able to modulate several different biochemical
targets in lymphocytes that ultimately induce apoptotic death
through caspase activation.
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Caspase-9 Phosphorylation and Cleavage
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SUMMARY
     Caspase-9 is a cysteine protease that plays a central
role in mitochondrial-mediated programmed cell death.
Association with APAF-1 activates procaspase-9 in a
cytochrome c- and dATP-dependent manner. Akt, a
kinase that suppresses apoptosis, phosphorylates
caspase-9, thereby preventing activation of this protease.
Using a cell-free system obtained from B-chronic
lymphocytic leukemia cells, we demonstrate that the
phosphorylation at Serine 196 (S196) protects caspase-9
from autocatalytic activation induced by Apaf-
1/cytochrome c, but not from caspase-3 cleavage.
Moreover, we observed that deoxyadenosine
triphosphate (dATP) hydrolysis is required for
autocatalytic processing of caspase-9, but not for
caspase-3 cleavage. Transfection of either human
leukemic Jurkat or of breast cancer MCF-7 cells with
mutant procaspase-9 (S196) did not alter their
susceptibility to a variety of apoptotis-inducing anti-
cancer drugs. These findings suggest therefore that
autocatalytic cleavage of caspase-9 is not an essential
requirement for an effective apoptosis pathway.
INTRODUCTION
     Apoptosis is an evolutionary conserved process involved in
tissue homeostasis of multicellular organisms (1,2). A wide
variety of genetic and biochemical studies have revealed that
apoptosis is caused by caspases, a family of cysteine (3-5).
Usually present as zymogen pro-forms, caspases require
proteolysis at conserved aspartic acids for activation. Because
active caspases cleave substrate proteins at aspartic acid
residues, these proteases are capable of activating
themselves and each other through trans-proteolytic
mechanisms and cascades of sequential proteolysis.
     Caspases involved in apoptosis can be divided into two
groups: apical caspases such as caspases-2, -8, -9, and -10
and executioner caspases such as -3, -6, and -7 (6,7). Once
activated, the apical caspases transmit an apoptotic signal to
the executioners through proteolytic cleavage, activating a
cascade, which leads to apoptosis. The apical zymogens
contain large N-terminal prodomains, which mediate
interactions with caspase-activating proteins.  One of these
prodomain structures is the CARD domain (Caspase
Recruitment Domain), which is found in several initiator
caspases. The CARD domain of procaspase-9 binds Apaf-1
(Apoptotic Protease activating factor-1) in a cytochrome c-
dependent manner in a mitochondrial pathway of cell death
(8).
    Granzyme B is the only other mammalian protease with
specificity for Asp, playing a role in lymphocyte granule-
mediated apoptosis for protection from pathogens and tumor
cells (9,10). It is able to activate most caspase zymogens,
except for caspase-1 (7).
     UV light, g-irradiation and chemotherapeutic drugs induce
apoptosis largely through cytochrome c release from
mitochondria, resulting in activation of procaspase-9 (11-13).
Using purified components, several of the steps in this
mechanism have been elucidated. First cytochrome c binding
to Apaf-1, in conjunction with dATP, allows self-
oligomerization of Apaf-1, and induces a conformational
change in Apaf-1 structure leading to the exposure of its
CARD domain, thus permitting binding to the CARD domain of
procaspase-9. Closely juxtaposed caspase-9 zymogens
assemble on the Apaf-1 oligomeric complex, then trans-
proteolyze each other, resulting in cleavage of procaspase-9
molecules at amino acid residue 315. Procaspase-3 is then
recruited in this complex, called the “apoptosome”, and
activated by caspase-9-mediated cleavage (14,15). Active
caspase-3 then cleaves apoptosome-associated caspase-9 at
aspartic acid residue 330 (16).
The regulation of the “apoptosome” pathway can
occur at different levels. We previously demonstrated that the
5’-triphosphate metabolites of adenine deoxynucleosides,
similar to dATP, can cooperate with cytochrome c and APAF-
1 to trigger a caspase pathway in a chronic lymphocytic
leukemia cell-free system (17). In the same experimental
system, ATP and ADP were shown to act as inhibitors, but the
inhibitory mechanism remained unclear.
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     Post-translational modifications have also been reported to
regulate the apoptosome pathway. Phosphorylation of
caspase-9 and its proform at residue Ser196 by the kinase
Akt (also known as protein kinase B or PKB) was recently
shown to inhibit its protease activity, interfering with
cytochrome c-mediated activation of caspases (18). In this
study we analyzed the role of Ser-196 phosphorylation in both
the autocatalytic and caspase-3-induced cleavage of
procaspase-9, and the effect of Ser-196 phosphorylation on
the susceptibility of cells to undergo programmed cell death
triggered by a variety of anti-cancer agents.
In this study, we analyzed the role of caspase-9
phosphorylation on the cytochrome c/dATP-induced
apoptosome activation, and reevaluated the inhibitory activity
of ATP and ADP.
EXPERIMENTAL PROCEDURES
Cell-Free Extract Preparation
Heparinized peripheral blood samples from patients with CLL
containing at least 80% malignant cells were fractionated by
Ficoll/Hypaque sedimentation. Cells were then washed at 4°C
and resuspended in a hypotonic extraction buffer (HEB;
containing 50 mM PIPES/ 50 mM KCl/5 mM EGTA/2 mM
MgCl2/1 mM DTT/0.1 phenylmethanesulfonyl fluoride). The
cells were centrifuged at 1000 g to form a tight pellet, and the
volume of the cell pellet was approximated. The supernatant
was discarded and HEB buffer was added to a volume
between 0.5 and 1´  the pellet volume. The cells were allowed
to swell for 20-30 minutes on ice and then lysed in a Dounce
homogenizer with 100 strokes of a B-type pestle. The extent
of lysis was monitored under the microscope by erythrosin B
staining. The cell lysate was centrifuged for 60 minutes at
100,000 g. The clarified supernatant was used immediately or
stored in aliquots at -80°C. The cytoplasmic fraction did not
contain microscopically visible whole cells, nuclei, or
mitochondria.
In vitro caspase-9 and caspase-3 assay
Full-length human Procaspase-9 wild-type (WT) and S196A
expression plasmids (18), were subcloned into pcDNA3
(Invitrogen, San Diego, CA). The respective procaspases
were in vitro translated in presence of [35S]-methionine with a
Promega (Madison, WI) TNT transcription/translation kit and
purified from radioactive methionine and ATP through a p-10
desalting column (Bio-Rad, Richmond, CA). The recombinant
caspases were incubated 30 minutes at 37 ° C with the
cytosolic extract in presence of the indicated amount of
nucleotide triphosphates. Inhibition assays were performed
after activation with 250 µM dATP and inhibition with different
concentrations of ATP.
Assays for the characterization of the D315 and D330
cleavage site
For the characterization of the two cleavage sites, the
caspase-3 D330 and the caspase-9 D315, recombinant [35S]-
caspase-9 wild-type (WT) and mutants were treated with 20
µM recombinant active caspase-3 (provided by G.S.
Salvesen, Burnham Institute, La Jolla, CA), 200 ng granzyme
B (provided by D.R. Green, La Jolla Institute for Allergy and
Immunology), or activated in a cell-free system with 250 µM
dATP. Specific caspases were inhibited with DEVD-CHO
(Molecular Probes, Eugene, OR), z-VAD-fmk (Calbiochem,
San Diego, CA)) or depleted with specific monoclonal
antibodies for caspase-3 (Transduction Laboratories,
Lexington, KY) and polyclonal for caspase-9, kindly provided
by X. Wang (Howard Hughes Medical Institute, Dallas, TX).
Selection of the transfected clones of MCF-7
Full-length human procaspase-9 WT and S196A expression
plasmids, which contain neomycin-selectable markers, were
transfected into human breast adenocarcinoma MCF-7 cell
line (ATCC HTB 22) and human T cell leukemia Jurkat cell
line (ATCC TIB 152) with liposome-mediated Effectene
reagent (Qiagen, Valencia, CA) according to the
manufacturer's instructions. Efficiency of transfection was
quantified by concomitant transfection of a plasmid encoding
for the GFP protein (kindly provided by Jacques Corbeil, VA
Medical Center San Diego, CA) followed by flow cytometry
analysis of the cells after 48 h. Selection of stable
transformants was performed in the presence of 1 mg/ml
(Jurkat) and 0.5 mg/ml (MCF-7) geneticin (Sigma, St. Louis,
O). Individual clones were obtained by limiting dilution.
Cytotoxicity assays
Forty-eight hours after transient transfection with the mutant
caspase-9 vectors, MCF-7 cells were tested against
staurosporine, paclitaxel (Taxol), cladribine (2CdA), and
indanocine (19) at different concentrations chosen according
to the IC50 of the untransfected cells. For assays using stable
transfectants, cells were grown under continuous neomycin
selection (1 mg/ml) until two days before the assay. Cells
were then washed and resuspended in neomycin-free
medium for two days, before various concentrations of the
indicated drugs were added. Cells were cultured for three
days in presence of the indicated drugs and cytotoxicity was
measured with an MTT assay and monitored with a
spectrophotometer (20). The data collected for the single
drugs were analyzed using non-parametric curve fitting to
obtain the IC50 values (Prism, GrahPad Software, San Diego,
CA).
Whole Cell Assay for Caspase Activity
MCF-7 transfected cells were treated with 1 µM 2CdA or 1 µM
staurosporine for 24 hours at 37 ° C to induce caspase-9
activation. Cells were washed twice with PBS and the pellets
were resuspended in caspase buffer (50 mM Hepes, pH 7.4,
100 mM NaCl, 1 mM EDTA, 0.1% Chaps, and 5 mM
dithiothreitol) for 30 min at 4 °C. Lysates (10-20 µg of total
protein) were mixed with 50 µl aliquots of caspase buffer, and
reactions were initiated by addition of 50 µM of the specific
substrate. After 1 hour incubation at 37°C, caspase-9-like
protease activity was measured with the substrate Ac-LEHD-
AFC (sequence; N-acetyl-Leu-Glu-His-Asp-AFC (21)). Activity
was measured by the release of 7-amino-4-trifluoromethyl-
coumarin (AFC) monitoring fluorescence at excitation and
emission wavelengths of 400 and 505 nm, respectively.
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RESULTS
Comparison of wild-type and mutant S196A caspase-9
activation in a cell-free system
Recombinant wild-type (WT) or S196A mutant procaspase-9
was translated in vitro in the presence of [35S]-methionine.
When added to extracts prepared from CLL cells, the
combination of dATP and cytochrome c induced cleavage of
both WT and S196A procaspase-9. The proteolytic cleavage
was equivalent for wild-type and Ser196A caspase-9 (Fig. 1a).
Interestingly, the cleavage of wild-type caspase-9 resulted in a
single large-subunit fragment with a molecular weight of about
37 kDa (p37), while the Ser196A caspase-9 protein produced
p37 plus an additional fragment with a smaller molecular
weight (p35).
Figure 1.  Comparison of dATP-induced procaspase-9 cleavage in
wild type (WT) and mutant non-phsosphoratable (S196A)
procaspase-9. Fig 1A.CLL S-100 extracts (100 µg) were incubated
with in vitro translated 35S-Caspase-9 WT or S196A (3 µl) and
cytochrome c (2 µM) and the indicated amount of nucleotide
triphosphates for 30 minutes at 37° C. Samples were separated in a 4-
20% SDS-gel, transferred to a PVDF membrane and exposed to X-
ray films using an amplifying screen (Biomax Transcreen LE, Kodak).
Fig 1B. Quantification of the dATP-induced p35 caspase-9 cleaved
fragment. The intensity of the p35 caspase-9 fragment was
determined by quantitative phosporimager analysis using a
PhosphorImagerTM (Molecular Dynamics). The results are
representative of 3 independent experiments using S100 extracts
from different CLL patients.
Cytochrome c-induced processing of S196A procaspase-
9 is regulated by dATP concentration
Increasing the dATP concentrations in cell extracts with
mutated S196A procaspase-9 dose-dependently increased
intensity of the p35 fragment (Fig 1A). At low dATP
concentrations, or using the less efficient analogue 2CdATP,
the p37 fragment is predominantly expressed. Increasing
dATP concentrations induces the disappearance of p37 and
the appearance of p35 (Fig. 1B).
Inhibition of the caspases by addition of ATP does not go
through Caspase-9 phosphorylation
We previously demonstrated that ATP can act as an inhibitor
of the apaf-1/caspase-9 pathway in cell-free extracts (11).
One possible explanation for this result is that addition of ATP
activated Akt kinase and enhanced the phosphorylation of
caspase-9, which could explain the observed inhibitory
activity. To test this hypothesis we compared the ATP
inhibitory activity in the dATP-activated cell-free system using
the WT and S196A caspase-9. No differences were observed
between the wild-type and mutant caspases in terms of the
ATP inhibitory activity (Fig. 2).
Figure 2. Comparison of the ATP-inhibitory activity on
cytochrome c/dATP-induced caspase-9 cleavage.  CLL S100
extracts (100 µg) were incubated with in vitro translated 35S-
caspase-9 WT or S196A (3 µl) and cytochrome c (2 µM) and the
caspase pathway was activated with 250 µM of dATP. Inhibition
assays were performed with addition of different ATP
concentrations for 30 minutes at 37C. Samples were
fractionated in a 4-20% SDS-gel, transferred on a PVDF
membrane and exposed to X-ray films.
Characterization of the two bands of caspase-9
The activated caspase-9 fragment p37 is known to be the
result of the cleavage by caspase-3 at Asp 330, and the
fragment p35 is the product of the autocatalytic processing at
Asp 315 (22). To identify the nature of the observed caspase-
9 fragments, we used the following approaches: (a) treatment
with specific caspase inhibitors; (b) incubation with
recombinant active forms of caspase-3 and granzyme B; and
(c) immunodepletion with specific anti-caspase antibodies.
Inhibition of caspase-3 by the specific inhibitor DEVD-CHO, in
the cell-free system activated by 250 µM dATP, blocked the
appearance of the p37 fragment of caspase-9 S196A and
lmost reduced completely the activation of the wild-type
caspase (Fig. 3A lanes 1 and 2). Depletion of caspase-3 by
immunoprecipitation with monoclonal anti-caspase-3 antibody,
resulted in the removal of the p37 fragment, leaving behind
the smaller p35 (Fig. 3B lanes 1 and 2). Incubation of the
recombinant caspases with active recombinant caspase-3
resulted in the cleavage of both types of caspase-9, but only
at D 330 resulting in the fragment p37 (Fig. 3A lanes 5 and 6).
Granzyme B treatment produced both bands (Fig. 3A lanes 3
and 4), but resulted in the cleavage only at the expected Asp
315 when caspases were inhibited with zVAD-fmk (Fig. 3B
lane 5).
Experiments with transfected MCF-7 and Jurkat cells
The human T lymphoblastoid cell line Jurkat and the human breast
cancer cell line MCF-7, were used to assess the role of
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Figure 3.  Determination of the cleavage fragments of WT and S196A
procaspase-9. Fig. 3A Recombinant caspase-9 (3 µl) was incubated
with CLL extract (100 µg), activated with 250 µM dATP in presence of
cytochrome c (2 µM) and caspase-3 was inhibited by the specific
inhibitor DEVD-CHO at 1 µM (lanes 1 and 2). In lanes 3 and 4
recombinant caspase-9 was incubated with 200 ng granzyme B and
in lanes 5 and 6 with 20 µM active recombinant caspase-3, all at 37° C
for 30’. Fig. 3B 3 µl of 35S-Caspase-9 S196A was incubated with 100
µg of CLL extract, 2 µM cytochrome c and 250 µM dATP for 30’ and
60’ respectively, after immunodepletion of caspase-3 (lanes 1 and 2)
and immunodepletion of caspase-9 (lanes 3 and 4) with specific
antibodies. In lane 5 recombinant caspase-9 S196A was incubated
with 200 ng of granzyme B in presence of 1 µM ZVAD-fmk for 30’ at
37° C. All the samples were electrophorated in a 4-20% SDS-gel,
transferred to a PVDF membrane and exposed to X-ray films, as
described in the previous figures. The results are representative of 3
independent experiments.
phosphorylation mutation of caspase-9 on susceptibility to
drug-induced apoptosis. Cells transiently or stably expressing
wild-type and S196A mutant procaspase-9 were generated,
and their susceptibilities to apoptosis were tested using the
following cytotoxic drugs: staurosporine (23), taxol (24), 2CdA
(17), and indanocine (19). To confirm the presence of the
plasmid in the cells, we performed PCR analysis for exon 2
and 3 of caspase-9 (data not shown). Serial-dilution of the
drugs was performed to determine their IC50 values on the
tested cell lines. No difference was observed in the toxicity of
the four compounds tested in the stably transfected Jurkat or
MCF-7 cells (Fig. 4). Transiently transfected cell lines also
exhibited the same apoptotic responses to these drugs (data
not shown). Caspase activity analysis was performed using
lysates from drug-tested cells by fluorometric analysis with
specific caspase-3 and -9 substrates. No difference was
detected in the intensity or kinetics of drug-induced caspases
activation, comparing WT and S196A transfected cells (data
not shown).
DISCUSSION
Phosphorylation of procaspase-9 by Akt was reported to
inhibit its activation and to down-regulate apoptosis in cells
(18). We showed in a previous report that ADP is an
endogenous inhibitor of the dATP-mediated activation of
APAF-1/cytochrome c apoptotic pathway, probably through
competitive inhibition of the binding of dATP to APAF-1 (11).
     In this study, we analyzed the role of procaspase-9
phosphorylation on nucleotide-induced caspase activation.
For this reason, mutants of caspase-9 at the phosphorylation
site Ser 196 were employed. We observed a difference in
cleavage between the wild-type and the mutant S196A
procaspase-9 after activation with dATP, with mutant
procaspase-9 S196A exhibiting a smaller p35 cleaved
fragment. Procaspase-9 is known to possess two different
cleavage site at aspartic acid residues 330 and 315. The first
is believed to be specific for feedback activation by caspase-
3, and the second is the autocatalytic site and cleavage site
for granzyme B (22). To identify the fragments observed in our
blots, several approaches were taken, including (a) cleavage
with granzyme B; (b) recombinant active caspase-3; and (c)
depletion or inhibition of specific caspases with specific
antibodies. Our results indicate that the two bands observed
represent the previously described fragments. The activated
caspase-9 produced the p37fragment, reflecting cleavage at
D330, the cleavage site of caspase-3. In contrast the mutant
S196A was cleaved at both sites, D330 and D315. Therefore
it appears that phosphorylation at S196 protects procaspase-9
from its autocatalytic processing. This result explains previous
observations that Akt-mediated phosphorylation of
procaspase-9 prevents activation of the protease by
cytochrome c (18).
Figure 4. Chemosensitivity of MCF-7 cells stably transfected with full-
length human procaspase-9 and mutated caspase-9 S196A.
Cytotoxic assays were performed as indicated in the experimental
procedures section after 72 hours drugs exposure by MTT reduction.
Cells were grown under continuous neomycin selection until two days
before the assay. Cells were then washed and resuspended in
neomycin-free medium, for two days before different concentrations of
the indicated drugs were added. The top panel represents the MTT
assay for staurosporine. The y-axis is optical density measured at 570
nm. The x-axis indicates the various concentrations of staurosporine,
expressed in Log10 nM.  The lower panel represents the results of the
assays performed with the indicated drugs. The IC50 was calculated
using non-parametric curve fitting software (Prism, Graphpad, San
Diego). The results are representative of 4 independent experiments.
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     Hu et. al. recently reported that energy is required for the
activation of procaspase-9 in the APAF-1-mediated pathway
(25). ATP-analog hydrolysis is a requisite for the assembly of
APAF-1 molecules (11). Our data suggest that energy is also
needed for the autocatalytic cleavage of procaspase-9.
Titration of dATP in the S196A mutated system induces a
linear appearance of the p35 fragment of caspase-9.
     We investigated the possibility that previously observed
ATP inhibition of the dATP-induced caspase activation (11)
was mediated by the phosphorylation of procaspase-9 by an
activated upstream kinase, such as Akt. The results obtained
in this report seem to exclude this hypothesis. In fact, the
ATP-based inhibitory activity for both wild-type and mutated
S196A recombinant procaspase-9 was similar. Therefore ATP
inhibition appears occur by a phosphorylation-independent
mechanism. Finally, stable or transient transfected cell lines
showed no difference in the response to cytotoxic drugs nor in
caspase activation i vivo. We can not exclude the possibility
that the endogenous procaspase-9 present in the cells may
still be functional, and that the “dominant negative”
overexpression approach used in our experiments is not
suf icient to completely block its function. Nevertheless, the
data suggest that phosphorylation of Ser 196 does not greatly
influence the apoptotic cascade in vivo. We speculate that the
Ser196 residue of caspase-9 may be constitutively
phosphorylated in vivo and, as already reported (16), and thus
its cleavage may not be a crucial step. Phosphorylation may
play a role in the prevention of undesired spontaneous
apoptosis, by blocking the apical caspase autoactivation.
Association of procaspase-9 with the cofactor APAF-1
appears to be more important than its cleavage for the
ctivation of the apoptotic cascade, and phosphorylation of
procaspase-9 may interfere with this protein interaction.
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NEOPLASIA
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic
leukemia cells by damaging the DNA and by directly affecting the mitochondria
Davide Genini, Souichi Adachi, Qi Chao, David W. Rose, Carlos J. Carrera, Howard B. Cottam, Dennis A. Carson, and Lorenzo M. Leoni
Adenine deoxynucleosides induce apopto-
sis in quiescent lymphocytes and are thus
useful drugs for the treatment of indolent
lymphoproliferativediseases.Toexplainwhy
deoxyadenosine and its analogs are toxic to
a cell that is not undergoing replicative DNA
synthesis, several mechanisms have been
proposed, including the direct binding of
dATP to the pro-apoptotic factor Apaf-1 and
the activation of the caspase-9 and -3 path-
ways. In this study it is shown, by means of
several assays on whole cells and isolated
mitochondria, that 2-chloro-2*-deoxyade-
nosine (2CdA) and 2-choloro-2*-ara-fluoro-
deoxyadenosine (CaFdA) disrupt the integ-
rity of mitochondria from primary chronic
lymphocytic leukemia (B-CLL) cells. The
nucleoside-induced damage leads to the
release of the pro-apoptotic mitochondrial
proteins cytochrome c and apoptosis-induc-
ing factor. The other adenine deoxynucleo-
sides tested displayed comparable DNA-
damaging potency but did not affect
mitochondrial function. Interference with mi-
tochondrial integrity, thus, may be a factor in
the potent cytotoxic effects of 2CdA and
CaFdA toward nondividing lymphocytes.
(Blood. 2000;96:3537-3543)
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Introduction
The deoxynucleoside analogs 29-deoxyadenosine (dAdo), 2-chloro-
29-deoxyadenosine (2CdA, cladribine), 9-b-D-arabinofuranosyl-2-
fluoroadenine (F-ara-A, fludarabine), and 2-chloro-29fluorodeoxya-
denosine (CaFdA) have achieved an important role in the treatment
of indolent lymphoid malignancies, including hairy cell leukemia
(HCL), chronic lymphocytic leukemia (CLL), and low-grade
lymphoma, because of their ability to kill nondividing cells. The
cytotoxicity of these drugs depends mainly on the accumulation
of their triphosphate metabolites (dATP, 2CdATP, F-araATP,
CaFdATP) in lymphocytes because of the high deoxycytidine
kinase levels and the low 59-deoxynucleotidase activities in these
cells.1 Different concentrations of the 2 enzymes in malignant cells
may explain resistance between patients.2 Once transformed into
the triphosphate form, adenine deoxynucleosides can induce DNA
damage2,3 and trigger the apoptotic cascade.4
Apoptosis is characterized by the activation of cysteine pro-
teases called caspases, which cleave proteins essential for the
survival of the cell. Furthermore, these caspases have been shown
to activate the endonuclease responsible for the internucleosomal
cleavage of genomic DNA.5
Mitochondria play a key role in the events leading to caspase
activation in cells undergoing apoptosis. Alteration of their func-
tions can induce the release of cytochrome c and apoptosis-
inducing factor (AIF) from the intermembrane space into the
cytosol, triggering activation of caspases and endonucleases.6-8
Bcl-2 family members, some of which are located in the mitochon-
dria, control those events, by either inducing (eg, Bax, Bad, Bak,
Bid, Bim) or inhibiting (eg, Bcl-2, Bcl-XL, Mcl-1) apoptosis.9,10
Cytochrome c released by the mitochondria and a cytosolic apopto-
sis protease activating factor (Apaf-1) oligomerize into a large multi-
meric complex, called the apoptosome.7 This complex itself is sufficient
to recruit and activate procaspase-9. Once activated, caspase-9 cleaves
the downstream caspases, such as caspase-3, and activates the pro-
grammed cell death cascade.11 In addition to cytochrome c, AIF is
normally confined to mitochondria. The release of AIF to the cytosol is
followed by its relocalization to the nucleus. Recombinant AIF causes
chromatin condensation in isolated nuclei and large-scale fragmentation
of DNA.12
Several anticancer drugs induce DNA damage, which can lead
to the phosphorylation of p53 and the subsequent transcriptional
activation of p53-dependent proteins such as p21, Bax, and Hdm-2,
leading to growth arrest, repair, or apoptosis. One of the target
genes involved in p53-dependent programmed cell death might be
Bax, a pro-apoptotic Bcl-2 family member protein. Bax overexpres-
sion has been linked to cytochrome c release from the mitochon-
dria13 and can induce apoptosis.14
The assembly of the apoptosome requires dATP, which binds to
Apaf-1. In a previous study, we compared several clinically
relevant adenine deoxynucleotide analogs for their capacity to bind
APAF-1 and to activate caspase-9.15 In this study we analyzed and
compared the effect of the corresponding nucleosides on both
mitochondrial function and DNA integrity.
Materials and methods
Cell lines and drugs
Human fibroblasts HS-68 (ATCC CRL 1635) and human leukemia T
lymphoblast CEM cell lines stably transfected with pZipneo vector
(CEM/Neo) or with vector encoding BCL2 (CEM/Bcl-2)16 were cultured in
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complete medium (RPMI-1640 supplemented with 10% fetal bovine
serum). The deoxynucleoside analogs dAdo and fludarabine were from
Sigma (St Louis, MO); cladribine and CaFdA were synthesized by
published procedure.17 F-AraATP and CaFdATP were kind gifts of Dr W.
Plunkett (University of Texas M. D.Anderson Cancer Research Center, Houston,
TX), and 2CdATP was synthesized in our laboratory by Dr Q. Chao.18
Cell isolation and analysis
Written informed consent was obtained to procure peripheral blood from all
patients. Patients had to have B-CLL according to National Cancer Institute
criteria of any Rai stage. Criteria for requiring therapy were as follows:
disease-related symptoms; anemia, thrombocytopenia, or both; bulky
lymphadenopathy, clinically relevant splenomegaly, or both. Heparinized
peripheral blood samples from different patients with CLL and containing
at least 90% malignant cells were fractionated by Ficoll-Hypaque sedimen-
tation. Nonadherent mononuclear cells were resuspended in complete
medium (RPMI-1640 supplemented with 10% fetal bovine serum) at a
density of 1 to 2 3 106/mL. Cells were incubated at 37°C in an atmosphere
of 5% CO2 with the indicated drugs. In some experiments, frozen cells were
used. dAdo was used in cells that were pretreated for 1 hour with 50 mmol/L
of the adenosine deaminase inhibitor deoxycoformycin.
Cellular assay for caspase activity
At the indicated time points, CLL cells were washed twice with phosphate-
buffered saline (PBS), and the pellet was resuspended in caspase buffer (50
mmol/L HEPES, pH 7.4, 100 mmol/L NaCl, 1 mmol/L EDTA, 0.1% Chaps,
and 5 mmol/L dithiothreitol [DTT]) for 10 minutes at 4°C. Lysates were
then stored at 280°C. The caspase enzymatic assays were carried out in
96-well plates. Lysates (10-20 mg total protein) were mixed with 50 mL
HEB buffer (PIPES 50 mmol/L, KCl 20 mmol/L, EGTA 5 mmol/L, MgCl2
2 mmol/L, and DTT 1 mmol/L, pH 7), and reactions were initiated by the
addition of 100 mmol/L of the specific substrate. After a 1-hour incubation
at 37°C, caspase-3-like protease activity was measured with the substrate
Ac-DEVD-AMC, and caspase-9-like activity was measured using Ac-LEHD-
AFC. Activity was measured by the release of 7-amino-4-trifluoromethyl-
coumarin (AFC) or 7-amino-4-methyl-cumarin (AMC), monitoring fluores-
cence at excitation and emission wavelengths of 400 and 505 nm, and 380
and 460 nm respectively.
Cytofluorometric analysis of mitochondrial transmembrane
potential (DCm) by DiOC6 and cell membrane permeability
by PI
CLL cells were treated with the indicated amount of the drugs either alone
or with 50 mmol/L of the cell-permeable caspase inhibitor Z-VAD-fmk
(Z-Val-Ala-Asp(Ome)-CH2F; Biomol, Plymouth Meeting, PA). Cells were
then incubated for 10 minutes at 37°C in culture medium containing 40
nmol/L 3,39 dihexyloxacarbocyanine iodide (DiOC6; Molecular Probes,
Eugene, OR) and 5 mg/mL propidium iodide (PI; Molecular Probes),
followed by analysis within 30 minutes of fluorochrome in a Becton
Dickinson FACScalibur cytofluorometer. After suitable compensation,
fluorescence was recorded at different wavelengths: DiOC6 at 525 nm
(FL-1) and PI at 600 nm (FL-3).
Measurement of alkali-sensitive sites in DNA
DNA damage was assessed by alkaline unwinding and ethidium bromide
fluorescence as previously described.19 Because ethidium bromide preferen-
tially binds to double-strand DNA (ds-DNA) in alkali, the relative amounts
of nonbroken ds-DNA and broken single-strand DNA can be assessed.
Fluorescence was determined with a CytoFluor fluorescence plate reader
(PerSeptive Biosystems, Framingham, MA) with excitation at 520 nm and
emission at 585 nm. Results are expressed as [% ds-DNA 5 [(F2Fmin)/
(Fmax2Fmin)]3100], where F is the fluorescence of the experimental
condition, Fmin is the background ethidium bromide fluorescence deter-
mined after conversion of all DNA into single-strand form by sonication,
and Fmax is the fluorescence determined after the addition of the mercapto-
ethanol solution before the alkaline solution to maintain the pH at 11.0,
which is well below that needed to augment unwinding of single-strand
DNA. The amount of single-strand DNA in alkali after sonication is
proportional to the number of DNA-strand breaks (either single or double),
which varies directly as a function of the extent of DNA unwinding.
Neutral comet assay of double-strand DNA breaks
The single-cell comet electrophoresis assay was performed according to the
Trevigen CometAssay (Trevigen, Gaithersburg, MD) reagent kit. CLL cells
were suspended in complete medium (RPMI-1640 supplemented with 10%
fetal bovine serum) at a density of 1 3 106/mL and treated with the
indicated drugs for 6 hours at 37°C. Then, 0.5 mL aliquots of 0.5% low
melting point agarose in PBS (Sigma, St Louis, MO) at 42°C were added to
tubes containing 50 mL each of the cell suspensions. Fifty mL of the mixture
was quickly pipetted onto a microscope slide, precovered with 0.5%
agarose, and allowed to solidify at 4°C. Slides were immersed for 30
minutes in prechilled lysis buffer (2.5 mol/L sodium chloride, 100 mmol/L
EDTA, pH 10, 10 mmol/L Tris base, 1% sodium lauryl sarcosinate, 0.01%
Triton X-100) at 4°. After lysis, slides were incubated for 30 minutes in
alkali buffer (0.3 mol/L NaOH, 1 mmol/L EDTA). TBE washed slides were
placed in horizontal gel electrophoresis chambers containing 1 L 90
mmol/L Tris/90 mmol/L boric acid/2 mmol/L EDTA buffer (TBE) at 1
V/cm for 10 minutes. DNA was stained after SYBR green was added to the
slides. A Zeiss Axioscope microscope (Carl Zeiss, Thornwood, NY)
attached to a camera and image analysis system was used to quantify the
different parameters of the comets. At least 100 cells were analyzed per
slide. Results were expressed in terms of percentage of comet cells divided
by total amount of cells.
Mitochondria isolation
The CLL cells were washed in ice-cold Dulbecco’s phosphate-buffered
saline for disruption by nitrogen cavitation.20 All subsequent steps were
carried out on ice or at 4°C. The cells were washed with MA buffer (100
mmol/L sucrose, 1 mmol/L EGTA, 20 mmol/L MOPS pH 7.4, 1 g/L bovine
serum albumin) then resuspended at 2 3 108 cells/mL in MB buffer (MA
buffer plus 10 mmol/L triethanolamine, 5% Percoll, 1 mmol/L phenylmeth-
ylsulfonyl fluoride, and an antiproteinase mixture consisting of aprotinin,
pepstatin A, and leupeptin, each at 10 mmol/L). The cells were then
disrupted by cavitation, after which lysates were centrifuged twice at 2500g
for 5 minutes to remove nuclei and unbroken cells then at 25 000g for 30
minutes to isolate mitochondria. The mitochondria were suspended in MC
buffer (identical to MA buffer except that the sucrose concentration was 300
mmol/L and an antiprotease mixture was included that consisted of
aprotinin, pepstatin A, and leupeptin, each at 10 mmol/L) and used for
measuring membrane potential alterations with DiOC6.
Flow cytometry analysis of AIF release
Nondividing CLL cells were treated with the nucleosides as indicated. Cells
were washed and permeabilized by 0.03% digitonin treatment for 15
minutes at room temperature. The concentration of digitonin used was
obtained by titration and is enough to permeabilize the outer membrane of
the cells without affecting the mitochondrial membrane. Cells were then
fixed with 2% paraformaldehyde and incubated with the primary antibody
to AIF (a kind gift from G. Kroemer, Institut Gustave Roussy, Villejuif,
France), washed, and stained with the fluorescent-labeled secondary
antibody (Alexa 488; Molecular Probes). An isotype-matched primary
antibody was used as control. Cells were postfixed by resuspending the
pellet in 2% paraformaldehyde and analyzed by flow cytometry.
Immunocytochemistry
One hundred microliters of the CLL cells at a concentration of 2 3 106/mL,
treated for 24 hours with the indicated drugs, was stained for the detection
of the mitochondrial membrane potential with 150 nmol/L Mitotracker
Orange (Molecular Probes) for 30 minutes at 37°C. Then 2 3 105 cells were
pelleted at 300g for 5 minutes on a slide. The cells were fixed for 10 minutes
in 4% paraformaldehyde, washed in PBS, and incubated for 2 hours with
the antibodies specific for AIF (supplied by G. Kroemer) and cytochrome c
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(clone 6H2.B4; Pharmingen, San Diego, CA), at a concentration of 2 to 10
mg/mL in I-Block blocking buffer (Tropix, Bedford, MA) supplemented
with 0.05% Triton X-100. Alexa 488 (green) and Alexa 568 (red) served as
species-specific secondary antibodies. The nuclear DNA was stained using
DAPI. Coverslips were washed successively in PBS and deionized H2O for
5 minutes and mounted in Fluoromount (Fisher, CA). Images were obtained
with a Zeiss Axioscope microscope.
Microinjection
HS-68 cells were grown on glass coverslips (Fisher, Pittsburgh, PA). The
triphosphate forms of the nucleosides analogs were dissolved at a concentra-
tion of 5 mmol/L in microinjection buffer consisting of 5 mmol/L sodium
phosphate and 100 mmol/L KCl (pH 7.4) containing a Dextran-FITC or
Dextran-TRITC fluorescent dye (Sigma). Approximately 100 cells/analog
were microinjected using glass capillary needles. The estimated final
concentration in the cells was 500 mmol/L, based on an estimated injection
volume of 50 fL. Cells were stained as described above.
Results
Cytotoxicity of the nucleoside analogs on CLL cells
For this study, we first screened 20 patients for their sensitivities to
the nucleoside analogs 2CdA, F-Ara-A, CaFdA and dAdo (plus
deoxycoformycin). We used equimolar concentrations of the
nucleosides because the principal aim was to compare their effects
on DNA and mitochondria integrity. CLL cells that were com-
pletely resistant to the nucleoside toxicity after 24 hours of
incubation at 10 mmol/L (less than 20% specific killing) were
excluded from analysis because these cells did not accumulate the
active triphosphate analog intracellularly.21 Five of 20 patients with
CLL were thus excluded. In the nucleoside-susceptible CLL
populations, loss of viability measured by dye exclusion was
already visible after a few hours (Figure 1A). Analysis of the
apoptotic mechanisms triggered by the different nucleosides showed
distinct peculiarities. Mitochondrial membrane potential measured
by flow cytometry decreased in CLL cells treated with 2CdA and
CaFdA already after 12 hours, but not after similar treatment with
dAdo and F-Ara (Figure 1B). Similarly, the kinetics of enzymatic
activation of caspase-9 and -3 (Figure 1 C,D) were different: 2CdA
and CaFdA were able to activate the caspases already after 12 hours,
whereas 24-hour incubation was required to see induction of the caspase
activity by F-Ara-A. The intensity of caspase-3 (Figure 1C) and
caspase-9 (Figure 1D) activation by F-AraA at 24 hours was also
reduced by at least 2-fold when compared to 2CdA or CaFdA.
DNA damage analysis
We used 2 different methods to study nucleoside effects on DNA
integrity, alkaline unwinding and comet assay. As assessed by the
unwinding assay, 2CdA, F-Ara-A and CaFdA at 10 mmol/L
generate approximately equivalent DNA breaks after 12 hours
(Figure 2A). The broad-spectrum caspase inhibitor z-VAD-fmk did
not protect the cells from early DNA damage (data not shown).
dAdo was less potent. To confirm these results, single-cell analysis
was performed. After 6 hours of continuous incubation with 10
mmol/L nucleoside, cells were placed on the slides in an agarose
layer and lysed. Current was applied for 10 minutes, and DNA was
stained with SYBR green. Damaged DNA migrated from the lysed
cell membrane, forming a DNA tail in a comet shape (Figure 2C).
Approximately 100 cells were counted, and the percentages of the
cells displaying comets were enumerated (Figure 2B). More than 20%
of the cells exposed to 2CdA, F-Ara-A, and CaFdA displayed a comet
shape, whereas dAdo was able to affect only 12% of the cells.
Mitochondrial damage
Mitochondria are known to contain their own deoxynucleoside ki-
nases.22 Mitochondria were isolated by cavitation from CLL cells and
treated for 10 minutes with different concentrations of the nucleoside
analogs. Both 2CdA and CaFdA were able to affect the membrane
potential of the mitochondria by reducing the incorporation of the dye
DiOC6 (Figure 3A). dAdo and F-Ara-A at the highest concentrations
tested (1000 mmol/L) did not affect the membrane potential. We then
analyzed the damage to mitochondria in whole CLL cells by measuring
the cytoplasmic fluorescence of AIF, after treatment with 10 mmol/L of
the analogs for 8 hours. Apparent relocalization of AIF was detected by
flow cytometric analysis after permeabilization of the cells with 0.03%
digitonin. This concentration of digitonin used had been shown in
preliminary experiments to permeabilize the outer membrane of the
cells without affecting the mitochondrial membrane. Only treatment
with 2CdA, but not F-AraA, increased AIF fluorescence (Figure 3B).
CaFdA behaved as 2CdA (data not shown). We believe that the
increased AIF fluorescence is a result of its relocalization from
mitochondria to the cytosol, as immunocytochemistry results also seem
to indicate (data not shown). Pre-incubation of the CLL cells with 100
mmol/L Z-VAD-fmk did not alter the 2CdA-induced AIF relocalization.
Overexpression of the anti-apoptotic protein bcl-2 protects cells
from direct mitochondrial damage.23 The CEM cell line overexpressing
bcl-2 (CEM/Bcl-2) and the control mock-transfected cells (CEM/NES)
were treated with 1 mmol/L 2CdA, CaFdA, and F-Ara-A. At different
time points mitochondrial membrane potential and caspase activation
were measured. There was no significant difference in the toxicity of
F-Ara-A toward the 2 cell lines. In contrast, Bcl-2 overexpression
significantly protected against early caspase activation and mitochon-
drial transmembrane alterations induced by 2CdA after 4 and 8 hours
Figure 1. Nucleoside cytotoxicity on B-CLL cells. (A) B-CLL cells were treated
with 2CdA (f), CaFdA (M), F-Ara-A (F), and dAdo (E) at 10 mmol/L for the indicated
time points. Viability was assessed by counting the cells after staining with erythrosin
B and is represented as percentage of the control. (B) The same cells were tested for
mitochondria membrane potential by flow cytometry analysis of incorporation of
DiOC6. (C) Cells were lysed in caspase buffer and incubated with 100 mmol/L of
fluorometric substrate, and caspase-9 activity was measured by fluorometric analy-
sis. (D) Caspase-3 enzymatic activity. These data (6 SD) were obtained from a single
patient studied in duplicate and are representative of 6 different patients.
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(Figure 3C). The protection was lost after 24 hours of incubation.
CaFdA behaved like 2CdA (data not shown).
Immunocytochemistry
To corroborate the biochemical results, we performed immunocyto-
chemical analysis of nucleoside-treated CLL cells. The effect of the
nucleoside analogs on B-CLL mitochondria was analyzed after
only 8 hours to exclude secondary effects related to caspase
activation. Alteration of the mitochondria membrane potential was
assessed by the incorporation of Mitotracker orange (MT orange)
and the release of cytochrome c. In control cells, cytochrome c and
MT orange colocalized in the mitochondria (Figure 4A). After
treatment with 2CdA, the mitochondrial cytochrome c signal was
strongly reduced, but the MT orange fluorescence remained
constant, indicating that the mitochondria may have released
cytochrome c but maintained the transmembrane potential (Figure
4B). F-Ara-A and dAdo did not visibly affect the mitochondria
(Figure 4C; dAdo data not shown). Finally, experiments performed
using the pan-specific caspase inhibitor Z-VAD-fmk indicated that
the nucleoside-induced release of cytochrome c was not caspase
dependent (data not shown).
Microinjection
To confirm, in a separate system, the direct role of nucleotides in
mitochondrial damage, we microinjected triphosphates into human
fibroblasts. Because of their size, HS-68 cells were relatively easy
to microinject. The results show that the triphosphates of 2CdA
(and CaFdA; data not shown) induced a change in the subcellular
distribution of mitochondria (Figure 5). To detect the mitochondria
in the cells, both MT orange staining and labeling using cyto-
chrome c antibodies were used, but only results using MT orange
are shown. The microinjected cells were identified by the co-
injection of florigenically labeled dextran (in green). The mitochon-
dria were arranged along microtubules, forming a fibrillar array
Figure 2. Nucleoside-induced DNA damage of B-CLL cells. (A) B-CLL cells from 4
different patients were treated at the indicated time points with 10 mmol/L of 2CdA,
CaFdA, F-Ara-A, and dAdo. DNA damage by alkaline unwinding was assessed. Data
are reported as percentage ds-DNA. (B) Single-cell DNA damage (comet assay) was
performed after 6-hour treatment with 10-mmol/L concentrations of the drugs. Cells
were plated on a slide in low-melting point agarose and lysed, and current was
applied for 10 minutes at 1 V/cm. At least 100 cells were counted, and the
percentages of the comets were determined. Columns represent the mean and error
bars the standard deviation obtained from 4 patients. (*) Statistically increased from
control untreated cells; P , .05 by the nonparametric Mann-Whitney test. (C)
Example of comets after treatment with F-Ara-A compared to control cells. These
data were obtained from a single patient and are representative for 4 patients.
Figure 3. Mitochondrial damage by nucleosides in B-CLL cells. (A) Mitochondria
from B-CLL cells were nitrogen isolated by cavitation, treated for 10 minutes with the
indicated concentrations of 2CdATP (f), CaFdATP (M), F-Ara-ATP (F), and dATP
(E), stained with 40 nmol/L DiOC6 for 10 minutes at room temperature, and rapidly
analyzed by flow cytometry. (B) B-CLL cells were treated with 10 mmol/L of the
nucleosides for 8 hours, then permeabilized with 0.03% of digitonin and fixed with 4%
paraformaldehyde. AIF release was detected by staining with specific antibody and
with fluorescence-labeled secondary Alexa 488 and measured by flow cytometry. (C)
Human leukemia T-lymphoblastoid CEM cell lines, transfected with bcl-2–expressing
vector (CEM/bcl-2) (E) or control vector (CEM/NEO) (F), were treated with 1 mmol/L
of the nucleosides. Membrane potential analyses and caspase analysis were
performed at the indicated time points. Error bars represent the SD obtained from 3
independent experiments.
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radiating toward the cell periphery. After microinjection with 2CdA
(Figure 5C,D), but not with F-AraA (Figure 5E,F), the mitochon-
dria retracted from the cell periphery and clumped around the
nucleus. Interestingly, this mitochondrial redistribution was not
accompanied by a dramatic change in cell shape or by cytoplasmic
cytochrome c release.
Discussion
Adenine deoxynucleoside analogs, such as F-Ara-A and 2CdA, are
used for the treatment of B-CLL. However, the mechanisms of
action of these drugs are not understood precisely. In this study, we
confirm with 2 different assays that all the cytotoxic adenine
deoxynucleosides induce DNA damage in CLL, as previously
reported.24,25 At equimolar concentrations, the DNA strand break
formation was comparable, and was at the early time points, when
the damage was a result of the direct effect of the drugs on DNA.
After 24 hours, a big difference between 2CdA/CaFdA and
F-Ara-A was observed. This was probably a consequence of the
activation of the caspases, leading to endonuclease-mediated
cleavage of the DNA,26 because caspase activity at 24 hours was
higher in 2CdA- and CaFdA-treated cells.
The data indicate that 2CdA/CaFdA and F-Ara-A have distinct
effects on mitochondria. Time-course analyses of mitochondrial
membrane potential in whole cells, release of AIF by flow
cytometry, cytochrome c release by immunofluorescence, and
studies of purified mitochondria demonstrated that 2CdA/CaFdA,
but not F-Ara-A, disrupted the mitochondrial integrity. These
conclusions were supported by analyses of fibroblasts microin-
jected with the respective triphosphates.
Only 2CdA and CaFdA reduced the incorporation of DiOC6 in
mitochondria at 8 to 12 hours, induced AIF release (probably as a
consequence of the opening of the PT pore12), stimulated the
release of cytochrome c, and disrupted the structural filamentous
arrangement of mitochondria, leaving the organelles dispersed in
the cytoplasm. The immunofluorescence images suggest that both
cytochrome c and AIF release preceded the loss of mitochondrial
transmembrane potential. Caspase activation also anticipated the
loss of the mitochondrial membrane potential, suggesting that the 2
Figure 5. Nucleotide microinjection experiments. Human HS-68 fibroblasts were
grown on coverslips. Nucleotide triphosphates were microinjected at an estimated
final concentration of 500 mmo/L. To identify the microinjected cells, fluorescein
isothiocyanate-labeled dextran was co-injected with the nucleotides; therefore, the
microinjected cells appear in green (C, E). Cells were incubated with 150 nmol/L MT
orange (red stain) for 30 minutes to stain for mitochondria membranes, and fixed in
4% paraformaldehyde, and DNA was dyed with DAPI stain (blue, A, C, E). Left panels
represent composite pictures that include DNA (blue), mitochondria (red), and
dextran (green for microinjected cells). Right panels (B, D, F) represent the stained
mitochondria alone. Cells treated with 2CdATP show a rearrangement of the
mitochondria. Cells treated with the same concentration of F-AraATP do not display
the same morphologic changes. Images were obtained with a Zeiss Axioscope
microscope, equipped with CCD camera, using a 40 3 1.3-na oil objective.
Figure 4. Immunocytochemistry of mitochondrial damage. B-CLL cells were
treated with the indicated drugs for 8 hours. Cells were stained for mitochondria
membrane potential with MT orange (red, A) for 30 minutes, pelleted on a slide at
300g, fixed in 4% paraformaldehyde, and stained for cytochrome c (green, B) with
monoclonal antibody and secondary antibody Alexa 488. DNA was visualized with
DAPI (blue, C). (D) Composite image. Arrows show cells affected by the drug, where
cytochrome c release is noticeable. Images were obtained with a Zeiss Axioscope
microscope, with CCD camera.
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events may be independent, as already demonstrated in staurospor-
ine-treated human tumor cells.27
Several explanations are possible for the severe and apparently
direct mitochondrial damage observed with 2CdA- and CaFdA-
treated CLL cells. First, the corresponding nucleotides could
directly bind to proteins that are known to regulate mitochondrial
functions, such as the F1-F0 ATPase (mitochondrial adenosine
triphosphate [ATP] synthase or complex V) or the adenine nucleo-
tide translocator (ANT). Both proteins are situated on the mitochon-
drial inner membrane and are actively involved in the process of
oxidative phosphorylation that produces most of the cellular
energy. The F1-F0 ATPase contains ATP and adenosine diphosphate
binding sites, and it has been shown to bind dATP with an affinity
similar to that of ATP.28 We recently demonstrated that the
nucleotide analogs can substitute for dATP in Apaf-1–mediated
caspase-9 activation,29 and it is thus conceivable that these analogs
could also bind the F1-F0 ATPase. The ANT, with the voltage-
dependent anion channel (VDAC, or porin), Bax, and cyclophilin
D, are thought to come together at the mitochondrial inner and
outer membrane contact points to create the mitochondrial perme-
ability transition pore (mtPTP).30,31 Recently, the mtPTP and
VDAC alone have been associated with the release of cytochrome c
and AIF that precedes caspase activation.32 It is conceivable that
the adenine nucleotide analogs, by binding to ANT, could affect the
opening of the mtPTP, allowing the release of AIF and cytochrome
c. Results with purified mitochondria indicate that the mitochon-
drial transmembrane potential is rapidly reduced. Unfortunately,
our analysis of AIF and cytochrome c release from isolated
mitochondria produced inconsistent results (data not shown), but
dATP-induced cytochrome c release from isolated mitochondria
has been demonstrated.33 The hypothesis of nucleotide-induced
mtPTP opening is also consistent with the protection observed in
Bcl-2–overexpressing cells, early after incubation with the 2CdA
and CaFdA.
A second explanation for the observed mitochondrial damage
may be the intramitochondrial accumulation of the triphosphate
analogs, leading to mitochondrial DNA damage followed by a
breakdown of metabolic functions. 2CdATP and CaFdATP may
accumulate more rapidly than F-AraATP in the mitochondria
because they are converted to their triphosphate forms with a
10-fold higher efficiency by the mitochondrial deoxyguanosine
kinase.34 Mitochondrial deoxyguanosine kinase-overexpressing cells
showed increased sensitivity to 2CdA compared to untransfected
cells.35 It is also conceivable that the 2-chloro derivatives are
slightly more hydrophobic than the corresponding 2-fluoro deriva-
tives and therefore may be able to insert more easily into the
mitochondrial membrane, affecting their integrity.
F-Ara-A also affected mitochondria, but only as a late event,
suggesting an indirect mechanism. DNA damage is known to
activate the p53 pathway by inducing phosphorylation of p53 and
transcriptional activation of pro-apoptotic genes. This leads to the
release of cytochrome c and the activation of the intrinsic apoptotic
machinery, resulting in caspase activation.13,36
In a previous study,29 we demonstrated that F-Ara-ATP is the
most potent nucleotide activator of Apaf-1, as assessed by pro-
caspase-9 and -3 cleavage. The current study indicates that APAF-1
binding is not the only determinant in the adenosine deoxynucleo-
side cytotoxicity pathway in B-CLL cells. 2CdA and CaFdA are
much more toxic to CLL cells than F-Ara-A, and only the
chlorinated analogs cause direct mitochondrial damage. Thus, the
mitochondrial effects of 2CdA and CaFdA may explain why these
drugs are toxic to CLL cells at concentrations 5- to 10-fold lower
than F-Ara-A. The different mechanisms for the toxicity of the
nucleoside analogs are summarized in Figure 6.
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ABSTRACT
Deoxyadenosine nucleosides are commonly used for the
treatment of Chronic Lymphocytic Leukemia (B-CLL),
their anti-cancer activity has been previously correlated
with mutations of the p53 gene. Disruption of p53
function may even be involved in the disease
progression, by reducing apoptosis, increasing cell
survival and producing multidrug-resistant phenotype. In
this study we show that upon DNA damage by
nucleosides such as fludarabine, p53 can be
phosphorylated and activated, leading to the
transcriptional activation of Hdm2 and p21, but not Bax.
The activation of p53 is followed by cytochrome c and AIF
cytoplasmic release, catalytic activation of caspase-9 and
3, downregulation of the endogenous caspase inhibitor
XIAP, and subcellular relocalization of p53. These events
occur in less than 24 hours post-treatment, and are
completely blocked by cell-permeable peptidic inhibitors
of caspases, suggesting the activation of programmed
cell death or apoptosis. After screening of 25 CLL
patients we identified a subset of CLL patients displaying
a non-functional p53 pathway that were resistant from
fludarabine-induced apoptosis. When incubated with
fludarabine, the cells isolated from the p53-null patients
showed loss of viability over a period of 3 days, that was
not prevented by caspase inhibitors, and did not display
all the biochemical indicators of apoptosis. We therefore
demonstrate that p53 is essential in fludarabine-induced
cell death of CLL cells, and that the activation of the
caspase-9/apaf-1 apoptosome is important in the
execution of apoptosis.
INTRODUCTION
Chronic lymphocytic Leukemia (CLL) malignancy is thought to
be caused by a defect in the normal mechanism of cell death,
increasing abnormally the number of cells in the patients
blood (1, 2).
CLL treatments, including chlorambucil (CLB) and
nucleosides analogs, such as fludarabine (F-ara-A) and 2-
chlorodeoxyadenosine (2CdA), induce DNA damage in CLL
cells. The nitrogen mustard alkylating agent CLB can bind to a
variety of cellular structures comprehending DNA, RNA and
proteins, however DNA crosslinking appears to be most
important for antitumor activity (3). In previous published data
we demonstrated that the cytotoxic mechanism of nucleoside
analogs involves direct damage of mitochondria, inducing
release of cytochrome c and apoptosis-inducing factor AIF (4)
and the binding and subsequent activation of caspase-
9/APAF-1 complex (5, 6). Purine deoxynucleosides can also
be incorporated into cellular DNA resulting in DNA damage (7,
8).
DNA-damage response involves stimulation of protein
kinases, distantly related to the intracellular signaling
molecule phosphatidylinositol 3-kinase (PI 3-kinase), of which
the prototypes are ATM (9) and DNA-dependent protein
kinase (DNA-PK) (10). Activation of these kinases triggers a
cellular response that includes growth arrest, damage repair
and apoptosis. The tumor suppressor protein p53 has been
shown to be a substrate of ATM and DNA-PK (11). p53 is a
transcription factor normally maintained at low levels through
interaction with several regulatory proteins, such as Hdm-2
that target it to proteasome degradation (12). DNA-damage
induces phosphorylation of p53, release from the Hdm-2
protein, multimerization into active tetramers, translocation to
DNA, and transcription activation of various proteins like p21,
Bax, Hdm-2, and others  (10, 11).
The activation of p53 through DNA damage can lead to cell-
cycle arrest and apoptosis. The cycline dependent kinase
(CDK) inhibitor p21 plays a major role on the p53-mediated
cell growth arrest. In contrast, the mechanism by which p53
induce apoptosis is still obscure. One of the target genes
might be Bax, a Bcl-2 family member protein capable of
triggering cytochrome c release from the mitochondria (11).
Recent evidence suggests that caspase-9, and its cofactor
Apaf-1, are essential downstream components of p53-
mediated apoptosis (13).
Sensitivity in treatment of CLL with CLB and nucleosides
analogs has been correlated with p53 gene mutations (14,
15). Disruption of p53 function may be involved in the disease
progression, by reducing apoptosis, increasing cell survival
and producing multidrug-resistant phenotype (16). Multidrug
resistance in CLL has been observed in patients with mutated
p53, but has also observed in patients displaying a normal
p53 genotype, suggesting multiple mechanism of drug
resistance (15).
In this article we tested the hypothesis that the p53 pathway,
including the upstream kinases, and the downstream p53-
induced genes, is an important regulator of the cytotoxicity of
some, but not all, ourine nucleoside analogs.
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We show that upon DNA damage by nucleosides such as
fludarabine, p53 can be phosphorylated and activated, leading
to the transcriptional activation of Hdm2 and p21, but not Bax.
The activation of p53 is followed by cytochrome c and AIF
cytoplasmic release, catalytic activation of caspase-9 and 3,
downregulation of the endogenous caspase inhibitor XIAP,
and subcellular relocalization of p53. All of these events occur
in less than 24 hours post-treatment, and are completely
blocked by cell-permeable peptidic inhibitors of caspases,
suggesting the activation of programmed cell death or
apoptosis. Our screening allowed the identification of a subset
of CLL patients displaying a non-functional p53 pathway that
were completely resistant from fludarabine-induced apoptosis.
When incubated with fludarabine, the cells isolated from the
p53-null patients showed loss of viability over a period of 3
days, that was not prevented by caspase inhibitors, and did
not display all the biochemical indicators of apoptosis. We
therefore demonstrate that p53 is essential in fludarabine-
induced cell death of CLL cells, and that the activation of the
caspase-9/apaf-1 apoptosome is important in the execution of
apoptosis.
MATERIALS AND METHODS
Cell isolation and analysis
Heparinized peripheral blood samples from 15 different
patients with CLL containing at least 90% malignant cells,
were fractionated by Ficoll/Hypaque sedimentation. Non
adherent mononuclear cells were resuspended in complete
medium (RPMI-1640 supplemented with 10% fetal bovine
serum) at a density of 1 to 2 x 106 per ml. Cells were
incubated at 37°C in an atmosphere of 5% CO2 with the
deoxynucleoside analogs with or without the cell-permeable
caspases inhibitor IDUN 1965 (17) or z-VAD-fmk (Z-Val-Ala-
Asp(Ome)-CH2F, Biomol, Plymouth Meeting, PA) 9-ß-D-
arabinofuranosyl-2-fluoroadenine (F-ara-A, fludarabine) came
from Sigma (St. Louis, MO); 2-chloro-2'-deoxyadenosine
(2CdA, Cladribine) was synthesized by published procedure
(18).
Immunoblotting
Washed CLL cell were lysed in 2 X SDS-PAGE sample buffer
containing 10 mM DTT, for 5 minutes at 100°C. Alternatively,
washed cells were lysed in Lysis buffer (25 mM Tris, pH 7.4,
150 mM KCl, 5 mM EDTA, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 1 µg/ml aprotinin, 1 µg/ml leupeptin
and 1 mM phenylmethanesulfonyl fluoride, PMSF). Lysates
were centrifuged at 15,000 x g for 10 min to remove nuclei
and the protein content of supernatants was measured using
a modified Coomassie blue assay (Pierce, Rockford, IL).
Proteins were resolved at 125 V on 14% and 4-20% gels and
electrophoretically transferred to 0.2 µm polyvinylidene
fluoride (PVDF) membranes (Millipore, Bedford, MA) for 2
hours at 125 V. Membranes were blocked overnight in I-Block
blocking buffer (Tropix, Bedford, MA). Blots were then probed
for 1 hour with antibodies to p53 (clone PAb 1801), Hdm2
(clone SMP14), p21 (clone SX118) (Pharmingen, San Diego,
CA), to Phospho-p53 (Ser15) (Transduction Laboratories,
Lexington, KY), to Bax and XIAP (19).
The blots were developed with species-specific antisera, and
visualized by alkaline phosphatase-based enhanced
chemiluminescence (ECL; Amersham), according to the
manufacturer's instructions. The x-ray films were scanned,
acquired in Adobe Photoshop, and analyzed with NIH Image
software.
Cellular Assay for Caspase Activity
The method for the flourimetric detection of caspases activity
was previously described (4). Briefly, CLL cells lysed in
caspase buffer. Lysates (10-20 µg of total protein) were mixed
with HEB buffer and reactions were initiated by addition of 100
µM of the specific substrate. After 1 hour incubation at 37°C,
caspase-3-like protease activity was measured with the
substrate Ac-DEVD-AMC and caspase-9-like activity was
measured using Ac-LEHD-AFC. Activity was measured by the
rel ase of 7-amino-4-trifluoromethyl-coumarin (AFC) or 7-
amino-4-methyl-cumarin (AMC) monitoring fluorescence at
excitation and emission wavelengths of 400 and 505 nm, and
380 and 460 nm respectively.
Cytofluorimetric analysis of mitochondrial
transmembrane potential ( m) by DiOC6 and cell
membrane permeability by PI
CLL cells were treated with the indicated amount of the drugs
at the indicated time points. Cells were then incubated for 10
min at 37°C in culture medium containing 40 nM 3,3'
dihexyloxacarbocyanine iodide (DiOC6, Molecular Probe,
Eugene, OR) and 5 µg/ml propidium iodide (PI, Molecular
Probe), followed by analysis within 30 minutes of
fluorochrome in a Becton-Dickinson FACScalibur
cytofluorometer. After suitable compensation, fluorescence
was recorded at different wavelenghts: DiOC6 at 525 nm (FL-
1) and PI at 600 nm (FL-3).
Immunohistochemistry
100 µl of the CLL cells at a concentration of 2· 106 /ml treated
for 24 hours with the indicated drugs were stained for the
detection of the mitochondrial membrane potential with
Mitotracker Orange (Molecular Probes, OR) for 30 min at
37° C. 2· 105 cells were cytospined at 300 g for 5 min on a
slide. The cells were fixed 10 min in 4% Paraformaldehyde,
washed in PBS and then incubated for 2 hours with the
antibodies anti- p53 or anti- cytochrome c (clone 6H2.B4)
(Pharmingen, San Diego, CA), at a concentration of 2-10
µg/ml in I-Block blocking buffer (Tropix, Bedford, MA)
supplemented with 0.05 % Triton X-100. Alexa 488 (green)
and Alexa 568 (red) species-specific secondary antibodies
(Molecular Probes, OR) were used to visualize the proteins.
The nuclear DNA was stained using DAPI. Coverslips were
washed successively in PBS and deionized H2O for 5 min and
mounted in Flouromount  (Fisher, CA). Images were obtained
with a Zeiss Axioscope microscope.
Fluorescent in situ Hybridization for p53 gene detection
DNA probes specific for the p53-locus on 17p13 (directly
conjugated with SPECTRUM-Orange were purchased from
Vysis, Inc (Downers Grove, IL). Hybridization was performed
as detailed in a previous report (20). Slides were analyzed
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Patience p53 Phosph
o- p53
HDM2 P21 F-arA
Toxicit
y
#1 TJK 0052 + + + + +
#2 TJK0031 - - - - -
#3 TJK 0024 + +
#4 TJK 0018 + +
#5 TJK 0016 + + +
#6 TJK 0008 (+) + +
#7 TJK 0009 + + +
#8 TJK0017 + + +
#9 TJK 0054 +
#10 TJK 0023 + + + + +
#11 TJK0002 + (+) - - -
#12 TJK0035 + + - (+) -
#13 TJK 0011 + + + + +
#14 TJK 0033 + + + + +
#15 TJK0063 + (+) - - -
TABLE 1.  Screening of 15 B-CLL patients for p53 status.
15 B-CLL patients were tested for F-ara-A response and for p53
phosphorylation. The gene expression of p53-induced gene was
also tested. The patients with a p53 mutated pathway are bold-
highlighted.
analogues at a single concentration of 10 µM. p53 positive
patient displayed already after 8 hours incubations an
increase of total p53, as well as phosphorylated p53. The
p53 dependent genes p21 and HDM2 were also increased
at the same time point. Only Bax, did not appear to get up-
regulated. Interestingly XIAP, an anti-apoptotic molecule,
was found to be concomitantly down-regulated. The p53
negative patient on the other side did not show any p53
band, no phosphorylation of p53 or any increase of the p53
dependent genes. Also XIAP was not reduced (Figure 1).
Tubulin was used as a proof for loading.
RESULTS
p53 has been postulated to play a major role in the
pathogenesis of several tumors. In CLL the question of the
involvement of p53 in response to therapeutic treatment is still
unclear. Transfection of CLL is still a difficult method to
perform and therefore we proceeded with the screening of 15
patients to characterize their p53 status and we correlated the
response to the treatments (Table 1). What we observed in
the activation of p53 after incubation the cells with the two
deoxyadenosine analogs 2CdA and F-ara-A was the
activation of p53 by phosphorylation, the expression of p53
induced genes as p21 and HDM2, which were correlated to
the ability of the two drugs to induce apoptosis. Only 75% of
the patients were responsive to F-ara-A treatment at 10 µM
for 24 hours, whereas all the patients were 2CdA sensitive.
Viability was measured by dye exclusion. This inability of F-
ara-A to induce cell death was correlated to a lack of ability to
induce the p53 phosphorylation and expression of p53
dependent genes. This was completely reduced in patient
TJK0031 or partially reduced in patients TJK0002, TJK0035
and TJK0063. Patient TJK0031 did not even present an
inactivated form of p53, suggesting being a natural knock-out.
In this study we selected a p53 positive patient TJK0052
responsive to the treatment and the p53 null patient to
discriminate the involvement of p53 in the induction of
apoptosis by 2CdA and F-ara-A. The patients were
sequenced for mutations in p53 gene, where TJK0053 turned
out to be p53 normal, and patient TJK0031 resulted by FISH
analysis to be p53 homozygously deleted.
Western blot analysis of p53 dependent genes
To determine the p53 status of the two selected patients we
treated the CLL cells in a time course with the two nucleoside
Figure 1.  Expression of p53 induced proteins CLL patients after
treatment with 2CdA and F-ara-A.
 A p53 normal B-CLL patient (p53(+)) and a p53 negative patient
(p53(-)) were treated with 10µM of deoxynucleosides analogs
2CdA and F-ara-A in a time course. 5 x 106 cells were lysed in 100
µl lysing buffer. The protein concentration was quantified by
Coomassie blue assay. Cell extract (30 µg per lane) were
resolved by SDS-PAGE on 8-20 % gels and transferred on PVDF
membranes. The indicated antibodies were visualized by
enhanced chemiluminescence (ECL).
Induction of apoptosis in CLL patients is different for
2CdA and F-ara-A depending on the p53 status
The cells tested in previous experiment were also tested for
casapse-9 and -3 activation and for apoptosis analysis by flow
cytometry. 2CdA was the only one drug able to induce cell
death within 24 hours in p53 negative patient (Figure 2A). The
strength of the effect was reduced compared to the p53
positive patient. F-ara-A instead induced apoptosis only in the
p53 responding patient (Figure 2B) and this was correlated to
the ability of F-ara-A to activate the caspases-9 and -3 only in
the p53(+) patient after 12 hours, concomitantly to the
increase of apoptosis (Figure 3A and 3B).
Induction of apoptotic phenotype and release of
cytochrome c by F-ara-A only in p53 positive patient
CLL cells of the two patients were probed with MT orange,
cytochrome c and DaPi in immunofluorescence experiments
after treatment with 2CdA and F-ara-A. Cytochrome c (green)
colocalized with MT Orange (red) stain of mitochondria in
p53 (+) p53 (-)
2CdA 2CdAF-araA F-araA
C     4   8   12   16   24    8   12   16   24 C    4   8   12   16   244   8   12   16   24
p53
p53-Phospho
HDM2
p21
Bax
XIAP
Tubulin
control cells. Treated p53(+) cells presented typical apoptotic
phenotypes, displaying condensed nucleus (blue) and
cytochrome c was released from the mitochondria, whereas
MT orange was still detectable (Figure 4A). F-ara-A anyway
was not able to induce any cytochrome c release or any
apoptotic body in patient p53(-), cytochrome c and MT Orange
colocalized in treated cells (Figure 4B). Only 2CdA was able
to induce cytochrome c release and apoptotic phenotype in
p53 null patient (data not shown).
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Figure 2.  Induction of apoptosis by 2CdA and F-ara-A.
B-CLL cells from the normal (=) and the null  (<) p53 patient were
treated with (2A) 2CdA, and (2B) F-Ara-A at 10 µM for the indicated
time points. The cells were tested for mitochondria membrane
potential by flow cytometry analysis of incorporation of DiOC6. % of
the apoptotic cells to the control is represented in the diagrams.
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Figure 3.  F-ara-A induction of caspase-activity.
At the indicated time points, 5 x 106 F-ara-A treated B-CLL from the normal
(=) and the null p53 patient (<) were washed with PBS and lysed in
Caspase Buffer. (3A) Caspase-9 and (3B) caspase-3 activity of 10-20 µg of
total protein was measured with specific substrates (100µM) after 1 h
incubation at 37 ° C. The cleavage of the fluorometric AMC/AFC was
monitored fluorometrically at 400/380 nm excitation and 505/460 nm
emission. Activity is represented in relative units to the control without
treatment.
Relocalization of p53 in cells undergoing apoptosis
Stain of p53 with specific monoclonal antibody in whole cells
showed unibiquitous localization of the protein in CLL. In cells
undergoing apoptosis displaying condensed chromatin,
caused by treatment with 2CdA or F-ara-A, p53 relocalized
from the nucleus to the cytoplasm. Caspases-inhibitor z-VAD-
fmk was not able to protect the nuclear export of p53 (Figure
5).
Induction of cell death after longer exposition to the drug
F-ara-A of p53 negative CLLs
F-ara-A did not induce cytochrome c release and caspases
activation in p53 negative patient, and did not induce the
common pathway of apoptosis, but cells kept in culture for
three days in the presence of the drug died anyway. Flow
cytometry analysis showed an increase in the number of
apoptotic cells, from 39.7% in the control up to 55.1% for the
treated cells. The caspases inhibitor IDUN did not protect
CTRL
A
F-ara A
CTRL
B
F-ara A
Figure 4.  Cytochrome c release in p53 positive patient after
tr atment with F-ara-A, but not in p53 negative patient.
B-CLL cells were treated 24 hours with F-ara-A. (4A) p53 normal
patient and (4B) p53 null-patient cells were incubated for 30 minutes
with Mitotracker Orange at a final concentration 150 nm to stain
mitochondria (red, left panels). 2 x 104 cells were then cytospun at
300 g for 5 minutes on a slide and then fixed for 10 minutes in 4 %
paraformaldeyde. Cytochrome c primary antibody was incubated for 2
h, washed, and detected with the secondary Alexa 488-conjugated
antibody (green, center panel). Nuclear DNA was stained using DAPI
(blue, right panels in composite picture ). Micrographs (600´ ) were
obtained with a Zeiss Axioscope microscope.
CTRL
2CdA
2CdA +
 z-VAD-fmk
Figure 5.  Relocalization of p53 in cells presenting apoptotic
phenotype.
B-CLL cells were treated 24 hours with 2CdA in the presence or
absence of caspases inhibitor z-VAD-fmk. 2 x 104 cells were then
cytospun at 300 g for 5 minutes on a slide and then fixed for 10
minutes in 4 % paraformaldeyde. p53 primary antibody was incubated
for 2 h, washed, and detected with the secondary Alexa 568-
conjugated antibody (red, left panel). Nuclear DNA was stained using
DAPI (blue, center panels).  The right panels show the composite
pictures of DAPI and p53 and the arrows indicate p53 relocalization
from nuclei to cytoplasm in apoptotic phenotypic cells. Micrographs
(600´ ) (were obtained with a Zeiss Axioscope microscope.
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Figure 6.  Long-term cell death induced in p53 negative patient
by F-ara-A.
B-CLL cells from the p53 null-patient were treated for 48 and 72 hours
with F-ara-A in the presence or absence of caspases-inhibitor IDUN
1965. Apoptotic cells were detected by flow cytometry by testing for
mitochondria membrane potential by flow cytometry analysis of
incorporation of DiOC6. The percentage of apoptotic cells and viable
cells are represented in the diagrams.
DISCUSSION
The ability of many antitumor agents to induce apoptosis is
often dependent on DNA toxicity. As we previously
demonstrated, deoxynucleoside analogs can induce DNA
damage in non-dividing chronic lymphocytic leukemia cells (4,
7). In other systems DNA damage was correlated to p53
induced apoptosis (16, 21).
p53 is activated by phosphorylation following DNA damage,
p53-dependent genes are up-regulated and cells undergo
apoptosis (10, 11). In a previous publication we demonstrated
how 2CdA and CaFdA, but not F-ara-A, can induce apoptosis
in B-CLL also by damaging directly mitochondria (4). We
concluded that F-ara-A kills B-CLL only through DNA damage.
We used this concept to screen patients with different
sensitivity toward 2CdA and F-ara-A, and we correlated such
a response to the status of p53 activation. As we expected
patients resistant to F-ara-A were also p53 pathway mutated.
Only one patient was however completely resistant to a
treatment with high concentration of F-ara-A in short time
incubation (24 h) and the patient resulted to be p53
homozygously deleted. The other resistant patients, who
presented a mutation in the p53 gene sequence analysis,
displayed only a reduced toxicity for F-ara-A.
Our analyses were then focused on this p53-null patient (TJK
0031), compared to the p53 intact and F-ara-A responsive
patient (TJK0052). The ability of 2CdA to induce apoptosis
also in the p53 negative patient, confirmed our already
published data that 2CdA is able to induce cytochrome c
release early and efficiently, only by damaging directly
mitochondria (4). On the other hand, it appears that F-ara-A
requires the p53-signaling pathway to induce apoptosis
through the intrinsic pathway. Bax was postulated in other
systems to mediate the p53 response leading to cytochrome c
release (11, 22, 23). In our system, p53 was activated in the
patient with intact p53, but Bax was not up-regulated. Anti-
apoptotic protein XIAP (24) was down-regulated after the
treatment of p53 positive patients as well as in p53 negative
patients, suggesting XIAP to be downstream of caspases
activation and cytochrome c release and not induced directly
by p53. In fact, experiments carried out in presence of
casapse-inhibitor z-VAD-fmk confirmed the down-regulation of
XIAP due to caspase-activation. In our system probably
another protein mediate the release of cytochrome c in the
p53-signaling pathway. Our research is addressed to identify
this molecule.
It has become clear from chemosensitivity testing of human
cancer cell lines as a function of p53 status that there are
important tissue specific differences in cancer cell sensitivity.
For example, certain malignant hematopoietic cells are more
sensitive to DNA-damaging agents than solid-tumor cell lines,
regardless to p53 status. Also, p53 status does not always
correlate with chemosensitivity. p53 is the most commonly
mutated gene in human cancer, and it is clear that loss of p53
correlates with malignant tumor progression and drug
resistance in vivo in many tumor types (16, 25). In spite of the
recognition of the signaling protein inducing cytochrome c
r lease, in B-CLL it appears that multidrug resistance for
antitumor drugs is relatedto the status of p53 genes. This has
high clinical relevance, because the use of a different
treatment can be decided after a previous analysis of the
status of p53.
We observed that F-ara-A can kill p53 negative B-CLL if
incubated for a longer period of time. Caspases are also
activated in this system (data not shown), but pretreatment
with caspases inhibitors does not reduce the number of
apoptotic cells. Accumulation of the analog can cause an
imbalance in the nucleotides equilibrium in the cells, inducing
poisoning or disrupting the metabolism of the cell and
activation of the caspases. Caspase activity is however low
and the concentration of caspase inhibitor used blocks
completely their activity in a cell-free system, but does not
protect entirely from aspase-9 activation in the cells (data not
shown). Therefore the number of apoptotic cells is very
similar. Increasing the concentration of the inhibitor was
inducing toxicity by its own.
During our research we also interestingly observed an
unusual localization of p53 protein in B-CLL cells. Cytosolic
p53 in other cells is normally degraded in a proteasome-
dependent pathway. B-CLL present however a high
concentration of p53 in the cytosol. The lack of p53
degradation might play a role in the different sensitivity among
B-CLL and normal PBL toward antitumoral agents.
p53 was also observed to be exported from the nucleus when
apoptosis is occurring. When cells present the classical
apoptotic phenotype with condensed chromatin, p53
relocalize into the cytosol. Caspases inhibitors can not
prevent this event.
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ARTICLES
Indanocine, a Microtubule-Binding Indanone and a
Selective Inducer of Apoptosis in Multidrug-Resistant
Cancer Cells
Lorenzo M. Leoni, Ernest Hamel, Davide Genini, Hsiencheng Shih, Carlos J.
Carrera, Howard B. Cottam, Dennis A. Carson
Background: Certain antimitotic drugs have antitumor ac-
tivities that apparently result from interactions with nontu-
bulin components involved in cell growth and/or apoptotic
cell death. Indanocine is a synthetic indanone that has been
identified by the National Cancer Institute’s Developmental
Therapeutics Program as having antiproliferative activity.
In this study, we characterized the activity of this new anti-
mitotic drug toward malignant cells. Methods: We tested
antiproliferative activity with an MTT [i.e., 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] as-
say, mitochondrial damage and cell cycle perturbations with
flow cytometry, caspase-3 activation with fluorometry, alter-
ations of the cytoskeletal components with immunofluores-
cence, and antimicrotubule activity with a tubulin polymer-
ization assay. Results/Conclusions: Indanocine is a cytostatic
and cytotoxic indanone that blocks tubulin polymerization
but, unlike other antimitotic agents, induces apoptotic cell
death in stationary-phase multidrug-resistant cancer cells at
concentrations that do not impair the viability of normal
nonproliferating cells. Of the seven multidrug-resistant cell
lines tested, three (i.e., MCF-7/ADR, MES-SA/DX5, and HL-
60/ADR) were more sensitive to growth inhibition by in-
danocine than were their corresponding parental cells. Con-
fluent multidrug-resistant cells (MCF-7/ADR), but not drug-
sensitive cancer cells (MCF-7) or normal peripheral blood
lymphocytes, underwent apoptotic cell death 8–24 hours af-
ter exposure to indanocine, as measured by sequential
changes in mitochondrial membrane potential, caspase ac-
tivity, and DNA fragmentation. Indanocine interacts with
tubulin at the colchicine-binding site, potently inhibits tubu-
lin polymerization in vitro, and disrupts the mitotic appara-
tus in dividing cells. Implications: The sensitivity of station-
ary multidrug-resistant cancer cells to indanocine suggests
that indanocine and related indanones be considered as lead
compounds for the development of chemotherapeutic strat-
egies for drug-resistant malignancies. [J Natl Cancer Inst
2000;92:217–24]
Antimitotic drugs are a major group of antitumor agents,
whose varied mechanisms of action have been only partly elu-
cidated (1). Derivatives of natural products, such as the vinca
alkaloids, colchicine, cryptophycin, the combretastatins, and re-
lated compounds (2,3), as well as several different synthetic
heterocyclic compounds (4,5), inhibit tubulin polymerization
and prevent microtubule assembly. The taxanes, on the other
hand, prevent the depolymerization of tubulin, resulting in the
rearrangement of the microtubule cytoskeleton (6). Although
some of the antimitotic agents have broad-spectrum cancer che-
motherapeutic activity, others, such as colchicine and noco-
dazole, have no selectivity toward malignant cells. In general,
antimitotic agents take advantage of kinetic abnormalities of
cancer cells, such as their increased proliferation rate or loss of
mitotic checkpoints. Many newer antineoplastic agents focus on
biochemical abnormalities that differentiate malignant tumors
from most normal tissues (7–9).
The multidrug-resistant phenotype, although not strictly spe-
cific for cancer cells, is an attractive target for anticancer drugs
because it develops during chemotherapy with bulky hydropho-
bic antineoplastic agents, limiting their efficacy (10). Several
mechanisms may contribute to intrinsic and acquired cross-
resistance to multiple antineoplastic agents (clinical drug resis-
tance). They include decreased drug accumulation due to over-
expression of the P-glycoprotein drug efflux pump encoded by
the mdr1 gene (11,12), the multidrug resistance-associated pro-
tein (MRP) (13), and the p110 major vault glycoprotein (14). In
addition, multidrug resistance has been linked to decreased ex-
pression of topoisomerase IIa (15), to altered expression of
drug-metabolizing enzymes and drug-conjugate export pumps
(16,17), and to modification of the apoptotic machinery (18,19).
Various hydrophobic drugs with low toxicity for tumor cells
can partially reverse multidrug resistance in vitro and in vivo. In
contrast, cytotoxic compounds that preferentially target multi-
drug-resistant cells are not well described, but such agents
should be very useful in the treatment of cancer. The National
Cancer Institute’s Developmental Therapeutics Program has
identified indanocine, a newly synthesized indanone, as a com-
pound with antiproliferative activity.
In this article, we investigate the action of indanocine on
cultured multidrug-resistant cancer cells and their corresponding
parental (wild-type) cells.
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MATERIALS AND METHODS
Materials
Indanocine, NSC 698666 (Fig. 1, A), is one of a series of synthetic indanones
with antiproliferative activity (Shih H, Deng L, Carrera CJ, Adachi S, Cottam
HB, Carson DA: unpublished data). Solid idanocine is a white powder that is
stable when stored dry at room temperature or when dissolved in dimethyl
sulfoxide or in water containing cyclodextrins. Paclitaxel, vinblastine sulfate,
and nocodazole were from Calbiochem (San Diego, CA). Electrophoretically
homogeneous bovine brain tubulin was prepared as described previously (20).
Media and tissue culture supplies were purchased from Irvine Scientific (Santa
Ana, CA) and Fisher Scientific (San Diego, CA). All radiochemicals were from
NEN-Dupont (Boston, MA). Unless otherwise indicated, all other reagents were
obtained from Sigma Chemical Co. (St. Louis, MO).
Cell Culture
Cell lines from the American Type Culture Collection (Manassas, VA), prop-
agated according to the instructions of the supplier, were as follows: MES-SA
(human uterine sarcoma) and its multidrug-resistant variant MES-SA/DX5
raised against doxorubicin (21), monkey COS-1, and Hep-G2 (human hepato-
cellular carcinoma). KB-3-1 (human carcinoma) and KB-GRC-1 (a transfectoma
expressing high levels of the MDR1-encoded 170-kd P-glycoprotein) were pro-
vided by Dr. Stephen Howell (University of California San Diego, La Jolla) and
have been described previously (22). Dr. Michael J. Kelner (University of Cali-
fornia San Diego) provided the following cell lines: MV522 (human metastatic
lung carcinoma) and MV522/Q6 (a transfectoma expressing high levels of the
MDR1 gene-encoded 170-kd P-glycoprotein); MCF-7/ADR, a human breast
adenocarcinoma multidrug-resistant line selected against doxorubicin (express-
ing both gp170 and the embryonic glutathione transferase p isoform), and MCF-
7/wt, the parental (wild-type) line; MDA-MB-231, a human breast adenocarci-
noma line, and MDA3-1/gp170+, the doxorubicin-resistant daughter line
expressing the 170-kd P-glycoprotein; and HL-60, a human acute promyelocytic
leukemia line, and HL-60/ADR, the multidrug-resistant variant line selected
against doxorubicin and expressing the MRP/gp180 protein. Dr. William T.
Beck (Cancer Center, University of Illinois at Chicago) provided CEM, a human
lymphoblastoid line, and CEM/VLB100, a multidrug-resistant line selected
against vinblastine and expressing the 170-kd P-glycoprotein.
We incubated cells for 72 hours in 96-well plates with the test compounds and
then measured cell proliferation by reduction of the yellow dye MTT [i.e.,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] to a blue forma-
zan product. The cleavage is performed by the “succinate-tetrazolium reductase”
system, which belongs to the respiratory chain of the mitochondria and is active
only in viable cells. Therefore, the amount of formazan dye formed is a direct
indication of the number of metabolically active cells in the culture. The optical
density of the blue formazan product was measured at 570 nm with a Thermo-
Max (Molecular Devices, Sunnyvale CA) and analyzed with the Vmax Program
(BioMetallics, Princeton, NJ).
Cell Cycle Analysis
Cells were harvested, fixed in ice-cold 70% ethanol, treated with ribonuclease
A at 100 mg/mL, and stained with propidium iodide at 50 mg/mL for 1 hour at
37 °C. The DNA content of the cells was analyzed by flow cytometry (FACS-
calibur; Becton Dickinson Immunocytometry Systems, San Jose, CA), and the
cell cycle distribution was calculated with the ModFit LT 2.0 Program (Verity
Software House, Topsham, ME).
Caspase Analysis
Extracts were prepared by the suspension of 5 × 106 cells in 100 mL of a lysis
buffer (i.e., 25 mM Tris–HCl [pH 7.5], 150 mM KCl, 5 mM EDTA, 1% Nonidet
P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate), incubation
on ice for 10 minutes, and then centrifugation at 14 000g for 5 minutes at 4 °C.
The resulting supernatants were collected and frozen at −80 °C or used imme-
diately. Lysates (20 mL containing 5–10 mg of total protein) were mixed with 30
mL of assay buffer [50 mM piperazine-N,N’-bis(2-ethanesulfonic acid), 50 mM
KCl, 5 mM ethylene glycol bis(b-aminoethyl ether) N,N,N8,N8-tetraacetic acid,
2 mM MgCl2, 1 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride],
containing 100 mM of Z-DEVD-AFC (where DEVD is Asp–Glu–Val–Asp, Z is
benzyloxycarbonyl, and AFC is 7-amino-4-trifluoromethyl coumarin). Caspase-
3-like protease activity was measured at 37 °C with a spectrofluorometric plate
reader (LS50B; The Perkin-Elmer Corp., Foster City, CA) in the kinetic mode
with excitation and emission wavelengths of 400 nm and 505 nm, respectively.
Activity was measured by the release of 7-amino-4-methyl coumarin (AMC)
from the synthetic substrate Z-DEVD-AFC (Biomol, Plymouth Meeting, PA).
Mitochondrial Analysis
Cells were treated with the indicated amount of drug and 10 mM Ac-DEVD-
fmk (N-acetyl-Asp–Glu–ValAsp–fluoromethylketone; Enzyme System Prod-
ucts, Livermore, CA), the cell-permeable caspase-3/caspase-7-selective inhibi-
tor. Cells were then incubated for 10 minutes at 37 °C in culture medium
containing 40 nM 3,38-dihexyloxacarbocyanine iodide (DiOC6; Molecular
Probes, Inc., Eugene, OR), followed by immediate analysis in a FACScalibur
cytofluorometer. Fluorescence at 525 nm was recorded.
Immunofluorescence Assays
Hep-G2 (human hepatocellular carcinoma) cells were grown on glass cover-
slips in the presence or absence of drugs for 16 hours. Cells were fixed in
Fig. 1. A) Structure of indanocine. In panels B and C, HL-60 and HL-60/ADR
cells display collateral sensitivity to indanocine; i.e., the multidrug-resistant cell
line was substantially more sensitive to the growth-inhibitory effects of indano-
cine than the original parental cell line. B) Cytotoxic MTT [i.e., 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay of HL-60 cells.
Parental wild-type HL-60 and HL-60/ADR multidrug-resistant cells were plated
at low density (<5000 cells per well), and indanocine and paclitaxel were added
at 1 : 2 serial dilutions from column 2. Column 1 is the control without drugs.
The initial concentrations were 1 mM for indanocine and 10 mM for paclitaxel,
and the concentrations in column 12 were 1 nM and 10 nM, respectively. After
3 days, the MTT assay was used to quantitate viable cells. The picture of the
plate was obtained by optically scanning the 96-well plate. Dark wells represent
metabolically active cells, and clear wells represent metabolically inactive
cells. C) Graphic representation of the scanned plate for parental wild-type
HL-60 cells, with the calculated 50% inhibitory concentrations (IC50) shown (see
Table 1).
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paraformaldehyde, permeabilized in Triton X-100, and stained with an anti-b-
tubulin monoclonal antibody, followed by tetramethyl rhodamine B isothiocya-
nate-conjugated anti-mouse immunoglobulin G (IgG). To visualize filamentous
actin filaments, we stained the cells with fluorescein isothiocyanate-conjugated
phalloidin, as described previously (23). The type 1 nuclear mitotic apparatus
protein was detected with monospecific human autoantibodies, as described
previously by Andrade et al. (24). The secondary antibody was fluorescein
isothiocyanate-labeled goat anti-human IgG (Tago, Burlingame, CA). Nuclei
were stained with the DNA-binding dye 48,6-diamidino-2-phenylindole dihy-
drochloride (Molecular Probes, Inc.) according to the manufacturer’s instruc-
tions.
Tubulin Assays
Assessment of the inhibition of tubulin polymerization and the evaluation of
the inhibition of [3H]colchicine binding to tubulin were performed as described
previously (25). In all experiments, tubulin without microtubule-associated pro-
teins (20) was used. In brief, for inhibition of assembly, 10 mM (1.0 mg/mL)
tubulin was preincubated with various concentrations of drug (4% [vol/vol]
dimethyl sulfoxide as drug solvent) and 0.8 M monosodium glutamate for 15
minutes at 30 °C. The reaction mixture was placed on ice, and guanosine 58-
triphosphate (0.4 mM) was added. Reaction mixtures were transferred to cuvettes
at 0 °C in Gilford 250 spectrophotometers (Beckman-Gilford, Fullerton, CA),
baselines were established, and the temperature was increased to 30 °C with
electronic temperature controllers (over a period of about 60 seconds). The IC50
value is the drug concentration required to inhibit 50% of the assembly, relative
to an untreated control sample, after a 20-minute incubation. It should be noted
that the bulk of polymer formed in the presence of glutamate consists of sheets
of parallel protofilaments. The drug effects in this system are similar to those
observed with a preparation containing tubulin and microtubule-associated pro-
teins (i.e., microtubule proteins). The chief advantage of the glutamate system is
that it unambiguously establishes tubulin as the drug target. For the colchicine-
binding assay, reaction mixtures contained 1.0 mM (0.1 mg/mL) tubulin and 5.0
mM [3H]colchicine and were incubated for 10 minutes at 37 °C before filtration
through a stack of two DEAE-cellulose filters. At this time in reaction mixtures
without inhibitor, binding is 40%–50% of maximum, so that the inhibition of the
rate of colchicine binding to tubulin can be measured accurately.
RESULTS
Inhibition of Cell Growth
In an initial screen performed by the National Cancer Insti-
tute’s Developmental Therapeutics Program, the mean 50%
growth-inhibitory concentration (GI50) of indanocine was less
than or equal to 20 nM. In 29 of 49 cell lines, including a
doxorubicin-resistant breast cancer line, the GI50 for indanocine
was less than the lowest concentration tested (10 nM). Because
the indanone is hydrophobic, its activity toward the multidrug-
resistant cells was surprising. To confirm this result, we com-
pared the effects of indanocine on the growth of the following
pairs of parent and corresponding multidrug-resistant lines
(Table 1): MCF-7 and MCF-7/ADR, MES-SA and MES-SA/
DX5, MDA-MB-321 and MDA3-1/GP170+3-1, HL-60 and HL-
60/ADR, CEM and CEM/VLB100, KB-3-1 and KB-GRC-1, and
MV522 and MV522/Q6 cells. The multidrug-resistant cell lines
have different multidrug resistance mechanisms, including alter-
ations of gp170 (mdr1 gene), gp180 (MRP gene), and the glu-
tathione transferase p isoform. In several of the cell lines tested,
the antiproliferative concentrations of indanocine were equiva-
lent or lower in the multidrug-resistant cells than in the corre-
sponding parent cells. Three of the cell lines tested (i.e., MCF-7,
MES-SA, and HL-60) showed collateral sensitivity; i.e., the
multidrug-resistant cell line was substantially more sensitive to
the growth-inhibitory effects of indanocine than the parental cell
line. An example of collateral sensitivity is shown in Fig. 1,
where HL-60 and HL-60/ADR cells were plated in a 96-well
plate and then treated for 3 days with decreasing (1 : 2 dilutions)
concentrations of indanocine (from 1 mM) or paclitaxel (from 10
mM). The MTT assay was then performed at day 3. To prove that
P-glycoprotein expression did not confer resistance to the inda-
none, we compared its effects on two carcinoma cell lines, KB-
3-1 and MV522, and their corresponding transfectoma clones
that overexpressed P-glycoprotein (the mdr1 gene product), KB-
GRC-1 and MV522/Q6 (22). These transfectomas were resistant
to paclitaxel, as expected, but retained complete sensitivity to
indanocine (Table 1).
Effect of Indanocine on Stationary-Phase Cells
The results obtained with the actively growing parent and
multidrug-resistant cell lines led us to test indanocine in station-
ary-phase cell lines. As determined by flow cytometry after
propidium iodide staining, up to 81% of stationary MCF-7/ADR
cells (1 week in confluent culture) were in the G1 phase of the
cell cycle (Fig. 2, B; middle panel). Remarkably, indanocine
treatment of stationary-phase multidrug-resistant cells, but not
parental cells, resulted in cell death (IC50 4 32 nM) (Fig. 2, A).
The cytotoxic effect of indanocine in noncycling MCF-7/ADR
cells was confirmed by the detection of an apoptotic sub-G0/G1
population by flow cytometry and by the activation of caspase-3
(Fig. 2, B; left panel). Parental (wild-type) MCF-7 cells were
similarly growth arrested but did not show apoptotic features
(data not shown). In addition, normal peripheral blood lympho-
cytes exposed to 1000-fold higher concentrations of indanocine
for 72 hours showed no loss of viability (data not shown).
Apoptosis
The study described above demonstrated that stationary
MCF-7/ADR cells, but not wild-type MCF-7 cells, were sensi-
tive to treatment with indanocine. To test this observation in
Table 1. Growth-inhibitory concentrations of indanocine and paclitaxel in
seven multidrug-resistant cell lines*
Cell line
GI50 (indanocine), nM GI50 (paclitaxel), nM
Wild type
Mutidrug
resistant Wild type
Multidrug
resistant
MCF-7 20 ± 5 4 ± 1† 50 ± 6 >10 000
MES-SA 85 ± 6 12 ± 3† <1 >1000
MDA-MB-321 10 ± 3 25 ± 2 50 ± 2 >1000
HL-60 40 ± 3 2 ± 0.2† <1 >1000
CEM 12 ± 2 20 ± 1 <1 606 ± 20
KB-3-1 7 ± 2 7 ± 3 7 ± 3 >1000
MV522 13 ± 3 8 ± 2 15 ± 4 358 ± 58
*The cells were treated with various concentrations of indanocine or paclitaxel
for 72 hours. Cell proliferation was assessed by the MTT [i.e., 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay. The results rep-
resent the 50% growth-inhibitory concentrations (GI50) (mean ± standard devia-
tion; n > 5). The human breast adenocarcinoma MCF-7/ADR cell line was
selected against doxorobucin and expresses both gp170 and the embryonic glu-
tathione transferase p isoform. The human uterine sarcoma line MES-SA/DX5
line was selected against doxorobucin (21). The doxorubicin-resistant human
breast adenocarcinoma cell line MDA3-1/gp170+ expresses the 170-kd P-
glycoprotein. The human acute promyelocytic leukemia line HL-60/ADR was
selected against doxorobucin and expresses the MRP/gp180 protein. The human
lymphoblastoid CEM/VLB100 line was selected against vinblastine and ex-
presses the 170-kd P-glycoprotein. The transfectoma KB-GRC-1 expresses high
levels of the MDR1-encoded 170-kd P-glycoprotein (22). The metastatic human
lung transfectoma MV522/Q6 expresses high levels of the MDR1-encoded 170-
kd P-glycoprotein.
†P<.001 versus wild-type value by Wilcoxon signed rank test.
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another cell line pair that displayed collateral sensitivity to in-
danocine in the multidrug-resistant derivative line, we selected
HL-60 and HL-60/ADR cells because of the exquisite sensitivity
of HL-60/ADR cells to indanocine. In the experiment shown in
Fig. 3, we tested the ability of indanocine to activate caspase-3
in parental and multidrug-resistant HL-60 cells. Caspase-3, con-
sidered an “executioner” caspase, is implicated in the last and
irreversible phase of the apoptotic caspase pathway and is acti-
vated by upstream “initiator” caspases, such as caspase-8 and
caspase-9 [reviewed in (26)]. Caspase activity was measured by
use of the fluorogenic caspase-3-specific substrate DEVD-
AMC. HL-60/ADR cells incubated with 10 nM indanocine
showed a time-dependent increase in caspase-3 activity com-
pared with untreated cells, reaching a maximum at 24 hours. In
contrast, wild-type HL-60 cells showed only a slight increase in
caspase-3 activity, about 25% of that obtained in the multidrug-
resistant cells (Fig. 3, A).
To determine the effect of indanocine treatment on the mi-
tochondrial transmembrane potential of multidrug-resistant and
wild-type cells, we used the fluorochrome DiOC6 (Fig. 3, B). In
apoptosis induced by various stimuli, a decrease in the mito-
chondrial transmembrane potential has been shown to precede
nuclear DNA fragmentation (27). The flow cytometry results
showed a visible reduction in DiOC6 fluorescence for HL-60/
ADR cells incubated with indanocine for 8 hours, indicating that
the mitochondrial transmembrane potential in these cells was
reduced. After 16 hours, the percentage of cells with reduced
DiOC6 fluorescence had reached 44%. HL-60 wild-type cells
incubated with the same amount of indanocine did not display
the same strong reduction in DiOC6 fluorescence.
Effect on Tubulin Polymerization
Indanocine did not change the flow cytometry profile of sta-
tionary-phase cells stained for DNA, other than to cause the
appearance of hypodiploid apoptotic cells in multidrug-resistant
cultures (Fig. 2). However, concentrations of the drug that in-
hibited cell proliferation caused a rapid increase in the number of
cells in G2/M phases in growing cultures (data not presented).
Antimitotic drugs usually interfere with cellular microtubules
by interacting with tubulin (3). Using glutamate-induced assem-
bly of purified tubulin (containing no microtubule-associated
proteins) as our assay, we found (Fig. 4, A) that indanocine
inhibited tubulin assembly in a manner comparable to that of
nocodazole rather than inducing polymerization as would pacli-
taxel. This observation led us to perform a quantitative analysis
(Fig. 4, B), in which we found that indanocine was nearly as
potent as combretastatin A-4 (a gift of Dr. G. R. Pettit, Arizona
State University, Tempe, AZ) as an inhibitor of tubulin assem-
bly. We measured the extent of tubulin assembly after a 20-
minute incubation at 30 °C and determined that the IC50 of com-
bretastatin A-4 was 1.20 ± 0.03 mM (mean ± standard deviation;
n 4 4) and that the IC50 of indanocine was 1.7 ± 0.1 mM (n 4
3). Both compounds practically eliminated the binding of 5 mM
[3H]colchicine to 1 mM tubulin when present at 5 mM—
combretastatin A-4 inhibited 98% ± 4% of colchicine binding (n
4 4), and indanocine inhibited 95% ± 2% of colchicine binding
(n 4 4). The effects of various concentrations of the two drugs
on colchicine binding are shown in Fig. 4, C. Neither agent
inhibited the binding of [3H]vinblastine to tubulin (single ex-
periment).
Cytoskeletal Effects of Indanocine
COS-1 and Hep-G2 cells were grown on glass coverslips and
treated with various concentrations of indanocine, nocodazole,
or vinblastine sulfate. The microtubule network was then visu-
alized by indirect immunofluorescence with an anti-b-tubulin
antibody, and the microfilament network was stained with fluo-
rescein isothiocyanate-coupled phalloidin. COS-1 and Hep-G2
Fig. 2. Effect of indanocine on resting multidrug-resistant
cells. A) Toxicity of indanocine on resting MCF-7 cells.
Parental wild-type MCF-7 and MCF-7/ADR multidrug-
resistant cells were maintained in a confluent state for 7
days by daily replacement of the medium. Indanocine was
then added at 10 mM in wells in column 2 and serially
diluted 1 : 2 in each successive column (reaching 10 nM in
column 12). Column 1 is the control, without indanocine.
After 3 days, the MTT [i.e., 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] assay was used to
quantitate viable cells. B) DNA content and caspase ac-
tivity of indanocine-treated cells. MCF-7/ADR multidrug-
resistant cells were harvested, permeabilized, and stained
with propidium iodide. The DNA content of cells was
established by flow cytometry. Solid peak 4 cells in the
G0/G1 phase; cross-hatched peak 4 cells in the S phase;
hatched peak 4 cells in the G2/M phase; shaded peak
(present only in the right panel) 4 hypodiploid, apoptotic
cells, as modeled with the ModFit Program. At the left are
normally proliferating cells, in the middle are confluent
cells (7 days), and at the right are indanocine-treated,
growth-arrested confluent MCF-7/ADR cells. The per-
centage of cells that are in G0/G1 phase or that are apop-
totic is indicated. The relative caspase activity is the fluo-
rometric measurement of the caspase-3-like activity
normalized to the control cells (left). For normally prolif-
erating MCF-7/ADR cells, the relative caspase activity is
100; for 7-day confluent MCF-7/ADR cells, it is 100; for
growth-arrested, confluent MCF-7/ADR cells treated with
indanocine, it is 450.
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cells were used for these studies because of their clearly defined
microtubule and microfilament networks, respectively. Un-
treated cells had extensive microtubule systems with perinuclear
organizing centers (Fig. 5, a and b) and had microfilament
bundles and stress fibers that were predominantly aligned with
the major axis of the cell (Fig. 6, a and b).
Treatment of COS-1 cells with 0.5 or 5 mM indanocine for 1
hour depleted the cells of microtubules, resulting in diffuse cy-
toplasmic staining with anti-b-tubulin antibody (Fig. 5, c and d).
Treatment with 0.55 mM (0.5 mg/mL) vinblastine sulfate (Fig. 5,
f) for 1 hour had a similar effect. Modifications induced by 3.3
mM (1 mg/mL) nocodazole (Fig. 5, e) for 1 hour were less
pronounced, and some of the perinuclear organizing centers
were still visible.
Indanocine-treated Hep-G2 cells had a rounded shape, and
the microfilament cytoskeleton in these cells was disorganized,
characteristic of treatment with a depolymerizing agent (Fig. 6,
c). After a 1-hour incubation in 0.5 mM indanocine, some cells
Fig. 4. Effect of indanocine on tubulin polymerization
and binding of [3H]colchicine to tubulin. Absorbance was
measured at 350 nm (A350). Inhibition of tubulin poly-
merization (A and B) and inhibition of [3H]colchicine
binding to tubulin (C) by indanocine and by combreta-
statin A-4. Panel A: For the tubulin polymerization as-
say, tubulin (10 mM) was incubated with indanocine at
the following concentrations: 0 for curve 1, 1.0 mM for
curve 2, 1.5 mM for curve 3, 2.0 mM for curve 4, and 3.0
mM for curve 5. At 0 time, the temperature controller was
set at 30 °C for 20 minutes to measure polymerization; at
20 minutes, the temperature controller was set at 0 °C to
measure the amount of cold-reversible tubulin polymer
formation. Panels B and C: Concentrations of indanocine
(n) and combretastatin A-4 (s) were as indicated. Panel
B: Values obtained for the inhibition of tubulin polymer-
ization in all experiments were averaged. For 1.0, 1.5, and 2.0 mM drug, there
were four values for combretastatin A-4 and five for indanocine. There were
fewer experimental values for the other concentrations. The mean control A350
value in these experiments was 0.382. Panel C: Indanocine inhibition of
[3H]colchicine binding to tubulin. In this assay, indanocine was added at various
concentrations to a reaction mixture containing purified tubulin and [3H]colchi-
cine and incubated for 10 minutes at 37 °C. The amount of [3H]colchicine bound
to tubulin was then measured after filtration on DEAE-cellulose. The experiment
shown in panel C was performed once with duplicate samples for each data
point.
Fig. 3. Indanocine induces apoptosis in multidrug-resistant cells. A)
Activation of caspase-3 by indanocine. HL-60 wild-type (wt) and mul-
tidrug-resistant (ADR) cells were treated with 10 nM indanocine; at the
indicated times, caspase-3-like activity was measured with the specific
fluorogenic substrate DEVD-AMC (Asp–Glu–Val–Asp coupled to
7-amino-4-methyl coumarin). The results are expressed as the means ±
standard deviation (error bars) and are representative of up to four
experiments. B) Reduction of mitochondrial transmembrane potential
by indanocine. HL-60 cells were treated with and without indanocine at
10 nM. After 16 hours of incubation, cells were incubated with 40 nM
3,38-dihexyloxacarbocyanine iodide (DiOC6), followed immediately
by flow cytometry in a FACScalibur. The x-axis represents the DiOC6
fluorescence. The y-axis represents the number of cells. The percentage
of low-DiOC6 fluorescence-gated cells is indicated.
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had a characteristic rounded shape, but other cells had normal
microfilament bundles (Fig. 6, d). A similar effect was observed
after exposure to nocodazole (Fig. 6, e) or vinblastine sulfate
(Fig. 6, f). This is probably an indication that the microfilament
breakdown observed at 5 mM indanocine is not a direct effect but
rather is a consequence of the rapid and potent disruption of the
microtubule network.
After treatment of Hep-G2 cells with 100 nM indanocine, the
subcellular localization of the mitotic apparatus (as shown by
human autoantibodies against the type 1 nuclear mitotic appa-
ratus protein) was determined by immunofluorescence. In con-
trol cells undergoing mitosis, the type 1 nuclear mitotic appara-
tus protein was localized at the poles of the mitotic spindle (Fig.
7, a). In cells exposed to 100 nM indanocine and arrested in the
M phase, type 1 nuclear mitotic apparatus protein was distrib-
uted in spots scattered over the nucleus (Fig. 7, b). A similar
effect was observed with 3.3 mM nocodazole (Fig. 7, c). Pacli-
taxel treatment did not interfere with the subcellular distribution
of the type 1 nuclear mitotic apparatus protein, although it af-
fected the formation of a functional mitotic spindle (Fig. 7, d).
DISCUSSION
Indanocine is a derivative of indanone with antiproliferative
activity (Shih H, Deng L, Carrera CJ, Adachi S, Cottam HB,
Carson DA: unpublished data). An initial screen of malignant
cell lines performed by the National Cancer Institute’s Devel-
opmental Therapeutics Program and the COMPARE Program
(28) suggested that these compounds had tubulin-binding prop-
erties. In this screening, the indanones, including indanocine,
retained activity toward multidrug-resistant breast cancer cells.
Indanocine interacts with tubulin at the colchicine-binding site,
and it inhibits tubulin polymerization with an IC50 value equiva-
lent to values obtained with podophyllotoxin and combretastatin
A-4 (29). Consistent with these biochemical effects, in intact
cells, indanocine disrupts intracellular microtubules including
those of the mitotic spindle and leads to redistribution of the
components of the nuclear mitotic apparatus. The discrepancy
between the micromolar concentration of drug required for in
vitro inhibition of tubulin polymerization and the nanomolar
concentrations of drug that blocked cell proliferation has been
Fig. 5. Effect of indanocine on the microtubular network. COS-1 cells were
incubated for 2 hours with dimethyl sulfoxide (a) or ethanol (b), 5 mM and 500
nM indanocine (c and d, respectively), 3.3 mM (1 mg/mL) nocodazole (e), or
0.55 mM (0.5 mg/mL) vinblastine sulfate (f). The cells were fixed, microtubules
were labeled (red) with an anti-b-tubulin antibody, and nuclei were stained
(blue) with 48,6-diamidino-2-phenylindole dihydrochloride.
Fig. 6. Effect of indanocine on the microfilament network. Hep-G2 cells were
incubated for 2 hours with dimethyl sulfoxide (a) or ethanol (b), 5 mM and 500
nM indanocine (c and d, respectively), 3.3 mM (1 mg/mL) nocodazole (e), and
0.55 mM (0.5 mg/mL) vinblastine sulfate (f). Cells were fixed, microfilaments
were stained with fluorescein isothiocyanate-coupled phalloidin (green), and
nuclei were stained with 48,6-diamidino-2-phenylindole dihydrochloride (blue).
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observed with other antitubulin agents (5,25,29). This discrep-
ancy may indicate that indanocine interacts with other nontubu-
lin cellular components to produce a cytotoxic response. This
hypothesis is supported by the ability of short-term treatment
with indanocine to trigger apoptosis in stationary multidrug-
resistant cancer cells (whose survival should not depend on
DNA synthesis or an intact mitotic apparatus) but not in control
cells.
Modification of the apoptotic machinery has been proposed
as an explanation for the de novo and acquired cross-resistance
to multiple antineoplastic agents. It has been shown that the
Bcl-2 protein may protect cancer cells from drug-induced apop-
totic cell death (18,30,31). Microtubule-disrupting drugs, such
as vincristine, vinblastine, and colchicine, and microtubule-
stabilizing drugs, such as paclitaxel and doxetaxel, induce
growth arrest, which is followed by phosphorylation and inac-
tivation of Bcl-2, which eventually leads to apoptotic cell death
in the G2/M phase of the cell cycle (32–34). In contrast, cells in
the stationary phase are generally resistant to many of these
agents, and phosphorylation of Bcl-2 in the G0/G1 phase is gen-
erally not observed. This property limits the utility of tubulin-
binding drugs for the treatment of malignant tumors containing
only a few proliferating cells (i.e., tumors with a low S-phase
fraction).
As with other microtubule-damaging drugs, indanocine ar-
rested the growth of multidrug-sensitive cancer cells at the G2/M
boundary and induced apoptotic cell death. The nanomolar con-
centrations of indanocine that induced apoptosis in multidrug-
resistant cells did not kill wild-type G1-phase cancer cells or
quiescent normal peripheral blood lymphocytes. Nanomolar
concentrations of indanocine forced stationary, multidrug-
resistant cells into the apoptotic program. That these cells were
arrested in the G0/G1 phase of the cell cycle was confirmed by
cytofluorometric analysis. Apoptosis, in these cells, was con-
firmed by the appearance of a subdiploid-DNA flow-cytometry
peak and by caspase-3 activation. Compared with their respec-
tive parental lines, five multidrug-resistant cell lines displayed
higher or indistinguishable sensitivity to indanocine toxicity.
The cell lines hypersensitive to indanocine have modified
various systems for multidrug resistance. MES-SA/DX5 cells
overexpress P-glycoprotein, and MCF-7/ADR cells overexpress
P-glycoprotein and also have an embryonic p isoform of gluta-
thione transferase (35). HL-60/ADR cells express the MRP/
gp180 protein. The other two cell lines that we examined, with
unaltered sensitivity to indanocine, only express P-glycoprotein.
The fact that sensitivity to indanocine was retained by all of
the multidrug-resistant cells tested, including both KB-3-1 and
MV522 transfectomas that overexpress the P-glycoprotein, sug-
gests that this agent acts independently of the P-glycoprotein
hydrophobic multidrug transporter and/or that the cytoskeletal
disorganization induced by the indanone interfered with P-
glycoprotein functions. In other experiments, indanocine did not
alter the rate of rhodamine efflux from loaded cells (data not
shown). Thus, it seems probable that the uptake and regulation
of indanocine do not depend on or directly influence the P-
glycoprotein multidrug transporter.
Several different microtubule-disrupting agents have been de-
veloped that do not depend on the 170-kd P-glycoprotein and
that display antiproliferative activity against multidrug-resistant
cancer cells (23,36). It should be of interest to determine whether
any of these agents, like indanocine, are cytotoxic to noncycling
mdr1-expressing cells. Such comparative studies could answer
the question whether the mechanism of action of indanocine is
related only to inhibition of microtubule function. If indanocine-
induced cell death involves another intracellular target, then
other microtubule-disrupting agents with antiproliferative activ-
ity toward multidrug-resistant cells should not be able to induce
apoptosis in the G0/G1 phase.
The observation that indanocine kills noncycling, multidrug-
resistant cells has practical implications. The low percentage of
cycling cells in many human solid tumors limits the potential of
antimitotic drugs. The combination of a drug that is selectively
cytotoxic to nondividing, multidrug-resistant cells and an anti-
neoplastic agent that kills tumors with abnormalities of cell
cycle checkpoints could represent an exceptionally effective ap-
proach to eradicating malignant cells while sparing most normal
tissues. Thus, we suggest that indanocine and related indanones
be considered lead compounds for the development of chemo-
therapeutic strategies for drug-resistant malignancies.
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Antimitotic drug-induced apoptosis in CLL
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ABSTRACT
    Despite their slow proliferative rate, chronic
lymphocytic leukemia cells (CLL) are hypersensitive to
the toxicity of some microtubule-binding antimitotic
agents. The biochemical basis for the hypersensitivity is
unknown, and has been difficult to exploit clinically.
Indanocine is a recently described tubulin-binding agent
that induces apoptosis in some stationary phase,
multdrug resistant cancer cell lines. We report here that
indanocine is also cytotoxic to CLL cells, but not to
normal peripheral blood lymphocytes. Within two hours
of CLL cell exposure to indanocine, Bcl-2
phosphorylation and dimerization increased, followed
quickly by a reduction in cytosolic Bax, the cytochrome c
release from mitochondria to the cytosol, and caspase
activation. Concomitantly to Bcl-2 phosphorylation,
activation of the JNK pathway was observed. Indanocine
did not induce detectable DNA strand break formation, or
p53 phosphorylation at Ser15, but stimulated a variety of
p53-inducible genes. The increased expression of Fas
ligand, and Apo2/TRAIL ligand, was a later event
occurring 12-24 hours after indanocine treatment.
Collectively, these results suggest that indanocine-
induced microtubule disruption in CLL activates an
internal apoptosis program, independent of both DNA
damage and cell cycle arrest.
INTRODUCTION
     Chronic lymphocytic leukemia (CLL) is the most common
leukemia in the U.S and occurs nearly exclusively in the
senior population. It is characterized by the clonal proliferation
and accumulation of neoplastic B lymphocytes in the blood,
bone marrow, lymph nodes, and spleen. The incidence rate of
this disease appears to be on the rise in association with the
aging of the American population (1).  Despite recent
advances in our understanding of CLL and leukemogenesis in
general, we still do not know the underlying genetic and
biochemical basis for this disease. Also, there is no
established cure.
     It was discovered several years ago that CLL cells
displayed in vitro hypersensitivity to colchicine toxicity (2). A
two-hour exposure of CLL cells to colchicine caused
ultrastructural changes in mitochondria, followed by apoptosis
(3). The exact biochemical basis for colchicine-induced
apoptosis could not be elucidated with the knowledge
available at that time. Moreover, the systemic toxicity of most
microtubule-binding drugs has hampered their routine use for
the treatment of CLL and other lymphoproliferative diseases,
except in refractory cases.
     Since these early reports, the understanding of the
molecular events that lead to drug-induced apoptosis has
rapidly evolved. Two main pathways are known to activate
programmed cell death; an extrinsic death receptor-activated
pathway and an intrinsic mitochondrial-mediated pathway (4).
Both pathways lead to the activation of effector enzymes
collectively known as caspases (5, 6). The extrinsic Fas
pathway is important in the regulation of lymphocyte
homeostasis (7). The cytoplasmic domain of Fas receptor has
no intrinsic activity, but contains a death domain for protein
interactions that recruit procaspase-8 to initiate the apoptotic
cascade (8, 9). Several other cell death induction proteins that
interact with Fas receptors have been identified and
alternative pathways have been described for the Fas
signaling pathway (10, 11).
The intrinsic apoptotic pathway often involves changes in the
mitochondria (4). Damage to the mitochondrial membrane
fosters the release from the intermembrane space into the
cytosol of apoptotic effector proteins, including cytochrome c
(4, 12), apoptosis-inducing factors (AIFs) (13), and
procaspases-2 and 9 (14). Procaspase-9 reacts with the
cytosolic apoptotic protease activating factor-1 (APAF-1), and
in the presence of dATP and cytochrome c oligomerizes to
form an active complex called the apoptosome (15, 16). The
apoptosome then induces the cleavage of procaspase-3. The
intrinsic apoptosis pathway is regulated by pro-apoptotic and
anti-apoptotic proteins of the BCL-2 family, which control the
integrity of mitochondrial membranes, inducing or preventing
cytochrome c release (17, 18). The ratio of anti-apoptotic
BCL-2 to pro-apoptotic BAX has been proposed to be a key
regulator of apoptosis in lymphocytes (19).
     We recently reported the synthesis and characterization of
indanocine, a tubulin-binding drug that potently inhibited cell
proliferation (20). Unlike other bulky hydrophobic tubulin-
binding drugs, indanocine was not a substrate for the
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multidrug resistant transporter systems. Moreover, indanocine
displayed a unique ability to kill multidrug resistant cancer
cells in stationary phase. Considering that CLL cells have a
very low rate of proliferation, and have been reported to
display colchicine hypersensitivity, we investigated the
potential cytotoxic activity of indanocine in CLL cells, and
studied its mechanism of action in light of recent findings in
the field of apoptosis.
MATERIAL AND METHODS
Patients, cell isolation and viability assays
    Written informed consent was obtained to procure
peripheral blood from all patients with normal healthy
volunteers. Patients had to have B-CLL according to National
Cancer Institute (NCI) criteria of any Rai stage.  Heparinized
peripheral blood samples from patients with CLL containing at
least 90 % malignant cells, were fractionated by
Ficoll/Hypaque sedimentation. Non adherent mononuclear
cells were resuspended in complete medium (RPMI-1640
supplemented with 10% fetal bovine serum) at a density of 1
to 2 x 106 per ml. Cells were incubated at 37°C in an
atmosphere of 5% CO2 with the indicated drugs. In some
experiments frozen cells were used. At the indicated times ,
viability assays were performed by erythrosin B dye exclusion.
Subcellular fractionation and Immunoblotting
     For total cell lysates, washed B-CLL cells were lysed in
Lysis buffer (25 mM Tris, pH 7.4, 150 mM KCl, 5 mM EDTA,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1
µg/ml aprotinin, 1 µg/ml leupeptin, 1 mM
phenylmethanesulfonyl fluoride, 1 mM sodium orthovanadate,
1 mM sodium fluoride). Lysates were centrifuged at 15,000 x
g for 10 min to remove nuclei and the protein content of
supernatants was measured using a modified Coomassie blue
assay (Pierce, Rockford, IL). For the isolation of the cytosolic
and membrane-bound proteins, cells were washed with PBS,
and incubated for 10 minutes on ice with frequent vortexing in
Hypotonic Extraction Buffer (HEB; containing 50 mM PIPES/
50 mM KCl/5 mM EGTA/2 mM MgCl2/1 mM DTT/0.1
phenylmethanesulfonyl fluoride) freshly supplemented with
0.05% digitonin (Sigma, St. Louis). The cells were then
centrifuged at 15,000 x g for 10 min at 4°C, the pellet
containing the nuclei and membranes was resuspended in
Lysis buffer. The supernatant represented the cytosolic
proteins. The concentration of digitonin (0.05%) used to
optimally recover the of cytosolic proteins but not to damage
the mitochondrial membranes was obtained by titration,
followed by immunoblotting of mitochondrial proteins residing
on the mitochondrial intermembrane compartment.  The
extracted proteins were resolved at 125 V on 14% and 4-20%
Tris-gly pre-cast gels (Novex, San Diego) and
electrophoretically transferred to 0.2 µm polyvinylidene
fluoride (PVDF) membranes (Millipore, Bedford, MA) for 2
hours at 125 V. Membranes were blocked overnight in I-Block
blocking buffer (Tropix, Bedford, MA). Blots were probed with
polyclonal antibodies anti-Mcl-1, anti-Bcl-2, monoclonal anti-
Bag-1 (all developed in J. Reed’s lab), monoclonal anti-XIAP
(Transduction Laboratories Inc.), monoclonal anti-PARP (gift
of N.A. Berger), or monoclonal anti-PPAR-g (Santa Cruz
Laboratories, California) antibody, followed by a secondary
antibody consisting of horseradish peroxidase (HRP)-
conjugated goat anti-rabbit (Mcl-1) or anti-mouse (PPAR-g)
IgG. Detection was performed by an enhanced
chemiluminescence (ECL, Amersham) method, followed by
colorimetric detection, using SG substrate. The X-ray films
were scanned, acquired in Adobe Systems Photoshop and
analyzed with NIH Image Software.
Cellular Assay for Caspase Activity
     At the indicated time point, CLL cells were washed twice
with PBS, the pellet was resuspended in caspase buffer (50
mM Hepes, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% Chaps,
and 5 mM dithiothreitol) for 10 min at 4 °C. Lysates were then
stored at -80 °C. The caspase enzymatic assays were carried
out in 96 well plates, lysates (10-20 µg of total protein) were
mixed with 50 µl of HEB buffer (PIPES 50 mM, KCl 20 mM,
EGTA 5 mM, MgCl2 2 mM, and DTT 1 mM, pH 7), and
reactions were initiated by addition of 100 µM of the specific
substrate. After 1 hour incubation at 37°C, caspase-3-like
protease activity was measured with the substrate Ac-DEVD-
AMC and caspase-9-like activity was measured using Ac-
LEHD-AFC. Activity was measured by the release of 7-amino-
4-trifluoromethyl-coumarin (AFC) or 7-amino-4-methyl-
cumarin (AMC) monitoring fluorescence at excitation and
emission wavelengths of 400 and 505 nm, and 380 and 460
nm respectively.
Cytofluorimetric analysis of mitochondrial
transmembrane potential ( m) by DiOC6, cell membrane
permeability by PI, Fas Ligand and Apo2L/TRAIL surface
expression
     CLL cells were treated with the indicated amount of the
drugs and/or with 50 µM of the cell-permeable caspase
inhibitors Z-VAD-fmk (Z-Val-Ala-Asp(Ome)-CH2F, Biomol,
Plymouth Meeting, PA)). Cells were then incubated for 10 min
at 37°C in culture medium containing 40 nM 3,3'
dihexyloxacarbocyanine iodide (DiOC6, Molecular Probe,
Eugene, OR) and 5 µg/ml propidium iodide (PI, Molecular
Probe), followed by analysis within 30 minutes of
fluorochrome in a Becton-Dickinson FACScalibur
cytofluorometer. After suitable compensation, fluorescence
was recorded at different wavelengths: DiOC6 at 525 nm (FL-
1) and PI at 600 nm (FL-3). For the detection of surface FasL
and Apo2L/TRAIL, cells (1 x 106) were washed in PBS, and
resuspended in 50 µl PBS containing 3% FBS with 1 µg
monoclonal antibody to Fas Ligand FITC labeled (Clone H11,
Apotech, Switzerland) or 1 µg of the FITC-labeled
recombinant fusion protein TRAIL-R2:Fc (Apotech,
Switzerland). Cells were incubated 30 min on ice, washed in
PBS and analyzed by flow cytometry.
Gene expression analysis
     Using the Perkin-Elmer ABI Prism 7700 and Sequence
Detection System software, the level of mRNA for human p53,
HDM2, DAXX, BAX, p21 and GADD45 were quantified. Total
RNA was isolated using the TRIzol Method (Gibco-BRL) and
treated with deoxyribonuclease (Boehringer-Mannheim) to
remove any contaminating genomic DNA. A control without
RT was used to control for the efficiency of this process. 10 µg
of total RNA were used to generate cDNA using a T7-poly dT
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oligodeoxynucleotide primer (ggc cag tga att gta ata cga ctc
act ata ggg agg cgg-T24) following the protocol for
SuperScript II (Gibco-BRL).  50 ng of cDNA were used in
triplicate and amplified with the TaqMan Master Mix supplied
by Perkin-Elmer. Amplification efficiencies were validated and
normalized against GAPDH and fold increases were
calculated using either the Comparative CT Method for
quantitation or by generating a standard curve (Ref: ABI Prism
7700 SDS User Bulletin #2 P/N 4303859 Rev. A
(http://www2.perkinelmer.com/ab/techsupp/7700.html)).
Sequences for primers and probes:
Taqman probes (T) are labeled with 5’ FAM and 3’ TAMRA,
forward (F) and reverse (R) primers are unlabeled (IDT,
Coralville, IA).  DNA oligo sequences are written 5’ to 3’ as
follows:
P53:  F-gcgtgagcgcttcgagat; R-cagcctgggcatccttga; T-
ccgagagctgaatgaggccttggaa
MDM2:  F-ctacagggacgccatcgaat; R-tgaatcctgatccaaccaatca;
T-cggatcttgatgctggtgtaagtgaacattc;
BAX alpha:  F-ctgatcagaaccatcatgggc; R-
gaggccgtcccaaccac; T-tccgggagcggctgttggg;
P21:  F-ctggagactctcagggtcgaa; R-cggcgtttggagtggtagaa; T-
acggcggcagaccagcatgac;
GADD45:  F-tctgcagatccacttcaccct; R-gctgacgcgcaggatgtt; T-
tccaggcgttttgctgcgagaac;
Patient IC50 FasL Apo2/TRAIL
B-CLL 850±60 Up Not tested
B-CLL 1100±100 Up Up
B-CLL 5600±110 Up Up
B-CLL 6700±80 Up Up
B-CLL 3600±50 Not Tested Not Tested
B-CLL 2500±70 Not Tested Not Tested
B-CLL 8000±120 Up Up
PBL >50,000 Unchanged Unchanged
PBL >50,000 Not tested Not tested
Table 1   Cytotoxicity of indanocine was tested in chronic lymphocytic
leukemia (B-CLL) cells and normal peripheral blood cells (PBL).
Cell count and viability were assessed by dye-exclusion and MTT
assay in cells after 3 days continuous exposure to decreasing
concentrations of the drug, starting at 50µM. The level of surface Fas-
ligand and Apo2/Trail was measured by flow cytometry using a
monoclonal antibody against Fas-ligand (clone H11, Apotech,
Switzerland) and using a recombinant chimeric protein TRAIL-R2:Fc
(Apotech, Switzerland), respectively.
RESULTS
Indanocine Selectivity Towards CLL
     As assessed by cell survival after three days incubation,
the median concentration of indanocine that killed 50% of CLL
cells was approximately 3.6 µM (range 0.85-8 µM, n=7),
whereas normal PBL were impervious to 50 µM indanocine
(<10% cell death, Table 1). Drug toxicity was both dose and
time dependent, with longer exposures producing more killing
(Figure 1A). Cell death occurred by the internal apoptosis
pathway, with caspase 3 activation preceding the activation of
caspase 8 (Figure 1B and 1C). Blockade of caspase activity
with a pan-specific peptidic inhibitor of these proteases (1-
Me,3-Me-indole-2)CO-V-D-fmk, (Idun-1965, IDUN
Pharmaceuticals, La Jolla) (21) protected B-CLL cells from
indanocine toxicity, consistent with an apoptotic mechanism of
c ll death (data not shown).
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Figure 1. Indanocine Selective Cytotoxicity to B-CLL Cells.
Figure 1A. B-CLL cells were incubated in presence of the indicated
concentration of indanocine. At the indicated time course, apoptosis
was assessed by flow cytometry using a double staining
DiOC6/propidium iodide(PI). Briefly, B-CLL were exposed for 10 min in
culture medium at 37°C to 40 nM DiOC6 and 5 µg/ml PI. The cells
were then rapidly analyzed using a Becton Dickinson FACS-Calibur.
The subset of apoptotic cells was defined as displaying low-DiOC6
(FL-1) and low PI fluorescence (FL-3), after suitable compensation.
B-CLL cells were incubated with 1 µM (left panel, Figure 1B) and 10
µM (right panel, Figure 1C) of indanocine. At the indicated times,
2x106 cells were washed once in ice-cold PBS and resuspended in 50
µl Caspase Buffer. The enzymatic caspase-3-like (s) and caspase-8-
like (n) activities were measured using the fluorometric substrates Ac-
DEVD-AMC and Z-IETD-AFC, respectively.
Indanocine Increases Bcl-2 Phosphorylation and Alters
the Subcellular Localization of Apoptotic Proteins.
In order to analyze the molecular events induced by
indanocine in B-CLL cells, the treated cells were fractionated
into cytosolic and membrane/nuclear fractions by hypotonic
buffer extraction in presence of 0.05% digitonin. The earliest
pro-apoptotic change observed in indanocine treated CLL
cells was Bcl-2 phosphorylation, which was detectable at 2
hours, and increased thereafter (Figure 2A, top). The total
amount of membrane-bound Bcl-2 did not change during the
same treatments (Figure 2A, middle), the cytosolic pool
showed a slight increase at 6 and 8 hours post-treatement
(Figure 2B, top).  In parallel to Bcl-2 phosphorylation, the
membrane-associated Bad was greatly reduced (Figure 2A,
bottom), the cytosolic Bax decreased, and cytochrome c was
released into the soluble cytosolic fraction. The observed
events are consistent with a model in which Bcl-2
phosphorylation induces its dissociation from Bax, which
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becomes free to inserts into mitochondrial membranes, thus
allowing cytochrome c release into the cytosol. The % of
apoptotic cells measured in the same cells by flow cytometry
using the DiOC6 staining, reported at the bottom of the gels,
shows that the induction of apoptosis is concomitant with the
cytochrome c release.
Ctrl 2 4 6 8     hrs
p-Bcl-2
Bcl-2
BAD
A
Bcl-2
Bax
Cyt C
actin
15 16 15 19 27
% apoptotic cells
B
Figure 2. Indanocine Increases Bcl-2 Phosphorylation and Alters
the Subcellular Localization of Apoptotic Proteins.
B-CLL cells were treated with 10 µM indanocine. At the indicated
time-points cells were incubated with an hypotonic extraction buffer
containing 0.05% digitonin. The membrane/nuclear (Figure 2A) and
cytosolic-enriched (Figure 2B) fractions were loaded on a 4-20% Tris-
gly SDS-PAGE gel, and blotted on a PVDF membrane. Antibodies
against phosphorylated Bcl-2 (Upstate Biotechnology), against Bcl-2,
cytochrome c (Santa Cruz Biotechnology), and Bad (New England
Biolabs) were used to quantifiy the apoptotic components.The total
amount of protein was analyzed by using an anti-actin antibody. The
percent of apoptotic cells (indicated at the bottom of figure 2B) was
measured by flow cytometry using a double labeling with DiOC6 and
propidium iodide (PI). The subset of apoptotic cells was defined as
displaying low-DiOC6 and low PI fluorescence. The results obtained
are representative of 3 different B-CLL patients.
Indanocine Activates the c-Jun Kinase Pathway.
     In order to determine the Bcl-2-phosphorylating enzymatic
cascade activated by indanocine on the quiescent B-CLL
cells, a variety of candidates were tested. Several phospho-
specific antibodies against ERK 1 and 2, and p38 kinase
obtained from a variety of vendors (NEB, Promega, Santa
Cruz Biotechnology) showed negative results (data not
shown), indicating that these two pathways are probably not
involved in the indanocine-induced cytoskeletal stress
pathway. On the contrary, indanocine induced a rapid and
strong phosphorylation of the transcription factors c-Jun and
ATF-2 (Figure 3, first and second panel), as well as JNK-1
and –2 (Figure 3, third panel), suggesting the activation of the
ASK/JNK pathway, as previously reported in proliferating cells
(22). The phosphorylation of ATF-2, c-Jun, and JNKs is
concomitant to the Bcl-2 phosphorylation, starting at 4 hours
and peaking at 8 hours.  Finally, the % of apoptotic cells
increases significantly after 8 hours, following the activation of
t e stress signaling pathway, and confirming the results
shown in figure 2 obtained in cells from a different CLL
patient.
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Figure 3. Activation of stress-signaling pathway by indanocine in
B-CLL.
B-CLL cells were treated with 10 µM indanocine, at the indicated time-
points total cell lysates were obtained as described in the Material and
Methods.  The lysates were loaded on a 4-20% Tris-gly SDS-PAGE
gel, and blotted on a PVDF membrane. Phospho-specific antibodies
from New England Biolabs were used to analyze the activation of the
transcription factors ATF-2 and c-Jun, of the c-Jun Kinases-1 and –2.
A monoclonal antibody was used to look at the level of Bcl-2 and at
the appearance of the Bcl-2 dimers. The total amount of protein was
analyzed by using an anti-actin antibody. The results obtained are
representative of 3 different B-CLL patients.
Indanocine Activates the p53 Pathway Without DNA
Damage.
     In order to verify if the induction of apoptosis by indanocine
was also mediated by a transcriptional activation of the pro-
apoptotic p53 pathway, we investigated the DNA damage
activity of indanocine and the expression levels of both mRNA
and protein of p53-inducible genes. As measured by a
se sitive alkaline DNA unwinding assay that could detect
amage inflicted by £ 1Gy, or with the single cell-based comet
assay, 20 m M indanocine did not induce DNA strand break in
CLL cells (data not shown). Immunoblotting analysis
confirmed the lack of direct DNA damage by indanocine. No
detectable phosphorylation of p53 at the serine 15 residue
was observed in indanocine-treated CLL cells from several
patients (Figure 4, top panels). As a positive control,
incubation of CLL cells with the DNA-damaging nucleoside
analog fludarabine (F-AraA) for 24 hours showed a strong
band, indicating Ser15 p53 phosphorylation. An antibody
recognizing p53 phosphorylated at residue Ser392 was also
tested, but no increase was observed with both fludarabine
and indanocine. Interestingly, quantitative mRNA analysis
(RQ-PCR, TaqMan analysis) of indanocine treated cells
showed up-regulation of the p53 inducible genes p21, Bax,
HDM2, and p53, suggesting the activation of a functional p53
pathway. The analysis of the protein expression levels of the
same p53-inducible genes confirmed the RQ-PCR results
showing induction of p21, Bax, p53, and HDM2 after
treatment with indanocine at 1 and 10 µM at 8 or 24 hours.
However, these changes were first apparent at 8 hours, after
the hyperphosphorylation of Bcl-2. Moreover, a CLL cell clone
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that failed to express detectable p53 in immunoblots still
underwent Bcl-2 phosphorylation and apoptosis after
incubation with indanocine (results not shown).
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1 CONTROL CLL#2 1.00 1.00 1.00 1.00
2 Indanocine 10µM 8hrs 2.32 0.88 1.63 1.70
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Figure 4. Indanocine activates p53-inducible genes.
B-CLL cells from two different patients (CLL#1 and CLL#2) were
incubated in presence of DMSO (lane 1), indanocine at 10 µM (lanes
2 and 4) and 1 µM (lane 3), or the DNA-damaging nucleoside
fludarabine (lane 5), for 24 hours (lanes 1, 3, 4, 5) or 8 hours (lane 2).
At the indicated time-points, cells were lysed and the (Ser15)-
phosphorylated p53 level was measured by immunoblotting (Fig. 4A).
The expression of the p53-inducible proteins p21, Bax, HDM2, the
total level of p53 were measured by immunoblotting using specific
antibodies. The table (Fig. 4B) represents the expression levels
quantified by scanning the autoradiography films. The relative
expression levels were calculated after analysis of the total amount of
protein per lane obtained by immunblotting with anti-actin antibody. In
bold are the conditions that showed up-regulation of the protein
expression from the controls. Total RNA was isolated from patient
CLL#2 and the mRNA levels of the p53-inducible genes (p21, Bax-
alpha, GADD45, HDM2, and p53) were quantified by RQ-PCR
(TaqMan) using specific primers (Fig 4C). Amplification efficiencies
were validated and normalized against GAPDH, and the results are
expressed as fold increase over the control (first column, normalized
to 1). The results are representative of two independent experiments.
Indanocine Induces a Late Induction of the Surface
Expression of the Death Ligands FasL and Apo2L/TRAIL.
     Phosphorylated c-Jun and ATF-2 can cooperate to
increase the transcription of stress-activated genes, that may
include the ligands for the death receptors Fas and
Apo2/TRAIL. In addition, these two ligands can be induced by
p53 transcriptional activation (23, 24). Fluorometric analysis
indeed showed that Fas ligand and Apo2/TRAIL ligand
expression increased 24 hours after indanocine treatment of
B-CLL cells (Figure 6). However, these events also occurred
subsequent to Bcl-2 phosphorylation and initial caspase-3
activation. The up-regulation of both FasL and Apo2/TRAIL
appears to be concomitant with the observed enzymatic
activation of caspase-8 (Figure 1), and may be responsible for
the killing of the cells that did not respond to the early
apoptotic induction.
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Figure 5. Surface expression of Fas-ligand and Apo2L/TRAIL in
indanocine-treated B-CLL cells.
A: Control antibody, B: Unstimulated B-CLL, C: B-CLL+Indanocine-P
10 µM for 24 hrs, D: Indanocine-P 10 µM 48 hrs.
Figure 5B. B-CLL cells isolated by Ficoll gradient were cultured in
RPMI-1640 supplemented with 10% FBS. B-CLL were exposed to the
indicated concentrations of indanocine. At the selected time point, B-
CLL (1x106) were washed in PBS and resuspended in 50 µl FACS
medium (culture medium with 0.03% sodium azide) containing 1
µg/ml of the FITC-labeled recombinant fusion protein TRAIL-R2:Fc
(Apotech, Switzerland). Cells were incubated 30 min at 4°C, washed
with FACS buffer and analyzed using a Becton Dickinson FACS-
Calibur.
DISCUSSION
     The progress of chemotherapy in CLL depends upon the
elucidation of biochemical differences between the malignant
B cells and normal cells. In general, drugs that inhibit tubulin
polymerization selectively arrest proliferating cells in the G2/M
phase of the cell cycle, and spare cells in G1. At first analysis,
it is paradoxical that indanocine, a tubulin binding agent,
should induce apoptosis in CLL cells, that have a very slow
turnover rate. Moreover, the malignant CLL cells are many-
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fold more sensitive to indanocine toxicity than are normal
peripheral blood lymphocytes (PBL).
     However, there is reason to suspect that the cytoskeletal
network may be regulated much differently in CLL cells than in
PBL. Unlike resting peripheral blood lymphocytes, CLL cells
spontaneously migrate under stromal cell monolayers, display
random chemokinesis, and express high levels of the
chemokine receptor CXCR3 and CXCR4 (25, 26). The
continuous movement of CLL cells would be expected to
require dynamic reorganization of the cytoskeleton. Similarly,
in cultured cells, cytoskeletal remodeling is a critical event at
the G2/M boundary. Thus, the shared sensitivity to tubulin-
binding agents of migrating CLL cells, and proliferating cells at
the G2/M check point, may reflect a shared dependence of
cell survival on cytoskeletal integrity.
     Exactly how inhibition of tubulin polymerization in CLL cells
triggers apoptosis is still not clear. Our data indicate that
neither DNA-dependent p53 activation, nor signaling through
the cell death receptors Fas and Apo2/TRAIL, are primary
events in indanocine-induced apoptosis. The results rather
point to a more proximal connection between the microtubule
network, mitochondria, and proteins of the BCL-2 family.
Recently, a BH3-only Bcl-2 family member called Bim,
normally associated to the microtubular network, has been
shown to translocate to the mitochondria, bind Bcl-2 and
neutralize its anti-apoptotic activity upon pro-apopotic
stimulation (27).
     In lymphocytes, the Bcl-2/Bax ratio has been proposed to
be a central regulator of the intrinsic apoptotic program (28,
29). The overexpression of the pro-apoptotic Bcl-2 family
member Bax sensitizes cells to death signals and is sufficient
to induce cytochrome c release and apoptosis (30). By
forming heterodimers with Bax, Bcl-2 can antagonize this
effect. Anticancer microtubule-binding agents have been
shown to induce phosphorylation of Bcl-2 and to diminish its
anti-apoptotic activity (31).  The mechanism of action may be
that Bcl-2 phosphorylation reduces its heterodimerization with
Bax, releasing the pro-apoptotic Bax protein for insertion into
mitochondrial membranes. Recently, mutation of the Bcl-2
phosphorylation sites to non-phosphorylatable residues has
been shown to enhance its anti-apoptotic activity (22). A
variety of different kinases have been reported to regulate the
drug-induced BCL-2 phosphorylation in malignant cell lines,
including Raf-1, PKA, and ASK/Jun N-terminal kinase 1
(reviewed in (32).
     BAD is a pro-apoptotic molecule that lacks the hydrophobic
c-terminal sequence typical of membrane-based BCL-2 family
members, but can bind to, sequester, and inactivate BCL-2
and BCL-XL (28). Serine phosphorylation of BAD in response
to cell survival factors renders it incapable of forming such
inactivating heterodimers (33). BAD phosphorylation is
controlled by several different kinases, including phosphatidyl
inositol-3 kinase (PI3-kinase), AKT, Raf p21 activated kinase
(PAK1), ERKs, and RSK (see (34).
     Treatment of CLL cells with cytotoxic concentrations of
indanocine for as little as 2-4 hours induced BCL-2
hyperphosphorylation, BAD relocalization to the cytosolic
compartment, and increased membrane-bound BAX. These
early events preceded p53 activation or FasL expression.
They were followed by the release of cytochrome c, and the
enzymatic activation of procaspases-9 and -3, prior to
procaspase-8. These data suggest that CLL cells, in common
with some proliferating malignant cells may have a distinct
cytoskeletal damage response pathway that is distinct from
both the DNA-damage and death-receptor response pathways
(35).
     Because it is difficult to manipulate genetically CLL cells by
ransfection, we could not discriminate the precise enzymes
r sponsible for BCL-2 phosphorylation and BAD
dephosphorylation, although indanocine did activate the JNK
pathway, as demonstrated by the early phosphorylation of
JNK-1 and-2, and of the two downstream transcription factors
ATF 2 and c-Jun. It also is possible that disorganization of the
cytoskeleton interfered with coordinated BAD phosphorylation,
and disturbed the cellular distribution of mitochondria. Future
experiments will need to discriminate the subcellular
localization of microtubules, protein kinases, BCL-2 family
members and mitochondria in CLL cells, compared to normal
lymphocytes, before and after indanocine treatment.
     Two factors that have impeded the use of microtubule
binding drugs for the treatment of CLL are toxicity to normal
cells, and the expression in CLL of a multidrug resistant
(MDR) phenotype (36). However, in vivo preclinical studies
have shown that parental indanocine is remarkably nontoxic
to mice (unpublished data). Moreover, malignant cells
resistant to vinca alkaloids and paclitaxel retain sensitivity to
indanocine toxicity (20). Taken together, these results suggest
that indanocine is a useful agent to dissect the cytoskeletal
damage response pathway in CLL, and may have potential
value for the treatment of refractory disease.
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ABSTRACT
     Nonsteroidal anti-inflammatory drugs (NSAIDs)
recently have attracted attention as
chemopreventive and chemotherapeutic agents
for malignant diseases. However, their
mechanisms of action, and spectrum of activity,
are poorly understood. We show here that
etodolac, a chiral NSAID that is taken as a
racemic mixture, increased apoptosis in B-
chronic lymphocytic leukemia cells (B-CLL), at
concentrations that did not kill normal B or T-
lymphocytes. Incubation of B-CLL cells with
etodolac caused rapid down-regulation of the
anti-apoptotic protein Mcl-1, reduced the
mitochondrial transmembrane potential, and
inhibited mitochondrial respiration. These effects
preceded the appearance of an apoptotic
phenotype. Both the etodolac enantiomers also
activated the peroxisome proliferator-activated
receptor-g, which was expressed in B-CLL cells at
approximately 10-fold higher levels than in normal
lymphocytes. CXCR3-dependent chemotaxis of B-
CLL cells was also activated by etodolac.
Challenge of B-CLL patients with low dose
etodolac (800 mg/day) reduced the subsequent
ex vivo  survival of the leukemic cel ls.  The same
doses of etodolac given for 30 days caused a
significant fall in circulating leukemic cells in 5 of
6 patients treated. These results demonstrate
that etodolac has diverse metabolic effects on
B-CLL cells that could contribute to their
elimination or redistribution in vivo. The R-
enantiomer of etodolac may represent a useful
adjunctive agent for the control of B-CLL
progression.
INTRODUCTION
     Recently, interest has arisen in the anti-cancer activity of
certain nonsteroidal anti-inflammatory agents (NSAIDs).
NSAIDs induce apoptosis in several cell types, including
myelocytic and lymphocytic leukemia cells, embryonic
fibroblasts, and colonic epithelial cells, at concentrations that
are nontoxic to many adult tissues (1-4). The mechanism of
death is apoptosis, since broad-spectrum caspase inhibitors
block cell killing by NSAIDs, but the molecular details of
NSAID-induced apoptosis are not understood.
     The in vitro toxicity of NSAIDs does not correlate with their
ability to inhibit cyclooxygenase 1 and 2 (COX-1,2) (5).
These planar hydrophobic compounds are known to insert into
membranes and to interfere with multiple signaling pathways.
NSAIDs can uncouple oxidative phosphorylation, and cause
the release of adenosine into the extracellular space (6).
Sodium salicylate causes swelling and impairs respiration in
isolated mitochondria (7, 8). Various NSAIDs at high
concentrations (100 µM and above) can bind and activate the
nuclear hormone receptor, peroxisome proliferator activated
receptor-g (PPAR-g) (9). In cells with high levels of PPAR-g,
maximal activation of the receptor can induce apoptosis (10).
     Etodolac is a chiral NSAID developed in the 1970s, and is
available in several countries for the treatment of arthritis and
the alleviation of pain (11). Etodolac is sold as a racemic
mixture, but only the S-enantiomer has been reported to have
potent COX inhibitory activity (12). The pharmacology of
etodolac differs from that of other NSAIDs in two aspects.
First, the two enantiomers are not readily interconvertible,
second, "inactive" R-enantiomer is metabolized much more
slowly than the S-enantiomer (11), and consequently
accumulates to 10-fold higher concentrations than the S-
enantiomer in plasma (11).
     Recently, Nardella and colleagues described a patient with
B-CLL, who fortuitously responded to etodolac therapy with a
drop in circulating lymphocytes (13). Treatment of the patient
with seven other NSAIDs did not induce lymphopenia. In this
study, therefore, we have investigated the in vitro and in vivo
activity of etodolac in B-CLL, and its mechanism of action.
The results demonstrate that both etodolac enantiomers can
reduce survival and stimulate chemotaxis of B-CLL cells in
vitro , and that even low dose etodolac can deplete circulating
B-CLL cells in B-CLL patients.
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Figure 1. Cytotoxic effect of etodolac on B-CLL cells and normal
lymphocytes.
(1A) Dose-response and time-course of the cytotoxic effect of
racemic etodolac on B-CLL cells. Cells were incubated for the
indicated times with various concentrations of racemic etodolac.
The results show the mean % viability ± SD (n = 4). (1B)
Comparison of the time-course of the cytotoxic effect of racemic
etodolac on B-CLL cells and normal lymphocytes. Cells from 4
patients (B-CLL) or 4 normal donors (normal lymphocytes) were
incubated for the indicated times with or without 500 µM racemic
etodolac (mean±SE). (1C) Etodolac does not induce apoptosis in
normal B CD19+ lymphocytes. Lymphocytes from normal donors
were cultured in vitro 24 hours with or without 1000 µM racemic
etodolac, which killed >80% of B-CLL. The x-axis shows DiOC6
(FL-1) fluorescence and the y-axis shows CD19-PE (FL-2)
fluorescence. Cells in the upper-left quadrant are apoptotic B
lymphocytes (CD19-positive low m). Cells in the lower left
quadrant are apoptotic non-B cells (CD19-negative low m). The
upper right quadrant (CD19-positive high m cells) shows viable
B cells, and the lower-right quadrant (CD19-negative high) shows
viable non-B cells. (1D) Dose-response and time-course of the
cytotoxic effect of purified R-etodolac and S-etodolac on B-CLL
cells. Cells from 4 patients were incubated for the indicated times
with various concentrations of R- and S-etodolac. (1E) Inhibition
of etodolac-induced apoptosis in B-CLL by the pan-specific
caspase inhibitor IDUN-1965 (16).
RESULTS
Etodolac is more toxic to B-CLL than to normal B
and T lymphocytes.
     Compared to normal peripheral blood lymphocytes (PBL),
B-CLL have reduced spontaneous survival in vitro (Figure 1
and (14)). As little as 200 µM etodolac accelerated the rate of
B-CLL cell death (Figure 1A). Among 15 patients samples
tested, 12 were found to be sensitive (IC50<500 µM at 72
hours) and 3 were resistant (IC50>1 mM). In contrast, all the
tested normal PBL samples (n=4) were etodolac resistant
(IC50>1 mM, Figure 1B). The etodolac sensitivity of normal B
lymphocytes was assessed by double-labeling with
fluorescent antibody to a B cell marker (CD19) and a
mitochondria-specific dye (DiOC6), which measures
mitochondrial transmembrane potential (DY m) (15). Culture of
normal PBL with 1 mM etodolac for 24 hours did not affect the
DY m of CD19-positive cells (Figure 1C), whereas an
equivalent exposure of B-CLL to the drug induced a dramatic
reduction of the DY m followed by cell death (Figure 2A).
Blockade of caspase activity with a pan-specific peptidic
inhibitor of these proteases (1-Me,3-Me-indole-2)CO-V-D-fmk,
(Idun-1965, IDUN Pharmaceuticals, La Jolla) (16) protected
B-CLL cells from etodolac toxicity, consistent with an
apoptotic mechanism of cell death. An apoptotic demise of
etodolac-treated cells was also supported proteolytic
processing of caspase-9, caspase-3, and poly(ADP-ribose)
polymerase (detected by immunoblotting), and by flow-
cytometric detection of hypodiploid DNA (data no  shown).
Purified R-etodolac and S-etodolac enantiomers were
equivalently toxic to the B-CLL cells (Figure 1D).
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Figure 2. Flow cytometric analysis of B-CLL cells after in vitro
culture of racemic etodolac.
(2A) Effect of racemic etodolac on mitochondrial membrane potential and
apoptosis. B-CLL cells were incubated for 12 hours with the indicated
concentrations of etodolac. Cell membrane permeability and DY m were
assayed by incubating the unfixed cells for 10 min at 37°C in presence of 5
µg/ml propidium iodide (PI) and 40 nM DiOC6. The x-axis is DiOC6 (FL-
1) fluorescence, and the y-axis is PI (FL-3) fluorescence. Numbers refer
to the percentage of cells in the upper-left quadrant (dead cells), lower-
right quadrant (low DY m cells, apoptotic cells), and the lower-right
quadrant (normal cells). (2B) Effect of the purified R- and S-enantiomers
of etodolac on mitochondrial membrane potential. (2C) Effect of racemic
etodolac on the oxidation of dihydrorhodamine (DHR). B-CLL cells were
incubated for 3 hours with indicated concentrations of etodolac. Oxidation
of DHR was assessed by fluorescence intensity at 525 nm. DHR
fluorescence in the presence of KCN (10 µM) indicated non-mitochondrial
respiration (background).
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Etodolac reduces mitochondrial transmembrane
potential in whole cells and isolated
mitochondria, and inhibits mitochondrial
respiration.
     A reduction in mitochondrial transmembrane potential
(DY m) is an early event in apoptosis induced by internal
stimuli and has been shown to correlate with loss of viability
and onset of apoptosis in B-CLL cells treated with nucleoside
analogs (15). Even short-term treatment (12 hours) of B-CLL
cells with etodolac reduced the DY m, as measured by DiOC
6
fluorescence (Figure 2A). To determine if etodolac had a
direct effect on mitochondria, the organelles were purified
from B-CLL cells by a gentle nitrogen cavitation method (17),
and were incubated for 10 min at 37°C with different
concentrations of etodolac. Both the R- and S-enantiomers of
etodolac reduced the DY m of purified mitochondria in a dose-
dependent manner (Figure 2B).
     The flow-cytometric measurement of dihydrorhodamine
(DHR) oxidation in lymphocytes has been shown to correlate
with the respiration of mitochondria, as assessed with an
oxygen electrode (18). The oxidation of DHR depends upon
the availability of substrate (succinate + ADP) and is inhibited
by the addition of KCN. B-CLL cells incubated with etodolac
for 3 hours displayed a dose-dependent decrease in DHR
oxidation (Figure 2C). Taken together, the data with intact B-
CLL cells and their isolated mitochondria suggest that
inhibition of mitochondrial respiration is an early event in
apoptosis induced by etodolac.
Rapid down-regulation of Mcl-1 correlates with B-
CLL sensitivity to etodolac.
     The balance in the levels of pro-apoptotic and anti-
apoptotic members of the Bcl-2 family is an important
regulator of apoptosis in lymphocytes. Levels of the anti-
apoptotic protein Mcl-1 have been shown to correlate with
sensitivity of B-CLL to chemotherapy (19). Therefore, we
examined the time-dependent effects of etodolac on the
expression in CLL of the Bcl-2 family proteins Mcl-1 and Bcl-2.
Expression of the caspase inhibitory protein XIAP, the Bcl-2
binding protein BAG-1, the caspase substrate poly(adenosine
5'-diphosphate)-ribose polymerase (PARP) were also
examined (Figure 3D). The levels of Mcl-1, but not Bcl-2,
XIAP, or BAG-1 fell in B-CLL cells by 2 hours after etodolac
incubation. Mcl-1 levels did not decline in etodolac-resistant
B-CLL cells or in normal PBL (Figure 3A), suggesting that Mcl-
1 down-regulation correlates with cellular sensitivity to
etodolac. Pretreatment of etodolac-sensitive B-CLL cells for
30 min with the proteasome inhibitors, MG-132 (Figure 3B) or
lactacystin (data not shown), prevented the drop in Mcl-1
protein levels. The etodolac-induced Mcl-1 downregulation
was quantified (Figure 3C), and found to be dose-dependent,
reaching a maximum (50%) at 500 µM. Subsequent to Mcl-1
degradation, etodolac exposure induced activation of
caspase-3, measured using the fluorometric substrate DEVD-
AFC (data not shown), and by the cleavage of PARP into an
86-kD proteolytic fragment (Figure 3D). Inhibition of the
caspases activity prevented the reduction of XIAP and BAG-
1 protein levels, suggesting that caspase activation was
associated with the degradation of XIAP and BAG-1 (data not
shown).
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Figure 3. Effect of etodolac on the apoptosis-regulating proteins.
(3A) Etodolac induced declines in Mcl-1 protein levels in B-CLL
cells in vitro. Representative immunoblot data are presented for B-
CLL cells that exhibited in vitro sensitivity (IC
50
<500 µM at 72
hours, left panel) or resistance (IC
50
>1 mM, middle panel), and for
normal peripheral blood lymphocytes (PBL, right panel). B-CLL
cells and PBL were cultured in vitro for 2 or 24 hours with 1mM
racemic etodolac. Detergent lysates from B-CLL cells and normal
lymphocytes were normalized for total protein content (20 µg per
lane) and analyzed by SDS-PAGE/immunoblot assay (4-20% gels).
(3B) Etodolac-induced Mcl-1 down-regulation is dose dependent
and inhibited by  proteasome inhibitors. B-CLL cells were
incubated for 2 hours with increasing concentrations of racemic
etodolac  (left panel), or pre-incubated for 1 hour with 5 µM of the
peptidic proteasome inhibitor MG132, and then exposed to
etodolac (right panel). Cells were lysed, and the Mcl-1 (top panel)
and tubulin  levels were analyzed by immunoblotting . (3C)
Quantification of the Mcl-1 dowregulation. The relative Mcl-1 level
was quantified by densitometry, performed  after immunoblotting
of  B-CLL cells treated with racemic etodolac for 2 hours. The Mcl-1
relative level was normalized based on the control lane, and based
on the intensity of the control tubulin band. The data are
expressed as the mean of 4 independent experiments, using cells
from B-CLL 4 patients  ± standard deviation. (3D) Expression of
apoptotic regulatory molecules in etodolac- treated B-CLL cells. B-
CLL cells treated for 2 and 24 hours with 1 mM racemic etodolac
were lysed, and expression of PARP, XIAP, Bag-1, and Bcl-2 was
analysed by immunoblotting.  Note that, while Mcl-1 levels fell after
2 hours in the sensitive B-CLL prior to apoptosis (3A), Bag-1 and
XIAP levels fell only after 24 hours, when PARP cleavage already
was complete.
Etodolac enantiomers activate PPAR-
     Indomethacin and various other NSAIDs have been shown
to bind and activate the nuclear receptor PPAR- g  (9). To
determine if etodolac also could activate PPAR-g , RAW 267.4
macrophages were incubated with various concentrations of
etodolac (racemic, S-, and R-enantiomers). As assessed by
stimulation of PPAR-g -dependent reporter gene, as little as 10
µM etodolac (racemic, S-, and R-etodolac) activated PPAR-g -
dependent transcription (Figure 4 A).
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     Immunoblotting experiments showed that PPAR-g  protein
levels were about 10-fold higher in B-CLL than in normal PBL
(Figure 4B). The combination of ligand activation of PPAR-g ,
together with protein kinase C activation by a phorbol ester,
has been reported to induce the scavenger receptor CD36 in
macrophages (20). Using CD36 as an indicator, 200 µM
racemic etodolac and 20 _M of the high affinity PPAR- g
activator troglitazone, displayed equivalent potency
(Figure 4C). Collectively, these results suggest that both the
R and S enantiomers of etodolac are PPAR-g  activators, and
that PPAR-g  is highly expressed in B-CLL.
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Figure 4. Activation of PPAR-
(4A) Activation of a PPAR- g  reporter construct (AOx)3-TK-Luc by
etodolac, indomethacin, and rosiglitazone in RAW 267.4 mouse
macrophages. Cells were transfected at a density of 3 x 105 cells/ml in six
well plates using Lipofectamine, the PPARg  expression vector pCMX-
PPAR g  (0.1 mg), and the PPARg  reporter construct (AOx)3-TK-Luc (1
mg). Cells were treated for 24 hours in 0.5% DME with the indicated
compounds, harvested and assayed for luciferase activity. Results were
expressed as the mean ± SD of three determinations. (4B) Expression of
PPAR- g  protein in cell lysates from B-CLL cells and normal PBL. The
results shown are representative of 16 B-CLL samples, and 5 normal
PBL. (4C) Enhancement of TPA induced expression the CD36 sca venger
receptor in THP-1 cells by etodolac and troglitazone (TGZ).
Patient ViabilityBefore ViabilityAfter % Increased
cell death
#1 90±8 78±5 13
#2 47±5 20±3 57
#3 75±6 31±5 69
#4 96±11 96±9 0
#5 50±6 33±4 34
#6 68±4 40±6 41
Table 1. Etodolac therapy enhances the spontaneous apoptosis of isolated
B-CLL cells. Isolated B-CLL cells before and after etodolac treatment (400
mg bid) were cultured in RPMI-1640 with 20% autologous plasma,
collected either before or after therapy. After 72 hour of incubation, viability
assays were performed by erythrosin B staining. Numbers indicate the %
of viable cells. Note that B-CLL cells die spontaneously over time and that
etodolac increased the cell death in 5 out of 6 patients. The 5 patients that
responded to etodolac were enrolled in the clinical trial, see figure 5.
Etodolac induces a reduction of lymphocyte
counts in B-CLL patients.
     To determine if etodolac could reduce B-CLL survival in
vivo, six B-CLL patients were enrolled in a first step challenge
assay for etodolac sensitivity. Each patient received one 400
mg etodolac tablet, and a second tablet 12 hours later. B-CLL
cells were isolated just before the first tablet, and 12 hours
after the second. B-CLL cells recovered from patients were
then cultured with 20% autologous plasma and apoptosis
rates were measured, either before or after etodolac
treatment. In 5 out of 6 patients, cells isolated after in vivo
etodolac challenge displayed more ex vivo  spontaneous
apoptosis than cells obtained just before etodolac therapy
(Table 1). The five etodolac-sensitive patients were then
enrolled in a second-step clinical trial in which they took
etodolac for one month (400mg bid). After etodolac treatment,
blood lymphocytes counts of all of 5 patients had decreased
by 10-60% (Figure 5). When etodolac treatment was
interrupted, B-CLL counts rebounded to pre-treatment levels.
Two of the patients ubsequently were retreated, and the
circulating lymphocyte counts dropped again by almost 50%
over one month (results not shown).
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Figure 5. Etodolac leads to a reduction of the blood lymphocyte
counts in B-CLL patients.
 The white blood cell counts (WBC, cellsx103/µl, y-axis) of B-CLL
patients were measured before, during, and after the etodolac treatment
(400mg bid). The x-axis represents the time of the WBC cell count, the
beginning of etodolac therapy is labeled 0 (upward arrow) and the end of
the 1-month treatment is indicated with a downward arrow. The results
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obtained in the 5 patients enrolled in the clinical trial are represented.
Patient 4 was treated twice with etodolac, and is now under continuos
therapy.
Etodolac effect on lymphocyte mobility
     The reversible reduction in lymphocyte counts observed in
B-CLL patients treated with etodolac prompted us to assess
the drug’s effects on chemotaxis. B-CLL were pre-incubated
in the presence of various concentrations of etodolac for 16
hours, prior to loading in the upper part of a modified Boyden
chamber with pore size of 3 µm. The lower reservoir contained
either medium alone, or the CXCR3-binding chemokine IFN-
inducible protein 10 (IP-10, 200 ng/ml). After 2 hours of
incubation, the cells that traveled through the polycarbonate
membrane were enumerated by flow cytometry. We used IP-
10 because B-CLL cells express high levels of the CXCR3
chemokine receptor and are attracted by IP-10 (21). In all B-
CLL patients tested (n=4), etodolac increased the
chemotactic response of B-CLL cells to IP-10 (Figure 6A).
Enhanced chemotaxis was observed in B-CLL cells incubated
with 50 _M etodolac, well below the plasma concentration
expected in patients receiving 800 mg/day of the drug. At
concentrations of 500 µM and above, chemotaxis decreased,
due to a loss of cell viability. Not only the racemic (R/S)
mixture of etodolac, but also the purified R and S
enantiomers, enhanced B-CLL chemotaxis. Stimulation of
chemotaxis was not due to increased expression of the CXCR
receptor, as assessed by antibody staining (data not shown).
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Figure 6. Etodolac effect on B-CLL lymphocyte mobility
B-CLL lymphocytes from B-CLL patients were incubated in presence of
the indicated concentrations of etodolac (racemic R/S, purified R, and S
enantiomers) for 16 hours in RPMI-1640 medium supplemented with 10%
FBS. A total of 5 x 105 B-CLL cells (100 µl) were then added to the upper
chamber of the 24-well chemotaxis chamber. The lower chamber was
filled with 600 µl of culture medium containing 100 ng/ml of the human
CXCR3-dependent chemokine IP-10. After two hours incubation at 37°C,
the numbers of cells that migrated into the lower chamber were
enumerated by cytometry after gating the B-CLL lymphocytes. Results
are expressed as number of B-CLL cells in lower chamber ± SD from
triplicate wells. The results are representative of separate experiments
using cells isolated from four different B-CLL donors.
DISCUSSION
     Treatment with racemic etodolac, an NSAID used for
control of pain and inflammation, reduced circulating B-CLL
cells in 5 out of 6 patients. The B-CLL cells recovered from
patients as early as one day after institution of etodolac
therapy had reduced survival in vitro, indicative of a metabolic
derangement. Analyses of etodolac effects on purified CLL
cells showed that the drug impaired mitochondrial respiration,
induced rapid degradation of the anti-apoptotic protein Mcl-1,
activated the peroxisome proliferator activated receptor _
(PPAR-g ), and stimulated CXCR3-dependent chemotaxis. The
purified R-enantiomer of etodolac, which has been reported to
be a poor COX inhibitor, displayed all the in vitro biochemical
effects toward B-CLL cells of the racemic mixture.
     Results obtained with isolated mitochondria from CLL cells
confirmed that etodolac interfered with substrate oxidation
and reduced the transmembrane potential. Mitochondria play
a key role in the events leading to caspase activation in cells
undergoing apoptosis because of DNA damage or disturbed
metabolism (22, 23). Alteration of the mitochondrial
transmembrane potential and release of pro-apoptotic
proteins, such as cytochrome c and apoptosis-inducing
factor (AIF), from the intermembrane space into the cytosol,
leads to the activation of caspases and endonucleases and
to the eventual appearance of an apoptotic phenotype.
     Bcl-2 family members regulate the release of pro-apoptotic
proteins. Mcl-1 is an anti-apoptotic member of the bcl-2
family, which is highly expressed in B-CLL and found in
mitochondria and light membrane fractions (24). Elevated
levels of Mcl-1 correlate significantly with failure to achieve
complete remission in B-CLL after single agent therapy,
suggesting that Mc1-1 is a natural regulator of apoptosis in
these leukemic cells. (19). Thus, it is notable that, as early as
two hours after incubation with etodolac, Mcl-1 expression fell
in B-CLL cells. Both R- and S-etodolac induced Mcl-1
degradation at equivalent concentrations, suggesting this
event is not due to COX2 inhibition. Etodolac could either
reduce the rate of Mcl-1 synthesis through effects on Mcl-1
gene transcription, or it could accelerate the rate of Mcl-1
protein turnover. In this regard, Mcl-1 is one of the few Bcl-2
family proteins which has PEST motifs associated with rapid
degradation (data not shown). Pre-incubation of the cells with
Idun-1965, a broad-spectrum caspase inhibitor, did not
prevent etodolac-induced Mcl-1 down-regulation, indicating
that this event is not a mere concomitant of apoptosis.
Furthermore, etodolac incubation did not alter the expression
levels of Bcl-2, Bax, and Bcl-XL. The mechanism by why
etodolac induces a rapid decline in Mcl-1 protein levels
remains to be elucidated. Regardless of the mechanism, the
down-regulation of Mcl-1 would be expected to render B-CLL
cells more susceptible to apoptosis.
     Various NSAIDs at relatively high concentrations (100 µM
and above) can bind and activate the nuclear hormone
receptor PPAR-g  (9). Both R and S etodolac at concentrations
of 10-100 µM stimulated a PPAR- g  reporter gene, and
increased expression of the PPAR-g  dependent scavenger
receptor CD36. Activated PPAR- g  dimerizes with RXR
receptors, and also binds co-activator molecules, such as the
cyclic AMP response element binding protein co-activator
protein (CBP) (25), and ARA70, a co-activator of the androgen
receptor that is overexpressed in hormone resistant prostate
ca cer (26). PPAR-g  regulates adipocyte differentiation, and
insulin sensitivity, and is the target for the thiazolidine-diones
used to treat type II diabetes. However, the ligand binding-
site on PPAR- g  is capacious, and potentially can
accommodate different ligands that might exert distinctive
metabolic effects (25). In some cells with high levels of PPAR-
g , maximal activation of the receptor can induce apoptosis
(10). The mechanism of PPAR- g -mediated apoptosis is
unclear, and it may be due to sequestration of CBP and other
transcriptional co-activators with subsequent squelching of
the production of labile survival factors.  The fact that
quiescent B-CLL cells expressed very high levels of PPAR-g
suggests that maximal activation of the receptor could
deplete co-activator molecules. PPAR- g  activation alone
probably was not sufficient to induce B-CLL apoptosis, since
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the high affinity PPAR-g  activator troglitazone was nontoxic at
concentrations £  100 µ_M (results not shown), which are
sufficient for receptor stimulation. However, the
sequestration of general transcription factors by ligand-bound
PPAR- g  could enhance the sensitization of B-CLL cells to the
other apoptosis-inducing effects of etodolac.
     Peak plasma concentrations (Cmax) of etodolac are attained
within 1 to 2 hours, and range from 33 to 77 µM after a single
200 mg dose (27). Thus, 800 mg potentially could achieve a
plasma concentration of 200 µM, which was sufficient to
reduce B-CLL survival in vitro. In an indolent disease such as
B-CLL, circulating leukocyte counts depend upon a delicate
balance between the relative rates of cell generation, death,
and distribution. Even a minor uncompensated decrease in B-
CLL life span will eventually produce a fall in circulating cells.
     The B-CLL patients on etodolac therapy did not have
clinically obvious changes in lymphadenopathy. To determine
if etodolac could alter the distribution of B-CLL between the
blood and lymphoid organs, the effects of the drug on CXCR3-
dependent chemotaxis were tested. Both the R- and S-
enantiomers of etodolac stimulated chemotaxis at
concentrations (50 µM) readily achievable in plasma. It is
possible the B-CLL cells exposed to etodolac therefore may
be sequestered within lymphoid organs, where chemokine
concentrations are likely to be higher than in the plasma (28).
Even if the early clearance of B-CLL cells from the circulation
resulted mainly from a change in cell distribution, the impaired
survival observed after in vivo treatment should be reflected
eventually by reductions in tumor burden.
     Our data indicate that B-CLL cells undergo more rapid
apoptosis at higher concentrations of etodolac than are
conventionally used for the treatment of pain and
inflammation. The dose-limiting side-effects of NSAIDs, such
as gastric ulcer and kidney dysfunction, are associated with
inhibition of COX-1 (29, 30). Insofar as (i) the R-enantiomer of
etodolac induces apoptosis, and stimulates chemokines in B-
CLL, (ii) plasma levels of the R-enantiomer are 10-fold higher
than those of the S-enantiomer, and (iii) other NSAIDs do not
induce B-CLL cell depletion, it is likely that R-etodolac is the
principal active agent. Because R-etodolac has much less
COX-inhibitory activity than S-etodolac, patients should
tolerate higher dosages of the former agent. Thus, treatment
of B-CLL patients with the isolated R-etodolac should allow
one to attain plasma concentrations within the in vitro
cytotoxic range with fewer side-effects. Thus, efforts should
be made to produce pure R-etodolac in the goal to increase
the anti-leukemic activity of this compound, in hope that it
may become a new drug for the treatment of B-CLL.
METHODS
Patients, cell isolation and viability assays
     Written informed consent was obtained to procure
peripheral blood from all patients and with normal healthy
volunteers. Patients had to have B-CLL according to National
Cancer Institute (NCI) criteria of any Rai stage. Criteria for
requiring therapy were as follows: disease-related symptoms,
anemia and/or thrombocytopenia, bulky lymphadenopathy,
and/or clinically relevant splenomegaly.  Mononuclear ells
were isolated by gradient centrifugation through Ficoll-Paque.
Cells were cultured at 2x106 per mL in RPMI 1640 with 20%
autologous plasma and antibiotics in 96-well plates without or
with various concentrations of etodolac (racemic, S-etodolac,
R-etodolac). At the indicated times, viability assays were
performed by erythrosin B dye exclusion.
Separation of etodolac enantiomers
     Etodolac isomers were separated by fractional
crystallization by a modification of the procedure of Becker-
Scharfenkamp and Blaschke (31). Briefly, pharmaceutical
grade tablets of racemic etodolac (6x400 mg) were crushed in
a mortar and pestle and extracted with hot ethyl acetate (2x50
mL) and filtered. Evaporation of the filtrate gave 1.52 g of
white powder (68% recovery). This material was dissolved in
2-propanol (10mL) and S- or R-phenylethylamine was added.
Th  clear solution was allowed to stand at 4°C for several
days. The resulting colorless needles were collected and
recrystallized from 2-propanol two times. The salt product was
decomposed by adding to ice cold 10% sulfuric acid and
extracting with ethyl acetate.  After evaporation, the syrupy
residue of R- or S-etodolac was crystallized from methanol-
water.  The enantiomeric purity of each product was at least
97% as assayed by HPLC on a chiral column (AGP,
ChromTech, Sweden).
Mitochondrial function assays
     Viability and mitochondrial transmembrane potential (DY m)
were concomitantly analyzed by 3,3' dihexyloxacarbocyanine
iodide (DiOC6) and propidium iodide (PI) staining as described
(15). Briefly, after etodolac treatment, B-CLL cells were
incubated for 10 min at 37˚C in culture medium containing 40
nM of DiOC6 and 5 µg/ml PI.
Mitochondrial respiration in intact cells was assessed by
dihydrorhodamine 123 oxidation (DHR) (Molecular Probes,
Eugene, Oregon), as described (18). B-CLL cells were
centrifuged at 200g for 10 min, resuspended in fresh
respiration buffer (250mM sucrose, 1g/L bovine serum
albumin, 10mM MgCl2, 10mM K/Hepes, 5mMKH2PO4 [pH 7.4])
and cultured for 10 min at 37˚C with 0.04% digitonin, 10 mM
ADP, and 5mM succinate. Cells were then incubated for 5 min
in 0.1 _M DHR in respiration buffer. Cells were analyzed within
30 min in a Becton Dickinson FACScalibur cytofluorometer.
After suitable compensation, fluorescence was recorded at
525 nm (FL-1) for DiOC6 and DHR at 525 nm (Fl-1), at 600 nm
(FL-3) for PI.
Mitochondria were isolated from B-CLL cells by nitrogen
cavitation as described (18). The B-CLL cells were washed in
ice-cold Dulbecco's phosphate-buffered saline for disruption
by N2. All subsequent steps were carried out on ice or at 4 °C.
The cells were washed with MA buffer (100 mM sucrose, 1 mM
EGTA, 20 mM MOPS (pH 7.4), bovine serum albumin 1 g/liter)
then resuspended at 2x108 cells/ml in MB buffer (MA buffer
plus 10 mM triethanolamine, 5% Percoll, and an
antiproteinase mixture consisting of aprotinin, pepstatin A,
and leupeptin, each at 10 µM, and 1 mM phenylmethylsulfonyl
fluoride). The cells were then disrupted by N2 cavitation using
a cavitation bomb (Parr Instrument Company, Moline, IL).
Lysates were centrifuged twice at 2500 g for 5 min to remove
nuclei and unbroken cells then at 25,000 g for 30 min to
isolate mitochondria. The mitochondria were suspended in MC
buffer (identical to MA buffer except that the sucrose
concentration was 300 mM and an antiprotease mixture was
included that consisted of aprotinin, pepstatin A, and
leupeptin, each at 10 µM) and incubated for 10 min at 37°C
with the indicated concentrations of etodolac. Isolated
mitochondria were incubated for 10 min at 37°C with 100 nM
DiOC6 and their __m was measured by flow cytometry at 525
nm (FL-1) and by gating on mitochondria size (FSC/SSC).
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Protein expression assays
     Washed B-CLL cells were lysed in Lysis buffer (25 mM
Tris, pH 7.4, 150 mM KCl, 5 mM EDTA, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 1 µg/ml aprotinin, 1 µg/ml
leupeptin, 1 mM phenylmethanesulfonyl fluoride, 1 mM sodium
orthovanadate, 1 mM sodium fluoride). Lysates were
centrifuged at 15,000 x g for 10 min to remove nuclei and the
protein content of supernatants was measured using a
modified Coomassie blue assay (Pierce, Rockford, IL).
Proteins were resolved at 125 V on 14% and 4-20% Tris-gly
pre-cast gels (Novex, San Diego) and electrophoretically
transferred to 0.2 µm polyvinylidene fluoride (PVDF)
membranes (Millipore, Bedford, MA) for 2 hours at 125 V.
Membranes were blocked overnight in I-Block blocking buffer
(Tropix, Bedford, MA). Blots were probed with polyclonal
antibodies anti-Mcl-1, anti-Bcl-2, monoclonal a ti-Bag-1 (all
developed in J. Reed’s lab), monoclonal anti-XIAP
(Transduction Laboratories Inc.), monoclonal anti-PARP (gift
of N.A. Berger), or monoclonal anti-PPARg  (Santa Cruz
Laboratories, California) antibody, followed by secondary
antibody consisted of horseradish peroxidase (HRP)-
conjugated goat anti-rabbit (Mcl-1) or anti-mouse (PPAR-g )
IgG. Detection was performed by an enhanced
chemiluminescence (ECL, Amersham) method, followed by
colorimetric detection, using SG substrate. The X-ray films
were scanned, acquired in Adobe Systems Photoshop and
analyzed with NIH Image Software.
PPAR-  assays
     The mouse macrophage RAW264.7 cells (ATCC) were
grown in DME with 1 gm/L glucose and L-glutamine and the
addition of 10% fetal bovine s rum (Gemini Bio-Products),
non-essential amino acids 100 mM (GibcoBRL) and penicillin-
streptomycin 100U/ml (Cellgro). Cells were transfected at a
density of 3 x 105 cells/ml in six well plates using
Lipofectamine, the PPAR-g  expression vector pCMX- PPAR-g
(0.1 mg), and the PPAR-g  reporter construct (AOx)3-TK-Luc (1
mg) as previously described (32). Cells were treated for 24
hours in 0.5% DME with the indicated compounds, harvested
and assayed for luciferase activity. Results were expressed
as the mean ± SD of three determinations. Activation of
PPAR- g  was also functionally assayed as previously
described (20). Briefly, human monocytic THP-1 cells (ATCC)
were grown in RPMI-1640 with 10% FBS and antibiotics,
treated for 5 days with 200 µM etodolac (racemic) and 20 µM
troglitazone as indicated, or for 48 hr with 40 ng/ml phorbol
ester (TPA). Cells were analyzed by flow cytometry using
unconjugated anti-CD36 and FITC-conjugated anti-IgG. A
population of 10000 viable cells was analyzed for each
treatment. Data are presented as the difference in mean
fluorescence between anti-CD36 antibody and control
isotype-matched antibody.
Migration/chemotaxis assay
     Cell migration was measured in a 24-well modified Boyden
chamber (Transwell, Corning-Costar, NY). The recombinant
human IP-10 chemokine (R&D Systems, McKinley Place, NE)
was diluted in RPMI-1640 medium at 200 ng/ml, and used to
evaluate the chemotactic properties of lymphocytes from B-
CLL patients. Polycarbonate membranes with pore size of 3
µm were used. A total of 600 µL of chemokines or control
medium was added to the bottom wells, and 100 µL of 2 to 5.0
x 106 cells/ml cells resuspended in RPMI-1640 were added to
the top wells. The chamber was incubated at 37°C with 5%
CO2 for 2 hours. The membranes were then removed, and the
cells present on the bottom well were quantified by flow
cytometry. For cell quantification, a fixed acquisition time of
30 seconds was used per sample, and beads were run during
each experiment to ensure a reproducible acquisition. All
assays were performed in triplicate.
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SPECIFIC AIMS
HIV-1 induces apoptosis and leads to CD41 T lympho-
cyte depletion in humans. It is still unclear whether
HIV-1 kills infected cells directly or indirectly. In this
study we provide a mechanistic view on how HIV-1
induces apoptotic death of infected primary human
CD41 T lymphocytes.
PRINCIPAL FINDINGS
1. HIV damages mitochondria, leading to cytochrome
c release and caspase activation
The time course of activation of the extrinsic and
intrinsic pathways of apoptosis was examined after
HIV-1 infection of primary CD41 T lymphocytes. The
percentage of cells undergoing apoptosis was quanti-
fied by flow cytometry and measuring the proportion of
cells with sub-G1 DNA content and correlating it with
HIV p24 production. Caspase activities were measured
at multiple time points after infection by using specific
fluorometric substrates (Fig. 1). The pattern of caspase
activation strongly suggested that the intrinsic pathway
of apoptosis induction was operational. This suggestion
was borne out by the following observations. The
catalytic activity of the apical caspase-2 and -9 increased
after 2 days, concomitantly with the activation of the
executioner caspase-3. Activated caspase-6 was detect-
able only 72 h after infection. No activity of the death
receptor-associated apical caspase-8 was observed dur-
ing the infection (up to 72 h). Caspase enzymatic
activities were corroborated by immunoblotting. Cleav-
age of the proform of caspase-3 was observed in all
samples, but in HIV-1 treated cells the ratio of the
cleaved and uncleaved pro-caspase product was in-
creased as early as 24 h and remained elevated up to
72 h relative to the control. The levels of the pro-
caspase-9 and -6 products were reduced 48 and 72 h
after infection, which suggests processing to their active
forms.
2. HIV induces p53 phosphorylation and activation
To study the role of p53 in the initiation of the
apoptotic pathway during HIV-1 infection, we mea-
sured the total level of p53 and its phosphorylation at
residue Ser15 by using a phospho-specific antibody.
Total and phosphorylated p53 levels increased 24 h
after HIV-1 infection. This HIV-triggered phosphoryla-
tion of p53 peaked at 48 h and remained detectable for
up to 72 h (Fig. 2). To confirm that phosphorylation
and induction of p53 resulted in the activation of the
p53 pathway, we analyzed the protein and mRNA levels
of p53-induced genes, p21/CIP1/WAF1 (p21), HDM2,
and Bax. Both Bax and p21 levels increased 48 h after
HIV-1 infection, and HDM2 increased after 72 h com-
pared to uninfected controls.
3. HIV up-regulates Fas ligand but only as a late event
To investigate whether HIV would activate an extrinsic
apoptotic pathway involving Fas ligand binding to Fas
receptor, we analyzed the expressions of signaling
proteins involved in the Fas signaling pathway. In
primary cells, the protein levels of Fas receptor and of
Fas ligand were not modulated by HIV infection (data
not shown), but the expression of surface Fas ligand
measured by flow cytometry was increased significantly
at 72 h. However, the Fas binding proteins FADD,
DAXX, and RIP were all down-regulated, which would
be expected to inhibit FasL-Fas-induced apoptosis.
CONCLUSIONS AND SIGNIFICANCE
We demonstrated that the intrinsic mitochondrial path-
way of apoptosis is the primary mechanism that induces
1 To read the full text of this article, go to http://www.fasebj.
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CD41 T cells to undergo apoptosis. Mitochondrial
membrane permeabilization may be a consequence of
the activation of the p53 pathway. Once phosphory-
lated, p53 induces up-regulation of Bax, which may
translocate to the mitochondrial membrane and pro-
mote cytochrome c and AIF release.
Furthermore, it appears that the Fas pathway does
not play a primary role in HIV-induced apoptosis of
CD41 T lymphocytes. However, it is possible that Fas
ligand might play a role in the depletion of noninfected
bystander CD4 cells or CD81 T cells by activating
caspase-8.
This phenomenon may be especially relevant in pri-
mary acute infection when high levels of virus are present
and no potent mechanisms of viral control are yet fully
operational. The primary infection stage has the highest
proportion of CD4 lymphocyte infected during the course
of HIV infection. This p53-mediated apoptosis may be
responsible for the precipitous drop in CD41 T cells seen
in primary acute HIV-infected patients, with eventual
stabilization of both CD4 and viral loads. These events set
the stage for determining the propensity for progression
to AIDS. In summary, CD4 T1 cell death as a result of
HIV-1 infection is mediated by the activation of p53 and
the intrinsic mitochondrial apoptotic pathway. The mech-
anism by which HIV mediates this process remains to be
further clarified.
Figure 1. Caspase activation in HIV-1-infected CD41 T cells.
At the times indicated, 2 3 106 PBL were washed with PBS
and lysed in caspase buffer. A) Caspase activity of 10–20 mg of
total protein was measured with specific substrates for
caspase-2 (f), 3 (squlo]), 6 (E), 8 (l), and 9 (F) (100 mM)
after 1 h incubation at 37°C. The cleavage of the fluorometric
AMC/AFC was monitored fluorometrically at 400/380 nm
excitation and 505/460 nm emission. Activity is represented
in relative units to the control without HIV.
Figure 2. Activation of the p53 pathway by HIV-1 infection.
Immunoblot analysis was performed on total cell lysates of 5 3
106 cells in 100 ml lysing buffer as described. The same mem-
branes were stripped and reblotted with specific antibodies,
including a tubulin antibody that served as a control for loading.
Figure 3. HIV-1 enters the cells, and its genome is reverse-
transcribed and integrated in host DNA. Less than 24 h after
the infection, phosphorylation of p53 at residue Ser15 is
observed. This p53 phosphorylation leads to its transcrip-
tional activation, either by increasing its protein levels or by a
conformational modification. Activation of the p53 pathway
increases the expression of the protein Bax. Bax multimerizes
and generates pores in the mitochondrial membranes and
allows the release of the pro-apoptotic protein cytochrome c
and apoptosis-inducing factor (AIF). The released cyto-
chrome c will bind to apaf-1 and, in the presence of dATP,
sequester and activate caspase-9 and caspase-3, which leads to
activation of the caspase proteolytic cascade and results in
apoptosis. The released AIF will localize to the nucleus and
promote chromatin condensation.
6 Vol. 15 January 2001 GENINI ET AL.The FASEB Journal
Temporal Gene Regulation During HIV-1 Infection
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CD4+ T-cell depletion is a characteristic of human immunodeficiency virus type 1 (HIV-1) infection. In this study,
modulation of mRNA expression of 6800 genes was monitored simultaneously at eight time points in a CD4+
T-cell line (CEM-GFP) during HIV infection. The responses to infection included: (1) >30% decrease at 72 h
after infection in overall host-cell production of monitored mRNA synthesis, with the replacement of host-cell
mRNA by viral mRNA, (2) suppression of the expression of selected mitochondrial and DNA repair gene
transcripts, (3) increased expression of the proapoptotic gene and its gene p53-induced product Bax, and (4)
activation of caspases 2, 3, and 9. The intense HIV-1 transcription resulted in the repression of much cellular
RNA expression and was associated with the induction of apoptosis of infected cells but not bystander cells.
This choreographed host gene response indicated that the subversion of the cell transcriptional machinery for
the purpose of HIV-1 replication is akin to genotoxic stress and represents a major factor leading to
HIV-induced apoptosis.
The depletion of CD4+ T cells during human immunodefi-
ciency virus type 1 (HIV-1) infection has been attributed to
numerous mechanisms including apoptosis (Ameisen et al.
1991; Laurent-Crawford et al. 1991; Terai et al. 1991). Apop-
tosis is invariably accompanied by a disruption of inner mi-
tochondrial transmembrane potential (Castedo et al. 1995).
This contributes to the release of cytochrome c sequestered in
the mitochondrion into the cytosol. In the cytoplasm, cyto-
chrome c combines with APAF-1 and caspase 9 to constitute
the apoptosome, which is responsible for the initiation of the
caspase cascade triggering the intrinsic apoptosis pathway
(Green et al. 1998; Roulston et al. 1999).
To analyze the effects of HIV-1 infection on T-cell tran-
scription, we used a cell line to minimize heterogeneous host-
cell responses to infection and to allow the precise enumera-
tion of infected cells. CEM-GFP cells are a CD4+ lymphoblas-
toid T-cell line modified to express the green fluorescent
protein upon productive HIV-1 infection (Gervaix et al.
1997). When infected by HIV-1, this cell line undergoes char-
acteristic changes including cell-cycle retardation in G2/M,
apoptosis, and high levels of virion production.
RESULTS
CEM-GFP cells were inoculated with HIV-1LAI at a multiplicity
of infection of 0.5, an inoculum sufficient to ensure that every
cell is contacted by virus particles. Aliquots of cells were ob-
tained at 0.5, 2, 4, 8, 16, 24, 48, and 72 h after infection. A
mock infection served as a control at each time point, essen-
tially replacing the volume of viral input by an equivalent
volume of culture medium from uninfected cells. Each sample
was tested on two chips and the average taken. Normalization
was done using global normalization and scaling.
At 72 h, HIV-1 transcripts represented more than 30% of
all mRNAs present (identical amounts of labeled RNA for con-
trol or infected conditions were loaded onto the arrays). This
was determined by assessing the level of GAPDH. The average
difference value for GAPDH (spanning the whole length of
the gene and representing the summation of 198 indepen-
dent probes) at 30 min in the HIV-infected cells was 18 462
2027 compared to 12 246 1318 at 72 h. A similar reduc-
tion also was corroborated with -actin probes. This reduction
of mRNA expression is consistent with previously published
results (Somasundaran et al. 1988). This intense viral replica-
tion was confirmed in the CEM-GFP cells and in primary-
activated CD4+ T lymphocytes as monitored by real-time ki-
netic RT-PCR. The levels of transcription representative of all
doubly and singly spliced (tat and vpr, respectively) as well as
all unspliced (gag) messages were measured. Fold increases in
the levels of expression of each of these three HIV-1 mRNAs
were determined at 48 and 72 h for both infected CEM-GFP
cells and primary CD4+ T cells and compared to that obtained
at 24 h. The increased expression was similar in both cell
types except that gag was expressed at higher levels in the
CEM-GFP cells (Table 1). Tat was the gene with the greatest
increase in expression, being up-regulated 315-fold at 72 h
when compared to the level determined at 24 h.
The percentages of CEM-GFP cells productively infected,
8Corresponding author.
E-MAIL jcorbeil@ucsd.edu; FAX (858) 552-7445.
Article published on-line before print: Genome Res., 10.1101/gr.180201.
Article and publication are at http://www.genome.org/cgi/doi/10.1101/
gr.180201.
Letter
1198 Genome Research 11:1198–1204 ©2001 by Cold Spring Harbor Laboratory Press ISSN 1088-9051/01 $5.00; www.genome.org
www.genome.org
the level of apoptosis, and cell-cycle profiles were assessed and
collected at 24, 48, and 72 h after infection using flow cytom-
etry. At 24 h, 29% of the cells were HIV-1-infected as reflected
by green fluorescent protein (GFP) expression with ∼9% of the
cells apoptotic as determined by the proportion of cells with
sub-G1 DNA content. At 48 h, 86% of the cells were GFP
positive and 22% apoptotic, while at 72 h, 92% were GFP
positive and 33% apoptotic (Fig. 1A,B). Orange-fluorescent
tetramethylrosamine was used to detect membrane potential
changes in mitochondria, a marker of induction of apoptosis.
Mitochondrial membrane potential was reduced over time,
specifically in HIV-1-infected cells as defined by the intersec-
tion of GFP positivity and low orange-fluorescent tetrameth-
ylrosamine signal (CMTMRos, bottom right quadrant in Fig.
1B). Uninfected cells in the inoculated culture retained mito-
chondrial membrane potential, a clear indication that HIV-1
infection altered the membrane potential of mitochondria in
infected but not bystander cells. At 72 h, 30% of GFP-positive
cells had low mitochondrial transmembrane potential as
measured by CMTMRos staining in contrast to <1% of GFP-
negative cells (Fig. 1B). To confirm the apoptotic phenotype,
caspase activity was assessed. Caspases 2, 3, and 9 but not 6
and 8 were found to be activated in HIV-1 inoculated cell
population (Fig. 1C).
Total RNA isolated at each time point for both control
and infected CEM-GFP was reverse transcribed, and labeled
RNA (cRNA) was generated. cRNA (15µg) was hybridized to
HuGeneFL 6800 array. Genes expressed in infected or unin-
fected cell populations and those common to both were de-
termined for each of the eight time points using GeneChip
analysis suite 3.1 and 2HAPI (High-density Array Pattern In-
terpreter) software packages (Fig. 2). At 30 min after inocula-
tion, 181 genes were expressed only in the HIV-inoculated
cells, representing genes that were induced by HIV-1 binding
or entry. In contrast, 588 genes were expressed only in the
control population, representing genes that are suppressed by
exposure to HIV-1. Most of the modulation in gene expres-
sion affected genes expressed at lower copy number (the data
can be viewed and queried at our 2HAPI web site located at
http://2hapi.ucsd.edu). A general downregulation of gene ex-
pression occurred over time, especially in the HIV-1 infected
population. At 72 h, transcripts of 760 genes were called pre-
sent in the HIV-1-infected cells (summation of genes ex-
pressed solely in HIV-infected cells and genes common to
both control and HIV-infected cells) and 805 genes were de-
tected in the control cells representing a downmodulation
compared to the earlier time points. Two independent pro-
cesses are operating; in the infected population, the cells are
killed by HIV infection and in the control, the culture reaches
confluence. This also was confirmed by the hierarchical clus-
ter analysis expressing ratios of expression of HIV over con-
trols. An impressive shutdown of numerous genes was ob-
served.
Table 1. Expression of HIV Transcripts
HIV
transcript
Cell
type 24 h 48 h 72 h
tat Primary 1 12.9 315.6
CEM-GFP 1 9.4 211.0
vpr Primary 1 8.0 35.5
CEM-GFP 1 26.3 82.3
gag Primary 1 7.1 21.8
CEM-GFP 1 23.2 193.6
Real-time PCR quantification of tat, vpr, and gag. The level ob-
tained at 24 h was arbitrarily given a value of 1.
Figure 1 Analysis of DNA content, cell cycle, percentage of infected
cells, mitochondrial membrane potential, and caspase activity. (A)
Cell cycle analysis and quantification of apoptosis. Control (mock-
infected) and human immunodeficiency virus type 1 (HIV-1) -infected
CEM-GFP cells were processed after 24 h, 48 h, and 72 h for DNA
content using propidium iodide staining. An assessment of the per-
centage undergoing apoptosis (upper right corners) was performed
by estimating the proportion of cells with subgenomic content of
DNA (labeled apo in the figure). The percentages for 24 h, 48 h, and
72 h were 9%, 22%, and 33%, respectively. (B) Determination of the
percentage of HIV-infected cells and evaluation of the mitochondrial
membrane potential (m). The percentage of GFP-positive cells (cu-
mulative of the percentage present in top and bottom right quadrants)
is an assessment of the number of cells productively infected. The
percentages for 24 h, 48 h, and 72 h were 29%, 86%, and 92%,
respectively. Cells were gated initially using forward and side scatter
criteria to exclude dead cells. Orange-fluorescent tetramethylrosa-
mine was used to assess the mitochondrial transmembrane potential.
Gating on live cells only, 28% of cells that were GFP positive (92%)
showed reduced staining at 72 h. (C) Cells were infected with HIV-1LAI
at 0.5 MOI. At the indicated time points, 2 106 cells were washed
with PBS and lysed in caspase buffer. Caspase activity of 10–20 µg of
total protein was measured with specific substrates for caspase-2 (), 3
(), 6 (❍), 8 () and 9 () (100 µM) after 1 h incubation at 37°C.
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Genes expressed early in HIV-1 infection (0.5, 2, 4, and 8
h) included some that were characteristic of cellular defense
mechanisms. These included members of the interferon alpha
family (accession no. J00212) at 2 h, 4 h, and 8 h, and MxB
(accession no. M30818), an antiviral interferon-alpha/beta-
inducible protein belonging to the family of large GTPases, at
30 and 2 h (Melen et al. 1996). Genes were grouped in clus-
ters according to patterns of coordinated expression over time
(Tamayo et al. 1999). A group of 12 representative clusters
represented the best fit with the most distinctive patterns of
expression (see supplemental information Fig. A). Cluster 9
shows an impressive increase in later time points for 333
genes. Conversely, cluster 3 represents genes that were down-
regulated with time (421 genes).
The similarities present in each cluster group based on
the enumeration of Medical Subject Heading (MeSH) key-
words were determined using 2HAPI. This approach also re-
vealed a dysregulation in gene expression associated with key-
words such as mitochondria (52 genes), apoptosis (75 genes),
p53 (18 genes), and repair (38 genes). Genes in the mitochon-
drial category included mitochondrial 3-ketoacyl-CoA thio-
lase beta-subunit of trifunctional protein, a gene located in
the mitochondrial matrix (D16481), human cytochrome c-1,
located in the mitochondrial inter membrane space (J04444),
ATP synthase alpha subunit found in the mitochondrion in-
ner membrane (D14710), cytochrome bc-1 complex core pro-
tein II localized in the matrix side of the inner mitochondrial
membrane (J04973), aconitase (U80040), and porin, which
forms a channel through the mitochondrial outer membrane
(L08666). All were down-regulated significantly in later time
points, indicative of mitochondrial dysfunction. A partial list
can be found in Fig. 3. Genes involved in DNA repair and
apoptosis also were significantly repressed. These include
DNA-PK (U35835), a DNA damage-activated enzyme respon-
sible for phosphorylating p53 (Cuddihy et al. 1999), HSP70
(L12723), a heat-shock protein capable of inhibiting apopto-
sis, and HHR23A (D21235), which has been shown to bind to
HIV-1 vpr (Withers-Ward et al. 1997; Gragerov et al. 1998). In
contrast, GADD45 (growth arrest and DNA-damage-inducible
protein: M60974) was slightly elevated.
These observations indicated DNA damage or genotoxic
stress and prompted an evaluation of the components of DNA
repair pathway in the infected cell population at the protein
level. p53 was phosphorylated in HIV-1 infected cells (Fig. 4).
p53 acts as an inducer of the potent proapoptotic gene Bax
(Miyashita et al. 1995; Marzo et al. 1998), which was up-
regulated only in HIV-infected cells (Smith et al. 1994). DNA-
damage inducible gene Gadd45 also was up-regulated (Zhan
et al. 1999). Human mdm2, an inhibitor of p53 function, was
down-regulated, possibly leading to an increase in p53 func-
tion and GADD45, a repair-sensing protein, was elevated in
the infected population (results not shown). This enhanced
expression of p53 protein and its stabilization by phosphory-
lation may be attributable to DNA breaks induced by the in-
tegration of the HIV-1 genome into the host genome, the
activation of the NFkB pathway (Wu et al. 1994), or the gen-
eral genotoxic stress induced by HIV-1 infection. The tran-
scription of most genes ultimately was down-regulated by
HIV-1 infection. One of the down-regulated genes has been
reported previously by Geiss and collaborators (Geiss et al.
2000). The gene prothymosin alpha (M26708) that is ex-
pressed to high levels was down-regulated to the same extent
in our own experiments. However, we saw a twofold expres-
sion enhancement at 30 min after infection. This points out
the importance of determining the expression for multiple
time points. The general downregulation contrasts with cyto-
megalovirus infection of primary human fibroblasts (Zhu et
al. 1998) for which remarkable amplification of genes resulted
from cytomegalovirus infection before the demise of the tar-
get cell. Another analysis of the process of HIV infection was
performed using differential display by Ryo et al. (2000). In-
terestingly, they also suggest that HIV exerts a strong cyto-
pathic effect on the host.
Using the cluster and treeview applications of Eisen et al.
(1998), we ordered the genes for similarity of expression over
time. The resulting ratios of expression for HIV over control
were clustered. A section of the hierarchical tree is shown in
Figure 5, representing a subset of genes whose expression lev-
els differed by at least fourfold between HIV and control. We
focused on a section where expression was increased in HIV-
infected cells at the later time point (16 h to 72 h). A selection
of these also is shown in supplemental Figure B in our 2HAPI
format. Interestingly, several genes were significantly up-
regulated.
One such gene identified by the 2HAPI overlap function
and the hierarchical clustering was Nuclear Factor I (NFIB-2).
This gene was highly expressed at all the later time points (16,
24, 48, and 72 h) during the process of HIV-1 infection.
NFIB-2 is part of a family of dimeric DNA-binding proteins
with very similar, possibly identical, DNA-binding specificity.
These proteins are required for cell-specific transcription of
many viral and cellular genes as cellular transcription factors,
and as replication factors for adenovirus DNA replication
(Qian et al. 1995; Chaudhry et al. 1997). NFIB-2 also has been
identified as a recurrent translocation partner gene of high-
mobility-group IC (HMGIC) in pleomorphic adenomas (Geu-
rts et al. 1998). This increase in NFIB-2 expression was con-
firmed using real-time RT-PCR; the values were 3.5-fold
greater at 24 h, 10-fold greater at 48 h, and 505-fold greater at
72 h when compared to the mock-infected controls. This in-
crease is remarkable in the face of a general down-regulation
Figure 2 Genes expressed in control uninfected and HIV-1-infected
cells. Stringent criteria were used for calling a gene present (i.e., a
gene that can be reliably detected and quantitated with accuracy). A
general down-regulation, especially with the HIV-infected population,
can be noted. Genes that are expressed in control only increase from
184 at 24 h to 805 at 72 h, while genes specific for HIV-infected cells
number 549 at 24 h and 148 at 72 h. Genes expressed in both
populations diminish over time as more genes are shut down in the
HIV-infected cell population.
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of host-cell mRNA expression in infected cells. Interestingly,
expressing this factor constitutively in a Jurkat cell line re-
sulted in decreased production of virus over time as moni-
tored by p24 expression possibly resulting from a reduction in
surface expression of the CD4 receptor (data not shown). The
role of this factor remains to be fully elucidated in the context
of HIV infection. Additionally, this observation was con-
firmed in primary CD4+ T lymphocytes infected with HIV-1
with a 55-fold increase of this transcript at 24 h (data not
shown). Real-time RT-PCR also confirmed that Bax and
GADD45 were up-regulated, 2- and 2.1-fold respectively, com-
pared to control cells at 72 h. Bax also was shown t be signifi-
cantly up-regulated by Western-blot analysis (Fig. 4). Other
genes of interest were: SH3GL3, reported to be involved in
selective neuronal cell death (Sittler et al. 1998), the type II
receptor for interleukin (IL) 1, characteristic of inflammation
processes, CD79B (M89957) associated with the immuno-
globulin gene superfamily, human pre-T/NK associated pro-
tein (CD73) involved in signal transduction associated with
increased purine salvage, and the generation of adenosine
(Ado) for Ado-receptor signaling (Peola et al. 1996).
DISCUSSION
This study shows that HIV-1 infection modulates the tran-
scriptional levels of a large number of host genes. Many genes
are either suppressed to undetectable levels or are signifi-
cantly up-regulated very soon after virus inoculation and be-
fore the initiation of virus transcription. The changes in-
volved in the culture system (infected and mock infected) are
all part of the process encompassing the response of the target
cells to productive HIV infection. The mock-infected cells
grew normally and cycled normally as seen in Figure 1A, but
the HIV-infected cells diverged significantly from the normal
cycling phenotype and displayed extensive apoptosis. Fluc-
tuations in gene expression are expected even in normally
cycling cells because of differences in proliferation and gen-
Figure 3 Selected mitochondrial-associated genes modulated by human immunodeficiency virus (HIV) infection. (Blue) control condition; (red)
HIV-infected cells. An additional link to GeneCard, Entrez, and PubMed also are displayed with the Entrez description for the gene. Clicking on the
graph itself provides the average difference values and call made by the initial GeneChip analysis suite software. Average difference values of <35
reflects that the gene is not present (includes negative values).
Figure 4 Western blot for p53, phosphorylated p53, and BAX. p53
concentration remained constant but phosphorylated p53 was mark-
edly increased in HIV 1 at 48 and 72 h, a situation mimicked for BAX.
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eration of different effectors during the course of the experi-
ments. The experiments were done in a cell line expressing
the green fluorescent protein, however, we controlled that
GFP had little to no impact on the target cell (using cell cycle
analysis as in Fig. 1A) compared to the virus by constitutively
expressing the protein in the CEM-GFP cell line (results not
shown). HIV-1 transcription usurps cellular transcription to
such an extent that a marked diminution of host-cell
transcription is observed. Changes in transcription include
genes that may be essential for mitochondrial function
and integrity (Chen et al. 2000) and to DNA repair mecha-
nisms leading directly to the induction of apoptosis of in-
fected cells. This situation applies to productively infected
CD4+ T-cell lines and possibly in the acute events following
infection in HIV-infected individuals when virus titers are
high.
Discovery-driven approaches in genomics using high-
density gene expression microarrays have permitted the
definition of new avenues of research and the identifica-
tion of pathways and signal transduction events pertinent to
the process of HIV-1 infection. High-density microarray inter-
rogation of gene expression represents a powerful tool to
dissect the relationships between an infectious agent and its
host.
METHODS
Cell Culture and Viral Infection
The CEM-GFP CD4+ lymphoblastoid T-cell line was devel-
oped as a reporter line to monitor productive HIV infection. A
plasmid consisting of the HIV-1 LTR driving the expression of
the GFP was introduced in the CEM parental cell line. Upon
productive infection, cells express GFP, which can be moni-
tored by flow cytometry. Virus stocks of HIV-1LAI were pro-
duced and titered in the same cell line and infectivity deter-
mined by the method of Karber. CEM-GFP cells were infected
at a multiplicity of infection of 0.5 in the presence of poly-
brene (2 µg/mL) added to both mock and HIV-infected cells.
Figure 5 Hierarchical cluster analysis. We selected genes with average difference values >50 for at least four out of the eight time points. Also,
the ratio of the average difference of HIV over control had to be 2 (422 genes met the criteria). The data then were processed using Cluster. The
values were log transformed, and self-organizing map was applied (100,000 iterations) prior to generating the hierarchical clusters. The display
software Treeview was used to render the figure. Cross section of the tree and magnification of a subset of the hierarchical cluster showing genes
that clustered with NFIB-2. These selected genes were overexpressed as compared to control at the later time points. Intensity of color from bright
green to bright red (log scale) is shown. (Green) overexpressed in control; (red) overexpressed in HIV-infected population.
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A mock-infected control was processed using supernatant of
cultured CEM-GFP cells. All the culture medium (for both
mock and infected culture) was removed and replaced with
fresh media after the initial 2-h incubation. Aliquots of cells
were taken at 0.5, 2, 4, 8, 16, 24, 48, and 72 h after infection
for both populations. Cells were washed once with PBS, re-
suspended in 250 µL of PBS to which 750 µL of Trizol (Gibco-
BRL) was added, and stored at 80°C.
CD4+ Lymphocyte Isolation and Infection
CD4+ lymphocytes were isolated from ∼300  106 PBMC us-
ing the Vario MACS CD4+ Cell Isolation Kit and Depletion
Columns (Miltenyi Biotec) according to the manufacturer’s
protocol. Purified primary CD4+ T cells were infected with the
same strain of HIV-1 at the same multiplicity of infection, two
days after stimulation with PHA and addition of IL-2 ( 20
unit/mL). Aliquots were taken at 2, 24, 48, and 72 h after
infection. Cellular and viral messages were quantified using
real-time RT-PCR quantification.
Cell Cycle, Apoptosis, and Mitochondrial Membrane
Potential Assays
DNA Fragmentation and Cell-Cycle Analysis
Cells (2 106) were washed in PBS, resuspended in 30% etha-
nol in PBS, and kept at 4°C until analyzed. Cells then were
treated with RNAse A (100 µg/mL) and stained with 50 µg/mL
of propidium iodide for 1 h at 37°C. Cells were analyzed by
flow cytometry as previously described (Telford et al. 1992).
Mitochondrial Transmembrane Potential
Cell pellets were resuspended in 100 nM of orange-fluorescent
tetramethylrosamine (CMTMRos, Molecular Probes) and in-
cubated at 37°C for 30 min under the normal growth condi-
tions. Cells were washed and fixed in 1% formaldehyde in PBS
and analyzed by flow cytometry (Poot et al. 1999).
Caspase Activity
Cells were resuspended in caspase buffer (50 mM Hepes, pH
7.4, 100 mM NaCl, 1 mM EDTA, 0.1% Chaps, and 5 mM
dithiothreitol) for 10 min at 4°C. Lysates (10–20 µg of total
protein) were mixed with 50 µL of HEB buffer (PIPES 50 mM,
KCl 20 mM, EGTA 5 mM, MgCl2 2 mM, and DTT 1 mM, pH
7), and reactions were initiated by addition of 100 µM of the
specific substrate. After 1 h incubation at 37°C, caspase-3-like
protease activity was measured bymonitoring the digestion of
its substrate Ac-DEVD-AMC, caspase-9-like activity using Ac-
LEHD-AFC, caspase-6-like protease activity with the substrate
Ac-VEID-AMC, caspase-8-like activity with Ac-IETD-AFC, and
caspase-2-like activity with Ac-VDVAD-AFC (Calbiochem).
Activity was quantified by the release of 7-amino-4-
trifluoromethyl-coumarin (AFC) or 7-amino-4-methyl-
cumarin (AMC) monitoring fluorescence at excitation and
emission wavelengths of 400 and 505 nm, and 380 and 460
nm, respectively, using a fluorimeter (Cytofluor 2000, Milli-
pore).
Immunoblots
Immunoblot analysis was performed on total-cell lysates of 5
 106 cells in 100 µL RIPA buffer (50 mM TrisHCl, pH 7.4, 50
mM NaCl, 1 mM EGTA, 20 mM glycerophosphate, 0.5% (v/v)
Nonidet P-40, 1 mM Na3VO4, 1 mM NaF, 1 µg/mL Aprotinin,
1 µg/mL leupeptin and 1 mM phenylmethanesulfonyl fluo-
ride (PMSF) at the indicated time points (24, 48, and 72 h).
Cell extracts (30 µg per lane) were resolved by SDS-PAGE on
8%–20% gels and transferred on PVDF membranes. The indi-
cated antibodies, p53 and phosphospecific p53(S15) (New En-
gland Biolabs, and BAX (N20) (Santa Cruz Biotechnology)
were visualized by alkaline phosphatase-based enhanced che-
miluminescence.
Expression Analysis
The preparation of labeled RNA (cRNA) was performed as de-
scribed by Affymetrix . The procedure to prepare material for
hybridization to the chips involved multiple steps (for more
details see our web site at: http://genomics.ucsd.edu).We used
10 million cells per time point and condition. Equal amounts
of labeled cRNA (15 µg) were used per GeneChip array. Two
chips were used for every time point and condition and the
average used for all subsequent analysis. In the case of the
HIV-1-infected sample, the viral mRNA contributes signifi-
cantly to the total RNA loaded into the arrays; however, glo-
bal normalization and scaling takes account of this contribu-
tion. Average difference (intensity of fluorescence) was plot-
ted for duplicate experiments. The variability was within
twofold. This was used as our reference for calling a modula-
tion significant (more than twofold). The level of gene expres-
sion was normalized for all conditions. The global normaliza-
tion is a computational technique in which the output of the
experimental array is multiplied by a factor (normalization
factor) to make the average intensity equivalent to the aver-
age intensity of all the other arrays used in the multiple chip
experiment. This is based on all probe sets present on the
chip. The output yields an intensity of expression and with
this and other parameters, a determination of the relative
number of copies for a specific mRNA transcript for which an
absolute call was made. The data were processed using
GeneChip analysis software suite 3.1 (Affymetrix) and then
imported into 2HAPI for further analysis (http://
array.sdsc.edu).
Real-Time RT-PCR Quantification
The level of expression of specific transcripts were determined
using the Perkin-Elmer ABI Prism 7700 (TaqMan) and Se-
quence Detection System software. Total RNA was isolated
using the TRIzol Method (Gibco-BRL) and then digested with
deoxyribonuclease to remove any contaminating genomic
DNA. Five micrograms of total RNA was used to generate
cDNA using a T7-poly dT oligodeoxynucleotide primer (GGC
CAG TGA ATT GTA ATA CGA CTC ACT ATA GGG AGG AGG-
T24) following the protocol for SuperScript II (Gibco-BRL).
Equal amounts of cDNA were used in triplicate and amplified
with the Taqman Master Mix provided by Perkin-Elmer. Am-
plification efficiencies were validated and normalized against
GAPDH and fold increases were calculated using the Com-
parative CT Method for quantitation. The primers and probes
used follow: NFIB-2 forward-TCT CAC CAA CGA AGG CTA
GGA, reverse-GCT TAT AAA ATG GCT GGC TCA TG probe-
CGG CGT CAG AGA TGC TGG GTG A; Bax-alpha forward-
CTG ATC AGA ACC ATC ATG GGC, reverse-GAG GCC GTC
CCA ACC AC, probe-TCC GGG AGC GGC TGT TGG G, and
GADD45 forward-TCT GCA GAT CCA CTT CAC CCT, reverse-
GCT GAC GCG CAG GAT GTT, probe-TCC AGG CGT TTT
GCT GCG AGA AC. The primers and probes are based on the
HIV-1NL4–3 sequence: tat forward-GCC TTC ATT GCC AAG
TTT GTT T, reverse-GTC GCT GTC TCC GCT TCT TC, probe-
CAA GAA AAG GCT TAG GCA TCT CCT ATG GCA; vpr for-
ward-GGC AGG AGT GGA AGC CAT AAT A, reverse-CTC
TCC TCT GTC GAA TTA TGC CTA T, probe-AAT TCT GCA
ACA ACT GCT GTT TAT TCA TTT CAG AA; gag forward-AAA
AGA GAC CAT CAA TGA GGA AGC, reverse-TGG TGC AAT
AGG CCC TGC, probe-CAG AAT GGG ATA GAT TGC ATC
CAG TGC A.
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Recent progress in molecular medicine has provided important tools to identify antigen-specific T
cells. In most cases, the approach is based on oligomeric combinations of recombinant major his-
tocompatibility complex–peptide complexes fixed to various rigid supports available for binding
by the T-cell receptor1–8. These tools have greatly increased our insight into mechanisms of im-
mune responses mediated by CD8+ T cells1,2. Examples of the diverse fields of application for this
technology include immunization, viral infections and oral tolerance induction1–6.
A stable interaction between antigen-presenting cells (APC) and
T cells is dependent not only on the absolute affinity between
the T-cell receptor (TCR) and its ligand but also on the relative
density of molecules available for contact at the interaction
site9. The proper ligand density is achieved by migration of the
relevant molecules toward the initial interaction site, a phe-
nomenon called ‘capping’, whose outcome is the formation of
the immune ‘synapse’, the machinery required for T-cell signal-
ing9. At present, methods for the detection of antigen-specific T
cells rely only on absolute affinity between the ligands and do
not allow the physiologic phenomenon of capping. This may
limit the use of these tools to detection, not manipulation, of
antigen-specific T cells. Low-affinity interactions, which may be
involved in processes such as autoimmunity, may also be
missed10–14. So far, examples of successful detection of class II-re-
stricted antigen-specific T cells by oligomeric major histocom-
patibility complex (MHC)–peptide complexes are also
limited1,2,15–17.
We have developed a system that mimics the physiological
interactions among T cells and APC. We use artificial antigen-
presenting cells (aAPC), composed of a liposome, in which
MHC class II–peptide molecules are incorporated. The composi-
© 2000 Nature America Inc. • http://medicine.nature.com
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tion of these aAPC allows free movement of the MHC–peptide
complexes in the artificial membrane. We show here active clus-
tering of TCR–MHC molecules at the immune synapse after in-
teraction between aAPC and T cells. This multivalent system
allows identification and stimulation of antigen-specific T cells,
thus offering a new tool to study and, in the near future, manip-
ulate immune responses.
aAPC as a tool to identify and stimulate T cells 
First, we defined optimal conditions for MHC class II–peptide
loading and aAPC formation. The size of the aAPC is 60–90 nm
and the number of incorporated MHC molecules is 60–160 per
aAPC. We evaluated the ability of the aAPC, presenting the syn-
thetic biotinylated peptide ovalbumin consisting of amino acids
323–339 (OVA323–339) in the context of MHC class II molecule IAd,
to allow visualization of the OVA323–339-specific, IAd-restricted T-
cell hybridoma 8D011B, by fluorescence-activated cell sorting
(FACS) analysis. The binding to 8D011B was made visible by
staining with cychrome–streptavidin-tagged aAPC. We mea-
sured 98% binding of the 8DO11B hybridoma to the aAPC (Fig.
1a; mean fluorescence intensity (MFI), 821.2). This interaction
was specific, as binding was dependent on the presence of the
proper MHC–peptide combination (Fig.1a; mean MFI, 253.6
with MHC class II molecule IEd, an ‘incorrect’ MHC), and as it
could be partially inhibited by the addition of antibody against
MHC (Fig. 1a; mean MFI, 634.3). We achieved 40% reduction in
staining of 8DO11B cells when we added equimolar amounts of
OVA323–339 (as a competitive inhibitor) and biotinylated OVA323–339
(data not shown). Additionally, binding was lost when we re-
placed biotinylated OVA323–339 with an irrelevant biotinylated
peptide (data not shown).
OVA323–339 peptide analogs, which have comparable IAd bind-
ing affinity, differ in activation of DO11.10, an OVA323–339–IAd-
specific T-cell hybridoma17. In stimulation assays using spleen
cells, peptide analog OVA331H-A seemed to be a weak partial
agonist, whereas analog OVA336E-A was a superagonist17. The
differing responses may have been the result of DO11.10 having
different TCR affinity for the IAd–peptide analogs. Here, we used
aAPC to determine whether these presumed low-affinity
TCR–MHC–peptide interactions could be made visible by FACS.
DO11.10 hybridoma bound to aAPC with IAd–OVA323–339 com-
plexes (MFI, 373.3) as efficiently as did OVA336E-A-loaded aAPC
(Fig. 1b). However, reduced cell-associated fluorescence (MFI,
77.1) resulted when we used OVA331H-A. Binding was lost (MFI,
46.9) when we used irrelevant peptide HA126–138. These results in-
dicate that the avidity of the multivalent aAPC is high enough to
allow visualization of specific low-affinity TCR interactions.
In related experiments, we stimulated DO11.10 cells with
aAPC loaded with OVA323–339 and measured interleukin (IL)-2 pro-
duction by intracellular staining by FACS. IL-2 levels were higher
than basal production in stimulated cells (MFI for OVA323–339,
338.07; basal MFI, 272). We also confirmed this by correspond-
Fig. 1 Identification of antigen-specific cells with
T-cell capture in a monoclonal TCR population. a,
OVA323–339–IAd-specific T-cell hybridoma 8D011B
cells were incubated with aAPC in complexes with
IAd and biotinylated OVA323–339 and were analyzed
by FACS. Before incubation, the hybridoma cells
were stained with PE-labeled antibody against CD4,
and the aAPC containing IAd and biotinylated
OVA323–339 were stained with streptavidin–cychrome.
.As control for specificity of the binding, 8DO11B
cells were incubated with aAPC in complexes with
IEd and biotinylated OVA323–339. Binding of hybridoma T cells to aAPC
could also be partially inhibited by incubation with monoclonal anti-
bodies against (anti-) IAd. Further specificity controls included competi-
tion with non-biotinylated peptide during aAPC formation and the use
of an irrelevant peptide. Data represent intensity of staining for strepta-
vidin–cychrome (CY)  in CD4-gated hybridoma cells (1 experiment of
20). Gates were set on irrelevant isotype controls for CD4, and on bind-
ing of cychrome-conjugated streptavidin to T cells–aAPC without bi-
otinylated OVA323–339. b, OVA323–339–IAd-specific T-cell hybridoma
a b
Fig. 2 Identification by T-cell capture of class II-restricted antigen-specific
mouse T cells after immunization. a, Increase of IAd–Iα52-specific cells after
immunization with Iα52. Cells were collected from inguinal draining lymph
nodes 3 d after the last immunization, stained with PE-labeled antibody
against mouse CD4 and incubated with aAPC encompassing IAd–biotinyated
Iα52, made visible by the addition of fluoresceinated streptavidin. Left, Mice
immunized with incomplete Freund’s adjuvant only; right, Iα52-immunized
CD4 cells. Vertical axes, CD4; horizontal axes, aAPC containing IAd–Iα52−
binding T cells. Numbers in upper quadrants represent % of antigen-specific T
cells. Conditions: 30x molar excess of Iα52 peptide:MHC ratio, pH 7.2, 18 h,
room temperature. b, T-cell proliferation in response to Iα52 after immuniza-
tion and in vitro expansion. Cells were collected from inguinal lymph nodes
and incubated for 3 d with 10 µg/ml Iα52. No proliferation was detected from
cells directly collected from lymph nodes (data not shown). Stimulation index
(vertical axis), c.p.m. of stimulated/unstimulated cultures. IFA, incomplete
Freund’s adjuvant.
a b
DO11.10 cells were incubated with Texas Red-labeled aAPC in com-
plexes with IAd–OVA323–339 (MFI, 373.3) or peptide analogs OVA331H-A
(MFI, 77.1) or OVA336E-A and were analyzed by FACS. MHC molecules
were preloaded with a 50× molar excess of peptide for 24 h at room
temperature and pH 5. Then aAPC were prepared and DO11.10 T-cell
hybridomas were incubated with aAPC. As control for specificity of the
binding, hybridoma T cells were incubated with aAPC in complexes
with IAd and HA126–138, resulting in low background staining (MFI, 46.9).
Data represent intensity of staining for Texas Red (FL3).
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ing differences in the expression of tyrosine kinases (data not
shown).
These preliminary results show that the interaction between
aAPC and TCR is essential for the engagement of T-cell activa-
tion pathways. Work now in progress will determine whether
the addition to the aAPC of co-stimulatory and accessory mole-
cules will provide a fully functional tool to modulate antigen-
specific T-cell responses.
To evaluate the efficiency of our aAPC system to identify MHC
class II-restricted antigen-specific T cells in a polymorphic popu-
lation, we studied the expansion in vivo of T cells specific for
Iα52, a naturally processed, antigenic peptide, presented by IAd
in BALB/c mice18,19. We immunized groups of eight BALB/c mice
with either Iα52 in incomplete Freund’s adjuvant or with adju-
vant alone. Then, 14 days after the last immunization, we col-
lected cells from draining lymph nodes and incubated them
with aAPC-presenting IAd–biotinylated Iα52 complexes. We
found that 5.4% of CD4+ T cells were Iα52-specific, whereas to
1α52–specific in the immunized mice, whereas only 0.7% of
CD4+ T cells showed staining with the cychrome-streptavidin-
tagged aAPC in the mice immunized with incomplete Freund’s
adjuvant only (Fig. 2a). In contrast, we detected specific T-cell
proliferation only when antigen-primed lymph node-derived
cells were expanded in vitro (Fig. 2b).
Interaction of aAPC with T cells allows physiological capping 
The immune synapse is the cluster of transmembrane molecules
that ensures specific interaction between T cells and APC. The
outcome of these interactions is an antigen-specific response by
the T cells, mediated by signaling through the TCR. Several fac-
tors contribute to the considerable quantitative and qualitative
differences in the responses provided by the T cells. These factors
include the affinity of the TCR for the MHC–peptide complex
and the number of ligands available for interaction9. The thresh-
old of response is achieved when enough ligands have migrated
to the initial interaction site on the cell surface. aAPC provide
hundreds of molecules available for binding by the T cell, and
mimic the physiologic interaction between T cell and APC by al-
lowing transmembrane proteins to migrate within the mem-
brane, toward the interaction site. Hence, both high absolute
numbers and relative concentrations of interacting molecules
are achieved using aAPC.
We studied the events occurring after the initial interaction
between aAPC loaded with IAd–OVA323–339 and the T-cell hy-
bridoma 8DO11B. To allow visualization of free movement of
the TCR in the T-cell membrane, we used a system in which the
migration of sphingolipid cholesterol-rich rafts in the cell mem-
brane is detected with fluorescein isothiocyanate (FITC)-conju-
gated cholera toxin B (CTB), which binds the GM1
glycosphingolipid20. We found co-localization on the cell mem-
brane when we overlapped images of FITC–CTB and TCRs la-
beled by Alexa-red 568 antibody against CD3, by confocal
microscopy (Fig. 3d). The process of TCR–aAPC interaction in-
volved active processes whose outcome was capping, as shown
using FITC–CTB to follow the movement of TCR molecules in
the T-cell membrane and phase-contrast imaging to allow
visualization of the liposomes (http://medicine.ucsd.edu/al-
bani/movie.mov). The process of constitution of the immune
synapse was completed in approximately 6 minutes, and was
strictly aAPC-dependent (Fig. 3e and f). Null MHC–peptide com-
plexes did not bind (data not shown). These data are in full
agreement with a report describing the time required by TCR
migration to interact with intracellular adhesion molecule
1–MHC–peptide complexes bound to planar membranes9. The
number of molecular interactions necessary to trigger a T-cell re-
sponse is estimated to be 200 (ref. 9). Images of T cells at inter-
mediate-to-end stages of capping showed that multiple aAPC
were involved in the immune synapse (Fig. 3a–d). Given an aver-
age number of 100 MHC–peptide complexes per aAPC, interac-
tion with just a few aAPC may provide the amount of interacting
molecules necessary for T-cell activation, when the contact oc-
curs in liquid phase.
In conclusion, we have shown here that aAPC can effectively bind
MHC class II-restricted T cells, thus providing an important new
tool for the identification and characterization of these cells.
aAPC can effectively mimic the physiologic interactions be-
tween T cells and APC, particularly in allowing migration of
molecules whose accumulation is an essential requirement to
induce T-cell activation. This system can be used to study
physiological mechanisms of T-cell activation, and, in the
near future, to manipulate the intensity and quality of the T-
cell response.
Fig. 3 Interaction of aAPC with T cells induces membrane capping. 8DO11B T-cell
hybridoma loaded with FITC–CTB, which co-migrates with CD3 molecules (stained
in d with Alexa-568), were incubated in the presence of aAPC with Iad–OVA323–339
complexes. a, Confocal fluorescence image shows the aggregation of the FITC–CTB
in the proximity of the aAPC. b, Confocal fluorescence image shows capping of CD3
molecules (detected by binding with Alexa-568 conjugated to antibody against
CD3) in exact correspondence with the localization of the CTB. c, Nomarsky phase-
contrast image of the same cells demonstrates the presence of the aAPC (small cir-
cles) on the cell surface, overlapping exactly the capping of the CD3 molecules. d, A
combined image showing the co-localization of the FITC–CTB, CD3 and aAPC. e,
Fluorescence images from a time-lapse sequence (1, 2, 3, 4, 5 and 6 min) of
FITC–CTB dynamics in T cells interacting with aAPC. There is a progressive increase
in fluorescence in the upper cell at about ‘7 o’clock’ and ‘4 o’clock’, followed by an
upward movement of the bright fluorescence spots. The lower-right T cell also
shows a ‘condensation’ event at about ‘6 o’clock’. The cell on the left could be con-
sidered a control, as it does not show any visible variations in the diffuse CTB fluores-
cence. f, Three-color overlay of images in e to show aAPC-induced membrane
capping in T cells. Images at 1, 3 and 5 min were encoded green, red and blue, re-
spectively. The upward shifting of the capping event in the middle cell may be ex-
plained by the fact that the cells are not fixed on solid phase, but are embedded in
soft agar, and therefore can freely rotate or move.
a
b
c
d
e
f
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Methods
Preparation of MHC. IAd and IEd molecules were purified from
the lysate of B-cell lymphoma A20.11 by immunoaffinity chro-
matography21 using monoclonal antibody against IAd (MKD6;
Pierce, Rockford, Illinois). Affinity-purified MHC molecules were
solubilized in a Tris buffer containing 50 mM diethylamine and
2% β-octyl-glucopyranoside (Calbiochem, San Diego,
California).
Peptide loading of MHC class II molecules. Optimum loading
conditions for MHC class II molecules were determined in a
MHC class II–peptide-binding assay as described before22.
Detergent-solubilized MHC class II molecules (3 µM) were incu-
bated with a 0.05- to 100-fold molar excess of biotinylated pep-
tide without the addition of protease inhibitors, in the following
conditions: pH 5 and pH 7; room temperature and 37 °C; 16, 24
and 40 h of peptide loading; and 0.05-fold, 1-fold, 10-fold, 60-
fold and 100-fold molar excess of peptide. MHC–peptide com-
plexes were analyzed using non-reducing SDS–PAGE. After
western blot analysis (Highland-ECL; Amersham), the biotiny-
lated peptides were made visible on ‘preflashed’ films
(Hyperfilm; Amersham) through enhanced chemiluminescence
(western blot ECL kit; Amersham). Optimum binding conditions
were established by evaluation of the density of the spots at the
position of the MHC class II dimer–peptide complexes.
Preparation of lipid solutions. Phosphatidylcholine (Sigma)
and cholesterol (Sigma) were combined in a glass tube at a
molar ratio of 7:2. For labeled liposomes, N-(fluorescein-5-thio-
carbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phospho-ethao-
lamine, triethylammonium salt (fluorescein-DHPE) or Texas Red
phosphatidylethanolamine (each from Molecular Probes,
Eugene, Oregon) was added at a final concentration of 1:1 or
1:2 (molar ratio of fluorescein to phosphatidylcholine), respec-
tively. The solvent was evaporated under an argon stream for
30 min and the lipid film was dispersed at a final concentration
of 10 mg/ml in 140 µM NaCl and 10 µM TrisHCl, pH 8 (buffer
A) containing 0.5% sodium deoxycholate. The solution con-
taining mixed micelles was sonicated until it was clear, 
was separated into aliquots and was stored at –20 °C.
Preparation of peptides. Peptide OVA323–339 (ISQAVHAA
HAEINEAGR) and analogs OVA 331H-A (weak agonist;
ISQAVHAAAAEINEAGR) and OVA336E-A (superagonist;
ISQAVHAAHAEINAAGR) and peptides HA126–138 (HNTNGV-
TAASSHE) and Iα52 (ASFEAQGALANIAVDKA) were synthesized
as C-terminal amides and purified by reversed-phase high-per-
formance liquid chromatography. Peptides were N-biotinylated
during synthesis (only one biotin molecule/peptide, 100% bi-
otinylation).
Cell lines. OVA323–339-specific hybridomas 8DO11B and
DO11.10 are two different lines from the same clone, using the
same TCR (a gift from A. Sette, Epimmune, La Jolla, California).
T-cell proliferation. To assess T-cell proliferation in response to
Iα52 after immunization and in vitro expansion, BALB/c mice
4–6 weeks old (Harlan, Indianapolis, Indiana) were immunized
subcutaneously with 100 µg Iα52 in complete Freund’s adju-
vant, followed by immunizations with 100 µg Iα52 incomplete
Freund’s adjuvant at days 7 and 14 after the initial immuniza-
tion. Cells were collected from inguinal lymph nodes and incu-
bated for 3 d with 10 µg/ml Iα52. Proliferation was measured
by thymidine incorporation and is expressed as a stimulation
index (c.p.m. of stimulated/unstimulated cultures). T-cell prolif-
eration assays were done on cells directly obtained from lymph
nodes or after 3 days of culture with 10 µg/ml Iα52. Standard
thymidine incorporation techniques were used.
Preparation of aAPC. MHC–peptide complexes were added to
the lipids in buffer A with deoxycholate at a ratio
(weight:weight) of MHC:liposomes of 1:7. Liposomes were
formed by detergent removal for 48 h through dialysis at 4 °C
against PBS in a 10K Slide A Lyzer (Pierce, Rockford, Illinois),
with two changes of solution. When biotinylated peptides were
used, the formed aAPC were incubated with streptavidin–cy-
chrome  (PharMingen, San Diego California) for 20 min before
the aAPC were added to the cells. For each T-cell capture sam-
ple 1 µg MHC per 6,000 cells was used.
Characterization of aAPC by size. The mean particle sizes of
the aAPC were determined both by FACS analysis in comparison
with beads of known size, and by dynamic light-scattering
analysis with a Malvern 4700 system, using a 25-mW Ne–He
laser and automeasure version 3.2 software (Malvern, Herren,
Germany)22. The particle size distribution as measured by dy-
namic light-scattering analysis was 63–87 nm.
In the FACS analysis, the size of the FITC–aAPC was compared
with the forward scatter of FITC-labeled calibration beads, rang-
ing in size from 40 to 60 nm and from 700 to 900 nm
(PharMingen, San Diego, California). This confirmed the mean
size of the aAPC as being close to 60 nm.
Characterization of aAPC by valency. To allow visualization of
MHC incorporation, aAPC were incubated with phycoerythrin
(PE)-labeled monoclonal antibodies against MHC class II or PE-la-
beled isotype controls and were analyzed for PE staining by FACS
(ref. 22). MHC incorporation was quantified by the Petterson
modification of the Lowry protein assay. To calculate the number
of MHC molecules per aAPC, the amount of incorporated MHC
(73–100% of the MHC added) and the size of the aAPC, as deter-
mined by dynamic light-scattering analysis22, were used to con-
vert the amount of incorporated MHC into the number of MHC
molecules per aAPC. The number of MHC molecules incorpo-
rated in each liposome varied between 60 and 160. The percent-
age MHC occupancy with a given peptide depended on the
peptide used, ranging from 12% to 60% (data not shown).
Staining of cells for FACS analysis. Cells were washed twice in
standard staining buffer and then incubated at 4 °C for 20 min
in FcBlock (PharMingen, San Diego, California). The cells were
stained for the surface markers and isotype controls for 20 min
at 4 °C, washed twice and resuspended in staining buffer.
Monoclonal antibodies against mouse CD3 and CD4, labeled
with PE, cychrome or FITC (PharMingen, San Diego, California),
were used.
T-cell capture. Cells were incubated with aAPC for 30 min at
room temperature. Before acquisition on the FACScalibur
(Becton Dickinson, San Jose, California), cells and aAPC were
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washed twice (5 min at 500 g) and resuspended in staining
buffer. For blocking of binding, aAPC were incubated for 20 min
with 50 µg/ml unlabeled antibody against IAd (PharMingen, San
Diego, California) before being incubated with the cells.
Stimulation of DO11.10 cells by aAPC and measurement of 
IL-2 production. aAPC were prepared as described above. Fresh
DO11.10 cells were plated in RPMI with 10% FCS at a density of
60,000cells/well along with aAPC (10 µg aAPC/well) for 8 h at 
37 °C. At the 4-hour time point, monensin (Sigma) was added,
at a final concentration of 1 µm. At the 8-hour time point, cells
were washed twice and stained for CD3 surface antigen and for
intracellular IL-2 (PharMingen, San Diego, California).
Confocal imaging on fixed cells. 8DO11B cells were loaded
with FITC–CTB (Sigma). Cells (5 × 105/ml; more than 95% vi-
able) and aAPC (0.25 × 106 aAPC/ml) were incubated in a vol-
ume of 200 µl at room temperature for up to 30 min, placed on
ice, and ‘cytospun’ at 300g for 5 min on poly-L-lysine-coated
slides (Sigma). Cells were fixed for 10 min in 4% paraformalde-
hyde in PBS, washed in PBS, and stained for 1 h at 37 °C with
the antibodies against CD3 and IAd (PharMingen, San Diego,
California) at a concentration of 2 µg/ml in I-Block blocking
buffer (Tropix, Bedford, Massachusetts). Alexa 568 (red) sec-
ondary antibody (Molecular Probes, Eugene, Oregon) was used
to detect the monoclonal antibodies. Images were acquired
using a confocal laser-scanning microscope LSM 510 equipped
with an argon laser module (Carl Zeiss, Thornwood, New York).
Time-lapse imaging on fresh cells. For time-lapse fluorescence
on fresh cells, 8DO11B cells were loaded with 8 µg/ml CTB and
then layered using a cytospin centrifuge on a glass slide covered
with three layers of low-melting-point (42 °C) agarose (0.5%).
aAPC (0.25 × 106 aAPC/ml) were then gently pipetted over the
cells, and a coverslip was added on top of the cells.
Fluorescence images were obtained just after the addition of
the aAPC every 6 s with a cooled, charged-coupled device cam-
era mounted on a Zeiss Axiophot epifluorescence microscope
using a 60 × 1.3-na oil objective (Carl Zeiss, Thornwood, 
New York).
ON THE MARKET
IN ISOLATION Easy-to-use nuclei isolation kits are now
available from Sigma, which are de-
signed for the reproducible isolation of
nuclei with high yield, purity and qual-
ity from a variety of mammalian cells
and tissues. The Nuclei EZ Prep kit offers
a method of nuclei isolation from both
suspension and adherent mammalian
tissue culture cells. The simultaneous
harvest and lysis is said to minimize po-
tential artifacts due to sample handling
time for adherent mammalian cell lines.
For more difficult cells, Sigma suggests
the Nuclei Pure Prep kit. This kit is de-
signed for the preparation of fragile nu-
clei and pure nuclei from mammalian
cell lines and solid tissues. The 
protocol incorporates ultracentrifuga-
tion through a dense sucrose cushion to
protect nuclei and strip away cytoplas-
mic contaminants. The sucrose cushion
concentration can be adjusted to meet
Nuclei isolation is a snap, says
Sigma, with its two new kits.
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EPILOGUE 
     Many drugs commonly used for the treatment of diseases induce apoptosis. The most common 
signaling pathway we found activated in our experiments was the intrinsic pathway of apoptosis. This 
resulted in the release of cytochrome c from mitochondria and activation of the complex Apaf-1 and 
caspase-9. The execution of the pathway appeared to be the same induced by different drugs as well 
as for HIV-induced CD4+ depletion. On the other hand the triggering events were distinct. In two of 
the studied systems we observed p53 activation, but the signaling pathways leading to the cytosolic 
release of cytochrome c were different. Bcl-2 family members were modulated to shift the equilibrium 
to the pro-apoptotic side in all the cases studied. It appears that, depending on the cell type and on 
the apoptosis-inducing stimuli, various Bcl-2 family members can modulate the regulation of 
apoptosis. So far, a lot is known about the execution of apoptosis, but much more has to be 
discovered about its initiation. Often, anti-cancer drugs target the signaling events upstream of 
cytochrome c release, and it is clear that understanding this signaling pathway is fundamental to 
optimize the drugs ability to induce cell death in cancer cells. This will allow the selection of new 
specific drugs able to target desired cell types and cell pathways, increasing the toxicity for the 
neoplastic cells and reducing the side effects on the healthy cells. For this reason the development of 
new drugs and the study of their mechanism of action is crucially important.  
     Understanding the biology of a cell provides a basis to interpret how a disease appears in the 
human body and may help prevent its development. The aim of the lab where I worked the last three 
years is to synthesize new drugs, to understand how they work in the cell, to identify their molecular 
targets and to select more potent and selective analogs. My thesis was situated perfectly in this 
context, in fact the results herein reported help elucidate how nucleoside analogs, the new drug 
indanocine, and the non-steroidal anti-inflammatory etodolac induce apoptosis in B-CLL cells. 
Hopefully these results will soon be translated into clinical application for better treatment of cancers. 
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